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Abstract
The genome is thought to be transcriptionally silent during mitosis. Decades of studies have used antibody-
based detection of proteins in fixed cells to show that the majority of transcriptional machinery is absent from
mitotic chromosomes. In addition, quantification of the incorporation of radio-labeled nucleotides has
indicated a large reduction in RNA synthesis during mitosis, suggesting a global decrease in gene expression.
Yet technical limitations have prevented the sensitive mapping of transcription during mitosis and mitotic exit.
Thus, the means by which the previous interphase pattern of transcription is transduced to daughter cells and
the hierarchy of gene reactivation during mitotic exit have been unclear.
Existing methodologies for labeling and sequencing nascent transcripts required lysis of the cell membrane
and subsequent isolation of nuclei as the labels were not cell-permeable. In mitosis, the nuclear envelope is
dismantled and no longer provides a barrier between the chromatin and the rest of the cell. As such, cell lysis
results in loss of chromatin. To circumvent this issue, we used the cell-permeable transcript label,
5-ethynyluridine, to pulse-label nascent transcripts during mitosis and mitotic exit in intact cells. We find that
many interphase genes exhibit measurable transcription in mitosis, as confirmed by interphase cell
contamination modeling, FITC-UTP labeling, RNA FISH, and RT-qPCR. Further, the first round of
transcription immediately following mitosis activates genes that are involved in the growth and rebuilding of
daughter cells, rather than genes that promote cell type-specific functions.
Like the majority of transcripts, enhancer usage – as quantified by eRNA transcription rate – was also
diminished in mitosis and reactivated in waves during mitotic exit. This observation is in agreement with
previous studies that showed that promoter and not enhancer accessibility is retained in mitosis. We therefore
propose a promoter-centric model of epigenetic memory during mitosis in which the basic cohort of genes
expressed in interphase is largely retained at a low level through mitosis, whereas the relative amplitude of
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GLOBAL MITOTIC TRANSCRIPTION AND REACTIVATION DURING 
MITOTIC EXIT: A POTENTIAL EPIGENETIC MECHANISM 
Katherine C. Palozola 
Kenneth S. Zaret 
 
 The genome is thought to be transcriptionally silent during mitosis. Decades of 
studies have used antibody-based detection of proteins in fixed cells to show that the 
majority of transcriptional machinery is absent from mitotic chromosomes. In addition, 
quantification of the incorporation of radio-labeled nucleotides has indicated a large 
reduction in RNA synthesis during mitosis, suggesting a global decrease in gene 
expression. Yet technical limitations have prevented the sensitive mapping of 
transcription during mitosis and mitotic exit. Thus, the means by which the previous 
interphase pattern of transcription is transduced to daughter cells and the hierarchy of 
gene reactivation during mitotic exit have been unclear. 
 Existing methodologies for labeling and sequencing nascent transcripts required 
lysis of the cell membrane and subsequent isolation of nuclei as the labels were not cell-
permeable. In mitosis, the nuclear envelope is dismantled and no longer provides a 
barrier between the chromatin and the rest of the cell. As such, cell lysis results in loss of 
chromatin. To circumvent this issue, we used the cell-permeable transcript label, 5-
ethynyluridine, to pulse-label nascent transcripts during mitosis and mitotic exit in intact 
cells. We find that many interphase genes exhibit measurable transcription in mitosis, as 
confirmed by interphase cell contamination modeling, FITC-UTP labeling, RNA FISH, 




activates genes that are involved in the growth and rebuilding of daughter cells, rather 
than genes that promote cell type-specific functions.  
 Like the majority of transcripts, enhancer usage – as quantified by eRNA 
transcription rate – was also diminished in mitosis and reactivated in waves during 
mitotic exit. This observation is in agreement with previous studies that showed that 
promoter and not enhancer accessibility is retained in mitosis. We therefore propose a 
promoter-centric model of epigenetic memory during mitosis in which the basic cohort of 
genes expressed in interphase is largely retained at a low level through mitosis, whereas 
the relative amplitude of transcription observed in interphase is re-established by 
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CHAPTER 1: INTRODUCTION 
	  
1.1 Mitosis: A Potential Challenge to Cell Identity 
 Every cell within a multicellular organism carries a fixed genome, which in 
humans is comprised of two copies each of twenty-three chromosomes. The 6 billion 
base pairs that make up the twenty-three human chromosomes encode approximately 
20,000 genes, and virtually countless DNA elements necessary to regulate the 
expression of these genes. Furthermore, the trillions of cells that make up a human 
consist of hundreds of different identities, each of which contribute to a specific tissue or 
organ’s function. The ability of the cells to carry out different functions, and thus have 
different identities, is largely due to their cell type-specific gene expression pattern, as 
the genomic sequence itself remains largely unchanged between cell types. Once 
established, the cell must maintain its identity to ensure its proper function. This process 
of identity maintenance may be challenged when cells divide. 
 Mitosis is the process of cell division, when one cell splits into two new daughter 
cells. If a cell needs to divide, it will first pass through the three stages of interphase: G1, 
S, and G2 (Figure 1 A to C). The first stage, G1, is a period of growth when the cell 
increases its mass so that each of the two daughter cells will inherit all of the cellular 
components necessary for proper function. Next is S phase, the period during which 
each chromosome is duplicated into two identical sister chromatids so that each of the 
two new daughter cells will inherit the complete set of genetic information. Once all 
chromosomes are duplicated, G2 is the final phase before division when a series of 




 Mitosis consists of six stages during which the newly duplicated genetic material 
is parsed into the two daughter nuclei (Figure 1 D). During the first stage of mitosis, 
prophase, the sister chromatids begin to condense and structurally rearrange, and the 
mitotic spindle begins to form (Figure 1 E). Late prophase, or prometaphase, is the time 
during which the sister chromatids continue to condense and the microtubules of the 
mitotic spindle attach to the kinetochore, a large protein complex at the centromere of 
each chromosome (Figure 1 F). This is also when the nuclear envelope is dismantled. 
By metaphase, the mitotic spindle has fully captured the chromosomes at their 
kinetochores, and the polarization of the microtubules between the kinetochores and the 
centrosomes on either side of the cell aligns the chromosomes down the center along 
what is termed the “metaphase plate” (Figure 1 G). The sister chromatids are now fully 
condensed and ready to be pulled apart. The first step in separating the sister 
chromatids, anaphase, involves removing the cohesin complexes that have held the 
sister chromatids together (Figure 1 H). During telophase, the mitotic spindle breaks 
down, the chromosomes begin to decondense, and a nuclear envelope forms around 
each set of chromosomes (Figure 1 I). Finally, the process of cytokineses separates the 
cytoplasm around the two nuclei resulting in two, separate daughter cells (Figure 1 J). 
The two daughter cells then re-enter G1 of interphase. 
 The massive condensation and rearrangement of the chromatin in mitosis is 
thought to pose a challenge to cell identity maintenance. First, the interactions between 
the genome and the nuclear envelope are cell type-specific (Talamas and Capelson, 
2015). Thus, when the nuclear envelope is dismantled, those cell type-specific 
interactions are lost and must be reformed when the nuclear envelope is reassembled. 
Second, the genome is packaged in a cell type-specific manner within the nucleus. 




et al., 2016; Naumova et al., 2013), yet must be reformed after cell division (Figure 2). 
The mechanisms by which the structural information of cell identity is inherited in light of 
its disassembly during mitosis has yet to be fully elucidated.  
 In addition, several studies have suggested that the vast majority of 
transcriptional machinery is evicted from the condensed mitotic chromatin (Martínez-
Balbás et al., 1995; Parsons and Spencer, 1997; Prasanth et al., 2003). This includes 
everything from chromatin remodeling and modifying proteins to general and cell type-
specific transcription factors to RNA polymerase II (RNAP2). Chromatin remodelers are 
the proteins that structurally re-arrange chromatin on a local level to facilitate or repress 
transcription, the act of gene expression in which DNA is converted to RNA, while 
chromatin modifiers deposit or remove informational marks that also facilitate or repress 
transcription. Transcription factors, whether they are expressed in multiple cell types or 
are specific to a certain tissue, are responsible for recruiting the enzymes necessary to 
transcribe a gene, and RNAP2 is the large protein complex that carries out transcription 
and is therefore required for gene expression in all cells, regardless of their identity. 
There are also a few classic papers that are routinely referenced as evidence that RNA 
synthesis is dramatically reduced in mitosis, indicating that there is no transcription/gene 
expression (Gottesfeld and Forbes, 1997; Prescott and Bender, 1962). If all of this 
machinery is removed and transcription is shut down in mitosis, then the cell type-
specific gene expression pattern that was established during development would be 
completely lost and need to be reset with every cell division.  
 The elaborate packaging of the genome and the tuning of the gene expression 
profile during development gives rise to the myriad of cell identities. Once established, 
the cell’s functional identity must then be maintained through the course of its life so as 




cell divides, it is imperative that it passes this identity, both the gene expression profile 
and chromatin structure, to the daughter cells. How cell identity is propagated through 
multiple cell generations is the basis of epigenetics and is the focus of this dissertation.  
 
1.2 Determinants of Cell Identity   
 During development, the fertilized, single-cell zygote embarks on a series of cell 
divisions that ultimately gives rise to the multicellular organism. This series of cell 
divisions drives cell identity lineage specification and differentiation which are in turn 
carried out by the successive expression of key transcription factors. At each 
developmental transition, transcription factors turn on and off the genes necessary to 
make the next step down a cell's path to terminal differentiation. It is for this reason that 
ectopic expression of cell type-specific transcription factors can be used to alter the 
developmental course of lineage-committed cells, as well as to change the identity of 
terminally differentiated cells (Graf and Enver, 2009). Furthermore, experimental studies 
have supported the notion that the hierarchal expression of transcription factors 
establishes the downstream transcription network and, ultimately, the cell's final fate 
(Iwasaki et al., 2006). These experiments underline the importance of different 
transcription factors in different cell identities and the order in which they act on the 
genome to set up the specific gene expression profile. 
 An additional contribution to cell identity is the way in which the 2 meters of DNA 
is packaged within the nucleus, the average diameter of which is only 10 nm in human 
cells. In order to fit the entire genome into the nucleus, the DNA of each chromosome is 
elegantly packaged. In the first level of packaging, the DNA (Figure 3 A) is  wrapped 




of 147 base pairs wrapped ~1.75 times around a histone octamer is termed a 
“nucleosome” and makes up the basic unit of chromatin. However, the nucleosomes are 
not evenly distributed. For instance, while the spacing of nucleosomes is partially due to 
intrinsic DNA sequence preference, they are also arranged based on the transcriptional 
state of the locus, with accessible DNA indicative of active transcription and nucleosomal 
DNA indicative of inactive transcription. In addition, the amino-terminal domains of the 
histone proteins carry multiple post-translational modifications (PTMs) that bind a variety 
of regulatory proteins which are the cause and consequence of the transcriptional state 
of the locus. 
 Chromatin is then arranged in three dimensions to make larger, complex 
organizational structures that can vary by cell type. The charges resulting from histone 
PTMs – mainly methylation, acetylation, and phosphorylation – together with the proteins 
that they interact with, provide an additional level of structural regulation that is cell type-
dependent (Figure 3 C). On this level, the chromatin is packaged into accessible 
domains, euchromatin, that tend to be transcriptionally active, and inaccessible domains, 
heterochromatin, that tend to be transcriptionally inactive. Because of their impact on 
gene expression, heterochromatin and euchromatin domains are cell type-specific. 
 The cell type-specific gene expression pattern is also a cause and consequence 
of regulatory loops. Sequences termed “enhancers” are utilized by transcription factors 
to recruit the proper transcriptional machinery to the promoter of a gene to be 
expressed. The looping of the enhancer, which can be hundreds of kilobases away from 
the target gene’s promoter, is another level of regulatory structure. Beyond the 
enhancer-promoter loop organization, chromosomes are arranged into megabase-scale 
topologically associated domains (TADs), larger chromosome compartments, and 




inactive genes, respectively (Dixon et al., 2012; Phillips-Cremins et al., 2013). While the 
boundaries between compartments and TADs are highly enriched for the insulator 
protein, CTCF, and are largely cell type-independent, cell type-specific chromatin 
interactions occur within TAD boundaries (Dixon et al., 2012; Dowen et al., 2014; 
Phillips-Cremins et al., 2013). TAD boundaries have also been shown to be the 
boundaries of replication domains (Pope et al., 2014), which are cell type-dependent 
(Hansen et al., 2010; Hiratani et al., 2010; 2008; Pope et al., 2012; Ryba et al., 2010). 
More importantly, disrupting the CTCF binding sites at TAD boundaries in embryonic 
stem cells results in aberrant transcriptional regulation of pluripotency and 
developmental genes (Dowen et al., 2014), thus further emphasizing the importance of 
these structures in cell identity. The genome is further regulated structurally through 
interactions with the nuclear envelope. For instance, genes are silenced upon 
recruitment to the nuclear lamina which lines the inner nuclear membrane (Peric-Hupkes 
et al., 2010). In contrast, genes associated with the nuclear pore tend to be active 
(Talamas and Capelson, 2015).  
 
1.3 RNA Pol II During Mitosis 
 The carboxyl-terminal domain (CTD) of RPB1, the largest and enzymatic subunit 
of RNAP2, is composed of multiple, conserved Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 
heptapeptide repeats (Figure 4 A). Many studies have described the role of CTD PTMs 
in the transcription cycle: recruitment of RNAP2 to the promoter, pausing until RNAP2 
receives a signal to proceeded, initiation of transcription, elongation of RNAP2 through 
the gene body as it transcribes, and termination of transcription and removal RNAP2 




followed by high throughput sequencing (ChIP-seq) against various CTD PTMs to show 
a correlation between each stage of the transcription cycle with different CTD PTMs. In 
general, phospho-Serine 5 (Ser5-P) is found at the transcription start site, and 
diminishes toward the 3' end, while phospho-Serine 2 (Ser2-P) is low near the 
transcription start site and increases toward the 3' end (Figure 4 B) (Heidemann et al., 
2013; Komarnitsky et al., 2000). Because of these observations, and Ser2-P’s 
dependence on the elongation factor P-TEFb (Shim, 2002), Ser5-P is considered the 
transcription initiating form of RNAP2 and Ser2-P is considered the elongating form of 
RNAP2. Despite the implications of these PTMs in transcription, both Ser2-P and Ser5-P 
can be detected during mitosis, though it is unclear if it is transcriptionally engaged 
(Bregman et al., 1995).  
 The phospho-status of RNAP2 and its implication in transcription are complicated 
by a study from the Manley lab. Pin1 stimulates RNAP2 CTD phosphorylation by the cell 
cycle regulatory complex, cdc2/cyclin B. Because cdc2/cyclin B initially phosphorylates 
Ser5 and Ser2 on the hypophospho form of RNAP2 to a hyperphospho form, the 
association of Pin1 results in a hyper-hyperphospho RNAP2 (Xu, 2003). This hyper-
hyperphospho form of RNAP2 accumulates in mitosis in a Pin1 dose-dependent matter, 
and specifically interacts with Pin1. Conversely, Pin1-/- cells accumulate hypophospho 
RNAP2 in mitosis. Importantly, short, 10 min pulses with radio-labeled uridine indicated 
that Pin1 expression inhibits nascent transcription by inhibiting hyperphospho RNAP2-
enhanced splicing (Xu, 2003). Thus, hyperphosphorylation of the CTD is not exclusively 
indicative of transcriptional activity. 
 The strongest evidence to date that transcriptionally-active RNAP2 is diminished 
from mitotic chromatin comes from the Price lab. Jiang and colleagues demonstrated the 




transcription termination factor, TTF2 (Jiang et al., 2004). However, despite these 
results, the complete absence of RNAP2 on mitotic chromatin has not been 
demonstrated (Ohta et al., 2010). Furthermore, Ser2 can be phosphorylated 
independent of P-TEFb by the atypical kinase, Brd4 (Devaiah et al., 2012), which is 
associated with mitotic chromatin (Dey et al., 2009), and is thought to aid in 
transcriptional memory, the process or remembering which genes are expressed and 
silent, through mitosis. Moreover, all of these studies have relied heavily on specific CTD 
antibodies: the H5 monoclonal antibody for Ser2-P and the H14 monoclonal antibody for 
Ser5-P. It is important to note that the distinction between the epitopes of these two 
antibodies has been vastly over simplified (Table 1). For instance, H5 does not 
recognize a CTD that is only phosphorylated at serine 2. Rather, the epitope appears to 
be Ser2-P followed by Ser5-P on the same heptapeptide unit (Chapman et al., 2007). In 
contrast, H14 recognizes Ser5-P on one heptapeptide unit followed by Ser2-P on the 
next, not simply a Ser2-P event as has been claimed throughout the studies discussed 
above (Chapman et al., 2007). Furthermore, neither of these epitopes has been shown 
to be exclusively masked by PTMs on the other peptides in the heptapeptide repeat 
chain. Thus, given the combinatorial potential for CTD PTMs, the transcriptional status of 
RNAP2 should not be reduced to a two epitope-based model. 
 
1.4 Mitotic Bookmarking 
 One potential mechanism of epigenetic inheritance of the cell type-specific gene 
expression program is provided by mitotic “bookmarks”. Though there are now several 
cell type-specific transcription factors thought to bookmark the mitotic genome, the first 




hepatoctyes (Caravaca et al., 2013). As with the chromatin modifiers MLL (Blobel et al., 
2009) and Brd4 (Zhao et al., 2011), as well as PARP1 (Lodhi et al., 2014), knockdown of 
GATA1 (Kadauke et al., 2012) and FoxA1 (Caravaca et al., 2013) resulted in the 
delayed reactivation of the bookmarked genes during mitotic exit. The authors thus 
concluded that bookmarks serve to promote the rapid reactivation of their target genes 
at mitotic exit. In contrast to this model, a recent study of Oct4 and Sox2 bookmarking in 
embryonic stem cells shows that bookmarked genes are not actually induced more 
rapidly than non-bookmarked genes at mitotic exit, though knockdown of these factors 
did decrease expression of pluripotency genes (Deluz et al., 2017). This is likely due to 
the fact that in each case only one bookmarking factor was interrogated at once. 
Perhaps the simultaneous knockdown of multiple bookmarking factors would uncover a 
difference in reactivation dynamics between bookmarked and non-bookmarked genes at 
mitotic exit. 
 In addition to the reactivation kinetics of bookmarked genes, there is also debate 
over their importance to cell identity maintenance. In the cases of GATA1 in 
erythroblasts and FoxA1 in hepatocytes, knockdown of the bookmarking factor during 
mitosis simply delayed reactivation of target genes and the resulting daughter cells from 
the symmetric division ultimately took on their proper identity (Caravaca et al., 2013; 
Kadauke et al., 2012). In contrast, knockdown of Oct4 (Liu et al., 2017b) or Sox2 (Deluz 
et al., 2016) in ES cells reduced the pluripotency of the resulting daughter cells. 
Knockdown of Sox2 also demonstrated it’s bookmarking role in promoting 
neuroectodermal differentiation – the first example of functional bookmarking during 
asymmetric division (Deluz et al., 2016).  
 However, there are conflicting reports in the two studies to date that have 




mitotically unstable (OSKM-MD) and stable (OSKM-MD*) reprogramming factors were 
ectopically expressed in mouse embryonic fibroblasts (MEFs). Upon induction with dox, 
the authors found no difference in the ability of OSKM-MD or OSKM-MD* to reprogram 
the MEFs to pluripotency (Deluz et al., 2016). In the second study, mitotically unstable 
(GDO) and stable (GMO) GFP-tagged Oct4 were ectopically expressed in MEFs. This 
time, Oct4-GDO resulted in decreased reprogramming of MEFs to pluripotency relative 
to Oct4-GMO (Liu et al., 2017b). The discrepancy in these results is unlikely due to the 
mitotic-specific degradation, since both studies employed the same approach. Instead, 
the OSKM cassette used in the first study may have lead to insufficient knockdown of 
Oct4.   
 Despite the insight of these and other bookmarking investigations, we have 
recently learned that mitotic chromatin is not as stripped of its transcriptional machinery 
as previously suggested. Recent studies have demonstrated the antibody- and fixation-
dependence of protein localization during mitosis. Specifically, Lerner and colleagues, 
during their investigation of the bookmarking role of HNF1β, found that HNF1β was 
localized to mitotic chromatin when assessed by live cell imaging or when fixed in 
methanol, but was evicted from mitotic chromatin when fixed in paraformaldehyde 
(Lerner et al., 2016). The Tijian lab followed up and compared fixed versus live-cell 
localization of several transcription factors in mitosis. They, too, found that the majority 
of the factors tested were indeed occupying mitotic chromatin in the absence of fixation 
(Teves et al., 2016). These studies, together with the issues of the RNAP2 antibodies 
discussed above, are strong indicators that the transcriptional and epigenetic state of 
mitotic chromatin has likely been vastly over-simplified.  
 Another form of bookmarking may lie in the retention of histone PTMs: those that 




genes were expressed or not in the parental cell, and thus which should be activated or 
repressed at the end of division. Globally, trimethylation of lysine 27 or lysine 9 on H3 
(H3K27me3 or H3K9me3), mono- and dimethylation of lysine 4 on H3 (H3K4me1 and 
H3K4me2), and acetylation of lysine 27 on H3 (H3K27ac) are retained in mitosis, while 
acetylated lysine 9 and 14 on H3 (H3K9ac and H3K14ac) levels decrease (Liu et al., 
2017b). Conversely, acetylation of lysine 27 and dimethylation of lysine 4 on H3 
(H3K27ac and H3K4me2) increase globally in mitosis compared to interphase (Liu et al., 
2017b). At a local level, H3 and H4 acetylation (Kouskouti and Talianidis, 2005) and 
H3K4me1 (Valls et al., 2005) are stable through mitosis at the promoters of genes that 
were active prior to mitosis, supposedly to ensure activation after division. Likewise, 
H3K79me2 (Kouskouti and Talianidis, 2005), H3K4me2/3 (Kouskouti and Talianidis, 
2005), and H3K12ac (Valls et al., 2005) are retained at nucleosomes throughout the 
gene body of previously, actively transcribed genes. 
 Mitotic bookmarks can also be provided by general transcriptional machinery and 
structural proteins. For instance, the transcriptional coactivator, Brd4 (Dey et al., 2009); 
the chromatin modifier, MLL (Blobel et al., 2009); the polycomb complex components 
RING1A and BMI1 (Arora et al., 2016); and the structural/insulator protein, CTCF, 
(Burke et al., 2005; Shen et al., 2015; Yan et al., 2013) have all been shown to remain 
bound in mitosis to a subset of their interphase binding sites. Because of their various 
roles in transcriptional regulation and structural maintenance of the cell type-specific 
interphase transcriptome, it is thought that their retention on mitotic chromatin serves to 
locally preserve interphase structure and transcriptional status at key identity genes 




1.5 Mitotic Chromatin Accessibility 
 In addition to the imaging of live versus fixed transcription factors, further 
evidence that mitotic chromatin is not as inaccessible as previously thought is provided 
by chromatin accessibility assays. Early studies used footprinting (Martínez-Balbás et 
al., 1995) and KMnO4 (Michelotti et al., 1997) assays to show that accessibility is 
maintained in mitosis at the promoters of genes that were active before mitosis began. 
More recently, a genome-wide comparison of DNase hypersensitivity in asynchronous 
and mitotic erythroblasts indicated that chromatin accessibility is globally maintained, 
especially at promoters, though accessibility was diminished at enhancers (Hsiung et al., 
2015). Another recent study used ATAC-seq to show the same global accessibility 
pattern in asynchronous and mitotic cells (Teves et al., 2016). These studies clearly 
demonstrate that the massive rearrangement of chromatin during the transition from 
interphase to mitosis does not impact its accessibility and thus its potential for 
transcription. 
	  
1.6 Centromeric Transcription 
 In keeping with the demonstrated accessibility of mitotic chromatin, it has also 
been shown that mitosis is not a period of complete transcriptional silence. Namely, 
RNAP2-dependent transcription not only occurs at centromeres, but is required for 
centromere establishment and segregation. Though the centromere consists of several 
repeat elements buried deep within heterochromatin, the RNAP2-dependent 
transcription of these repeats is required for proper centromere segregation since 
transcription inhibition results in anaphase-lagging cells (Chan et al., 2012). RNAP2-




for the CENP-A loading factor, CAL1, in Drosophila (Chen et al., 2015), and for 
recruitment of Sgo to the inner centromere (Liu et al., 2015). In the case of Sgo, the 
Bub1 kinase phosphorylates histone H2A at tyrosine 120 (H2ApT120), which in turn 
recruits Sgo to kinetochores and the inner centromere (Liu et al., 2015). Sgo, in turn, 
protects the centromeric cohesin during sister chromatid resolution, the process by 
which the cohesin that has held the sister chromatids together is removed everywhere 
but at the centromere. At the centromere, Sgo also specifically interacts with hyper-, but 
not hypo-, phosphorylated RNAP2 and inhibition of Bub1’s kinase activity prevents Sgo 
and hyperphosphorylated RNAP2 localization to the kinetochore and loosens 
centromere cohesion (Liu et al., 2015). Further, mitotic-specific RNAP2 knockdown or 
global transcription inhibition resulted in the redistribution of Sgo from the inner 
centromeres to the kinetochores and weakened centromeric cohesion (Liu et al., 2015). 
Based on additional experiments with microtubule inhibitors, the authors suggest the 
following model to explain the necessity for transcription: Bub1 places the H2ApT120 
mark at the kinetochores in prophase which directly recruits Sgo and RNAP2 to the 
kinetochores where RNAP2 begins transcribing the underlying repeat elements. This 
transcription presumably disrupts the H2ApT120-Sgo interaction, causing Sgo to be 
recruited to the inner centromere where it protects cohesin from removal during sister 
chromatid resolution. Then, once the mitotic spindle has properly formed at the 
kinetochore, the tension causes Sgo to move back to the kinetochores and thus no 
longer protects the centromeric cohesion from removal so sister chromatids can 
separate. This study thus provides the first strong evidence for the existence of 





1.7 Mitotic Transcription 
 There also exists evidence that mitotic transcription occurs outside of the 
centromere. Although routinely cited as evidence for transcriptional silencing in mitosis, 
the data from the early studies often suggest otherwise. For instance, early 
audioradiography assays indicated that RNA synthesis drops in mitosis to anywhere 
between 5 to 40% of interphase levels, depending on the gene assayed (Gariglio et al., 
1974; Johnson and Holland, 1965; Konrad, 1963). This wide range in RNA synthesis 
detection demonstrates that mitosis is not strictly a period of transcriptional silence, but 
could simply be a period of altered gene regulation. It is unclear how some of this 
residual mitotic transcription has been overlooked in the past few decades, but it may be 
due to the until-recently prevailing assumption that mitotic chromatin is simply too 
compact for transcriptional machinery access. 
 Furthermore, biochemical studies using the transcriptional inhibitors α-amanitin 
(Matsui et al., 1979) and flavopiridol (Liang et al., 2015) have shown that some RNAP2 
may be associated with mitotic chromosomes. In the case of a recent study from the 
Shilatifard lab, the existence of actively-elongating RNAP2 was uncovered in mitotic 
HeLa cells. Though the authors did not detect RNAP2 by ChIP-seq in mitotic cells, the 
addition of the transcription elongation inhibitor, flavopiridol, resulted in paused RNAP2 
peaks at several promoter in mitosis (Figure 5) (Liang et al., 2015). It is possible that, 
given the low detection sensitivity of formaldehyde-based assays such as ChIP-seq, that 
low level transcription is not detected by RNAP2 binding. If so, then it is possible that low 







 Mitosis is a period of complex chromatin rearrangements, protein relocalizations, 
and a global decrease in RNA synthesis. For these reasons, it has long been thought 
that mitosis poses a challenge to cell identity. However, recent studies have begun to 
uncover our misconceptions about the transcriptional state of mitosis, many of which 
were based on previous assumptions of the compaction of mitotic chromatin and the 
accuracy of antibody- and fixation-based techniques.  
 To avoid the pitfalls of antibody and fixation artifacts, and to get at the heart of 
how the cell type-specific transcriptome  emerges from its supposed silenced state in 
mitosis, I sought to directly measure transcripts as they were generated in cells while 
they transitioned from prometaphse to G1. My thesis work is the first to demonstrate, on 
a genome-wide level, that mitosis is not a period of transcriptional silence. Indeed, there 
is extensive, low-level transcription throughout the genome. Additionally, the cell type-
specific interphase transcriptome, the complete compilation of genes expressed in a 
given cell, is not re-established during mitotic exit in a synchronous fashion. Instead, 








Figure 1. The eukaryotic cell cycle 
 
The eukaryotic cell cycle consists of four phases, the first three of which make up 
interphase: (A) G1, (B) S, and (C) G2, and then (D) mitosis. Mitosis consists of six 
stages. (E) Prophase: the sister chromatids begin to condense and the mitotic spindle 




nuclear envelope breaks down and the spindle microtubles attach to the kinetochore. (G) 
Metaphase: the sister chromatids align down the middle forming the metaphase plate, 
and the microtubes attach the sister chromatids to opposite spindle poles. (H) 
Anaphase: the sister chromatids separate. (I) Telophase: the chromosomes arrive at 
their spindle poles and begin to decondense as the nuclear envelope reforms around 
them. (J) Cytokinesis: the contractile ring separates the cytoplasm of the two new 






Figure 2. Long-range interactions are lost in mitosis. 
 
Contact probability maps generated from Hi-C data for (A) HeLaS3 cells in G1, (B) an 
asynchronous populations of HFF1 cells, (C) an asynchronous population of K562 cells, 
and metaphase populations of (D) HeLa63, (E) HFF1, and (F) K562 cells. Adapted from 






Figure 3. Chromatin packaging within the nucleus is highly ordered and cell type-
specific. 
 
(A) The DNA double helix is the primary structure of chromatin. (B) The DNA wraps 
~1.75 times around a complex of 8 histone proteins, 2 each of H3, H4, H2A, and H2B, to 
form nucleosomes. (C) Chromatin is further packaged into three dimensional structures 
of loops and folds, that are often cell type-specific. (D) An schematic of a condense 






Figure 4. RNA Polymerase II carboxyl-terminal domain is regulated during the 
transcription cycle. 
 
(A) A schematic of the heptapeptide repeat unit of the RNAP2 carboxyl-terminal domain. 
green, phospho-Serine 2 (Ser2-P); red, phospho-Serine 5 (Ser5-P). (B) A schematic of 
the ChIP-seq profiles of Ser2-P, Ser5-P, and total RNAP2 over the transcribed region of 
a gene. TSS, transcription start site; polyA, transcription end site; H5, antibody against 
Ser2-P; H14, antibody against Ser5-P; blue, total RNAP2. Adapted from (Heidemann et 






Figure 5. Evidence of transcription in mitosis. 
 
ChIP-seq for RNAP2 in (A) asynchronous HeLa cells, (B) asynchronous HeLa cells 
treated with flavopiridol, (C) mitotic HeLa cells, and (D) mitotic HeLa cells treated with 
flavopiridol. Black arrows, RNAP2 binding; white arrows, no RNAP2 binding. Adapted 








Table 1. RNA Pol II carboxyl-terminal domain antibodies and epitopes. 
 
Blue peptides are those that are preferentially recognized by the antibody. Red peptides 
are those that mask antibody binding if carrying a post-translational modification. 
Adapted from (Heidemann et al., 2013).
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CHAPTER 2: MITOTIC TRANSCRIPTION AND WAVES OF GENE 
REACTIVATION DURING MITOTIC EXIT 
	  
2.1 Preface 
 The manuscript presented in this chapter was originally published online 14 
September 2017 (Palozola et al., 2017). It has been reformatted here in accordance with 
University of Pennsylvania dissertation formatting guidelines. Supplemental tables S5 
through S8 and S10 through S24 are publically-available with this dissertation at 
http://repository.upenn.edu/edissertations/. All sequencing data is available under GEO 
accession number GSE87476.	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2.2 Respective Contributions 
	   The majority of the experiments and analyses presented in this chapter were 
designed and performed by myself, under the guidance of Dr. Kenneth S. Zaret. Justin 
Becker optimized the EU-labeling of HUH7 cells and chose the labeling time points 
during mitotic exit, also under the guidance of Dr. Zaret. Greg Donahue provided custom 
scripts and advice for computational analyses, generated the plot in figure S3 B, curated 
and mapped the eRNAs, and performed the analysis in Figure 4 C. The RNA FISH 
images were collected by Allison Cote with guidance from Dr. Arjun Raj in the 
bioengineering school. The HeLa FITC-UTP labeling, image collection, and analysis was 
performed by Dr. Hong Liu in the lab of Dr. Hongtao Yu at University of Texas 
Southwestern Medical Center. The HUH7 and BJ fibroblasts FITC-UTP labeling, images 
collection, and analysis was performed by Dr. Liu at Tulane University School of 
Medicine. Dr. Gregory R. Grant performed the interphase contamination modeling. The 






 Although the genome is generally thought to be transcriptionally silent during 
mitosis, technical limitations have prevented sensitive mapping of transcription during 
mitosis and mitotic exit. Thus, the means by which the interphase expression pattern is 
transduced to daughter cells have been unclear. We used 5-ethynyluridine to pulse-label 
transcripts during mitosis and mitotic exit and found that many genes exhibit 
transcription during mitosis, as confirmed by fluorescein isothiocyanate-uridine 5’-
triphosphate labeling, RNA fluorescence in situ hybridization, and quantitative reverse 
transcription polymerase chain reaction. The first round of transcription immediately after 
mitosis primarily activates genes involved in the growth and rebuilding of daughter cells, 
rather than cell type-specific functions. We propose that the cell’s transcription pattern is 
largely retained at a low level through mitosis, whereas the amplitude of transcription 





 During mitosis, chromatin condenses (Antonin and Neumann, 2016), gene 
regulatory machinery is largely evicted from chromatin (Gottesfeld and Forbes, 1997; 
Martínez-Balbás et al., 1995; Prasanth et al., 2003), and transcription is thought to be 
silenced (Parsons and Spencer, 1997; Prescott and Bender, 1962; Taylor, 1960). Yet 
reactivation of a specific gene expression program is needed to maintain cell identity 
during exit from mitosis. Long-distance interactions across the genome are lost during 
mitosis (Naumova et al., 2013), as is hypersensitivity at distal enhancers, but not at 
promoters (Hsiung et al., 2015). “Bookmarking” transcription factors remain bound in 
mitosis to a subset of their interphase sites (Caravaca et al., 2013; Deluz et al., 2016; 
2017; Festuccia et al., 2016; Kadauke et al., 2012; Liu et al., 2017b; Teves et al., 2016).  
Knock-down of these factors during mitosis delays reactivation of target genes 
(Caravaca et al., 2013; Kadauke et al., 2012), although the proper transcriptome is 
eventually regenerated. Thus the basis for identity maintenance during mitosis remains 
unclear, and the hierarchy by which genes are reactivated during mitotic exit is not 
understood. 
 Because of nuclear envelope breakdown in mitosis and hence the inability to 
isolate nuclei for direct labeling of transcripts (Core et al., 2008), genome-wide studies 
during mitotic exit used RNA Polymerase II (RNAP2) cross-linking to assess active 
transcription (Hsiung et al., 2016; Prasanth et al., 2003) and found a burst in RNAP2 
binding to promoters ~60-90 min after release from mitotic arrest (Hsiung et al., 2016). 
However, the dynamic range of antibody-based methods is much less than from direct 
measurements of nascent transcription, and cross-linking artifactually causes protein 




elongation inhibition of prometaphase HeLa cells elicits paused RNAP2 at promoters, 
suggesting the presence of elongating enzyme, even though elongating RNAP2 was not 
detected directly (Liang et al., 2015). The study also mapped non-polyadenylated, 
chromatin-associated RNAs from prometaphase cells, but it was unclear whether these 
RNAs were transcribed during mitosis or, as suggested by the authors, at the G2/M 
transition. A study of pulse-labeled transcripts in arrested MCF-7 human breast cancer 
cells used nuclear isolation for bromouridine-5’-triphosphate labeling and hence did not 
appear to be assessing mitotic cells (Liu et al., 2017a). 
 
2.5 Results 
 To define the timing of transcription events during mitotic exit, we used the cell-
permeable 5-ethynyluridine (EU) to pulse-label nascent transcripts (Jao and Salic, 2008) 
in intact HUH7 human hepatoma cells during nocodazole-induced mitotic arrest, mitotic 
exit, and in asynchronous cells. Arrested cells, enriched by mitotic shake-off, were highly 
pure (figure S1, A to D) and re-enter G1 (figure S1, E to K). Previously, we labeled 
transcripts with EU during mitotic exit in HUH7 cells and attached azide-fluorophore, 
discovering that bulk global transcription initiates approximately 80 min after nocodazole 
wash-out (Caravaca et al., 2013). On the basis of this assessment of global reactivation, 
we pulse-labeled transcripts at 0, 40, 80, 105, 165, and 300 min after nocodazole wash-
out in HUH7 cells, but instead conjugated azide-biotin to the EU-RNA in order to 
measure the relative changes over time (Figure 1 A). The addition of biotin allowed us to 
use streptavidin beads to isolate EU-labeled transcripts from total RNA and generate 
cDNA libraries on the beads for sequencing (figure S2, A to E, and S3A and table S1). 




and generated biotinylated RNAs to add as spike-in controls (figure S2, C and F to H, 
and tables S2 to S4).  
 EU-RNA-sequencing (EU-RNA-seq) maps primary transcripts with high coverage 
(figure S3 B), because reads span introns and exons of annotated transcripts and are 
largely absent from intergenic regions (Figure 1, B and C, and figure S3 C), with 
reproducibility (figure S3 D). The distribution of asynchronous FPKMs (fragments per 
kilobase of transcript model per million fragments mapped) (figure S4 A) and wide 
dynamic range helps distinguish genes that can be reliably be detected (FPKM ≥ 19) 
(Figure 1 C and figure S4 B) from those that cannot (FPKM < 19) (figure S4 C). Reads 
from non-specific RNA, not transcribed during the pulse (“NoEU”), primarily mapped to 
exons of highly abundant, stable mRNAs, such as for ALB (figure S4 D), and were 
removed from all samples without affecting asynchronous FPKMs as compared to 
microarray data (figure S4 E). We conclude that EU-RNA-seq is a robust and reliable 
method for mapping the nascent transcriptome. 
 With three spike-in replicates, we observed 8,074 transcripts (3,689 genes) 
(figure S5 A) consistently expressed in mitosis (figure S5 B and table S5). The mean 
decrement in expression was fivefold, with a much narrower range in expression 
compared to that in asynchronous cells (Figure 1 D). Of the mitotic transcripts, 97% are 
expressed above 5% of their asynchronous level (figure S5 C), and the different relative 
rank expression profiles (figure S5 D) indicates that the mitotic transcriptome is distinct 
from that in asynchronous cells. Furthermore, 3,329  mitotically expressed genes are 
expressed higher in mitosis than can be attributed to the ~3% contaminating 
asynchronous cells, based on co-alignment of the mitotic and asynchronous reads with 




low level transcription seen in the mitotic population cannot be explained by 
contaminating interphase cells.  
 We quantified fluorescein isothiocyanate-uridine 5’-triphosphate (FITC-UTP) 
incorporation in mitotic HUH7 cells with or without the transcriptional inhibitor, α-
amanitin, which has detected transcription at centromeres (Liu et al., 2015).  Nascent 
RNA signals were evident across chromosome arms in metaphase spreads and were 
significantly reduced by the inhibitor (Figure 1, E to V, and figure S6, A and B).  
Chromosome arm transcription was also detected in BJ fibroblasts (figure S6, C to U), 
further confirming that mitotic transcription is not limited to the centromere and occurs in 
non-transformed cells.  
 We used quantitative reverse transcription polymerase chain reaction to 
independently assess transcripts that were called to be mitotically expressed or not, 
using intron-directed primers. Primer sets were confirmed to detect nascent transcripts, 
because treatment with triptolide, an RNAP2 inhibitor, diminished their signals but did 
not decrease signals for primer sets to glyceraldehyde-3-phosphate dehydrogenase 
mRNA (figure S7 A). All three mitotically expressed primary transcripts were detected in 
mitotic cells (figure S7 B) and were triptolide-sensitive (figure S7 C), demonstrating the 
dependence of their expression on RNAP2.  
 To test for expression of mitotically expressed genes in naturally occurring mitotic 
cells, we performed RNA fluorescence in situ hybridization in asynchronous cells (Figure 
2, A to L). Exon and intron probes were used because colocalization, together with 
chromatin, is indicative of a transcriptional event. We detected a significant occurrence 
of primary transcripts in mitosis for all three genes tested (figure S7 D). We also found 
789 transcripts (484 genes) that were higher in mitosis than in asynchronous cells 




structure and transcription (Figure 2 N and table S8) and were not specific to G2 or other 
non-mitotic phases (table S9) (Singh et al., 2013). 
 To assess whether there is a hierarchy of reactivation during mitotic exit, all 
transcripts expressed in asynchronous cells were parsed by the time at which their 
FPKM first increased 1.5-fold over that in mitosis (Figure 3 A, figure S8 A, and tables 
S10 to S15). The largest number of transcripts first increased at 80 min (figure S8 B and 
table S11) and were reactivated with the largest amplitude (figure S9 A), as seen 
previously (Caravaca et al., 2013; Hsiung et al., 2016). Of the transcripts first activated 
at 80 min in hepatoma cells, 55% maintained their transcription rate for the duration of 
mitotic exit (figure S9 B), similar to that seen in erythroblasts (figure S9 C) (Hsiung et al., 
2016). Yet the sensitivity of our approach allowed for the identification of additional 
waves of reactivation following the initial burst (Figure 3 and tables S12 to S14). EU-
labeling affords the sensitivity to detect 927 transcripts that first increase at only 40 min 
(Figure 3 and table S10), well before bulk transcription reactivation seen by EU-
fluorophore labeling or RNAP2 antibody staining and chromatin immunoprecipitation 
(Caravaca et al., 2013; Hsiung et al., 2016). 
  The first genes to increase have functions in lumen and envelope formation and 
translation (Figure 4 A and tables S16 to 17) (Huang et al., 2009; 2008). Therefore, 
genes that reconstitute basic cell structure and growth are prioritized immediately after 
mitosis, expanding on the ribosomal and metabolic genes seen elsewhere (Fukuoka et 
al., 2013). The next wave of reactivation is enriched for adhesion genes, which is 
consistent with the epithelial nature of HUH7 cells (tables S18 to S19). Last, the last 
transcripts to increase are involved in cell cycle and DNA replication (tables S20 to S21), 
as the cells are preparing for S phase. To determine when liver-specific genes first 




expressed in HUH7 cells – a number similar to that seen in cultured hepatocytes 
(Olsavsky et al., 2007) – first increases over mitosis. Although liver-specific genes are 
expressed throughout mitotic exit, most are reactivated at later stages (Figure 4 B and 
figure S10 A). Thus, HUH7 cells initially activate genes required for building daughter 
cells at the beginning of mitotic exit and then later activate cell type-specific genes.  
 Although the first transcripts to increase are among the shortest (figure S10 B), 
the longest early genes are still activated before the shortest late genes (figure S10 C). 
Gene Ontology (GO) analysis of the longest genes to come up at 40 and 80 min reveals 
basic cell functions (figure S10, C and D), as observed when considering all genes 
(Figure 4 A). Analysis of the shortest liver-specific genes indicates that they increase at 
later time points (figure S10, E and F). Thus, the time of activation of gene classes 
relates to their function and not primarily to gene size.  
 We also assessed enhancer RNA (eRNA) dynamics as a surrogate for enhancer 
activity. We curated all intergenic human enhancers (Leung et al., 2015) for detectable 
eRNAs in asynchronous HUH7 cells and found them significantly down-regulated in 
mitosis (figure S11 A).  The majority of eRNAs increased at the early time points during 
mitotic release (figure  S11 B), as did genes (Figure 3 A).  Curating for the enhancer 
subset within 100 kb of the nearest TSS, we found that eRNAs first increase around the 
same time as their putative targets (Figure 4 C). Therefore, enhancer and putative target 
gene reactivation appear concordant during mitotic exit. 
 
2.6 Discussion  
 We applied a sensitive approach to measuring the transcriptome during mitosis 




transcription reactivation during exit. RNA polymerases have long been known to be 
stable in chromatin, persisting during salt-washes of nuclei that cause loss of 
transcription factors (Derman et al., 1981).  Thus, a low level of transcribing RNAP2 
could contribute to the inheritance of a cell’s specific transcriptome pattern through 
mitosis.  Because deoxyribonuclease hypersensitivity also persists at promoters in 
mitosis, whereas hypersensitivity at enhancers (Hsiung et al., 2015) and long-range 
interactions generally do not (Naumova et al., 2013), we suggest that in mitosis, the 
promoter and its gene create rudimentary mitotic expression units (MEUs). MEUs retain 
residual activity and function along the general constraints of genes in yeast, which lack 
enhancers and long-range interactions. The MEU model posits that the transcription 
pattern is largely retained through mitosis by MEUs, whereas the amplitude of 








Figure 1. EU-RNA-seq and direct FITC-UTP labeling reveal extensive transcription 
in mitosis. 
 
(A) Pulse-labeling during mitosis and mitotic exit. (B) Reads span exons and introns, not 
intergenic regions; y-axis, fragments per million fragments mapped (FPM). (C) A 
representative transcript with an FPKM of 19. (D) FPKMs of mitotically expressed 
transcripts, in mitosis and in asynchronous cells; bar, mean; whiskers, quartiles; P < 
0.001, n = 8,074 transcripts. (E-G) Interphase or (H-M) mitotic cells labeled with FITC-
UTP; white boxes are magnified in (K) to (M). (N-P) Interphase or (Q-V) mitotic cells 
treated with α-amanitin and labeled with FITC-UTP. white boxes are magnified in (Q) to 






Figure 2. Markedly active genes in mitosis. 
 
Naturally-occurring mitotic cells in an asynchronous population stained for (A, E, I) 4’,6-
diamidino-2-phenylindole and (B, F, J) exonic and (C, G, K) intronic RNA. (D, H, L) 
Colocalization at primary transcripts. white arrows, exon; yellow arrows, intron. (M) 
FPKMs of mitotically enriched genes in mitotic and asynchronous cells. bar, mean; 
whiskers, quartiles; P < 0.001, n = 484 genes. (N) Representative GO categories for 







Figure 3. Transcription reactivation during mitotic exit. 
 
(A) z scores of transcripts (rows) that first increase >1.5-fold over mitosis, rank ordered 
within each time point (columns). (B) Liver genes during mitotic exit. y axis, FPM. 








Figure 4. Basic cell functions are prioritized over cell specificity during mitotic 
exit. 
 
(A) Representative GO categories for 40 to 80 min. (B) FPKMs of liver-specific genes. 
bar, mean; whiskers, quartiles; P < 0.001 from 300 min to asynchronous; n = 149 liver-
specific genes. (C) Increase in eRNAs (Leung et al., 2015) within 100 kb of transcription 
start site (TSS) during mitotic exit. bar, mean; whiskers, quartiles; n.s., not significant; 









figure S1. Quantification of mitotic index and successful cell cycle re-entry after 
mitotic release of HUH7 hepatoma cells.	  	  	  
 
(A) Synchronization, arrest, and release protocol. (B) The mitotic index of replicate 
shake-offs for each experiment. error bars, standard error of the mean; n = 3 replicates 
for experiment 1; n = 2 replicates for experiment 2; relevant data panels for each 




staining of mitotic cells indicates that the compact chromatin morphology is 
representative of mitosis. red arrows, condensed mitotic chromatin; yellow arrows, 
decondensed interphase nuclei. (E) Sample-blinded quantification of cells that have 
condensed and de-condensed chromatin after nocodazole wash-out and (F-K) a 







figure S2. The custom biotin-RNA control sequences retain their proportionality 
when pulled down and converted to cDNA. 	  
 
(A) Total RNA (black), including those labeled with EU (green), was recovered, (B) 
conjugated to biotin-azide (green circle), (C) biotin-RNA control sequences were spiked-
in at known quantities (red), (D) biotinylated RNAs were isolated with streptavidin-coated 
magnetic beads (gray circle), and (E) converted to cDNA libraries. (F) Experimental 
approach to validating controls. Ct values following RT-qPCR of (G) control #1 or (H) 
control #2, when added at the indicated levels to 1.5 ug of asynchronous biotin-EU-RNA 
and pulled down with streptavidin-coated magnetic beads; expected values are based 






figure S3. EU-RNA-seq robustly maps nascent transcripts.	  	  
 
(A) Average reads mapped (PCR-duplicates removed) for each time point. (B) 
Transcript coverage by tag count. (C) Read coverage over exons, introns, and intergenic 
regions (TSS-1kb) over all transcripts in asynchronous cells. bar, mean; whiskers, 
quartiles; P < 0.001. (D) Pearson correlation coefficient of the FPKM of each transcript in 






figure S4. Nascent transcripts are reliably detected above FPKM 19.	  	  
 
(A) Log2 histogram of spike-in-normalized FPKMs for all transcripts in asynchronous 
cells. y-axis, number of transcripts; x-axis, log2(FPKM) values; n, number of transcripts 
above cutoff. (B) Browser shot of GPSM1, a transcript with an FPKM of 19 in 
asynchronous cells (C) Browser shot of ZG16, a transcript with an FPKM of 14 in 
asynchronous cells (D) Upper track, browser view of a highly-abundant mRNA that is 
non-specifically pulled down during EU-RNA-Seq; lower track, same gene displayed 
after NoEU subtraction.  (E) Microarray expression score of 27,000 transcripts grouped 
by their NoEU-normalized FPKM in EU-RNA-seq for asynchronous HUH7. whiskers, 






figure S5. Global mitotic transcription in HUH7 cells is not the result of 
contaminating interphase cells.	  	  
 
(A) Log2 histogram of spike-in-normalized FPKMs for all transcripts in mitotic cells. y-
axis, number of transcripts; x-axis, log2(FPKM) values; n, number of transcripts above 




spike-in-normalized mitotic replicate. (C) The cumulative frequency of genes expressed 
in mitosis as a percentage of their asynchronous expression level, up to 100% (n = 
7,335 of 8,074 mitotically-expressed transcripts). (D) Spearman rank correlation 
coefficient between replicates for all transcripts with an FPKM ≥ 19 in mitosis (0’) after 
spike-in normalization. (E) Examples of genes whose minimum expression level (FG = 
FPM of a given gene) in the mitotic samples (n = 3 EU-RNA-Seq replicates) is higher 
than the maximum expression level (FG) among our asynchronous EU-RNA-Seq 
triplicates, as well as 222 adult human RNA-Seq studies (n = 225 non-mitotic studies), 
when co-aligned and normalized to sequencing depth; the numbers indicate the fold 
difference between the mitotic and non-mitotic FG values; i.e. how many times higher the 
gene would have to be expressed in our mitotic samples than the maximum non-mitotic 






figure S6. Mitotic transcription occurs in HUH7 hepatoma and nontransformed BJ 
fibroblast cells.	  	  
 
(A) Quantification of FITC-UTP signal over DAPI, with and without UTP or α-amanitin in 
interphase HUH7 cells. n = 8 nuclei for each condition; error bars, standard error of the 




UTP or α-amanitin in metaphase HUH7 cells. n = 40 chromosome arms (5 per cell) for 
each condition; error bars, standard error of the mean; P < 0.001. Interphase (C-E) or 
mitotic (F-K) BJ fibroblast cells labeled with FITC-UTP. white box, magnified in (I-K). 
Interphase (L-N) or mitotic (O-T) cells treated with α-amanitin and labeled with FITC-
UTP. white box, magnified in (R-T). (U) Quantification of FITC-UTP signal over DAPI, 
with and without α-amanitin in metaphase BJ fibroblasts. n = 40 chromosome arms (5 






figure S7. Nascent transcript quantification in mitotic cells.	  	  
 
(A) Asynchronous cells were treated with either DMSO or triptolide. error bars, standard 
error of the mean for 3 replicates. (B) Relative expression in mitotic and asynchronous 
cells, error bars, standard error of the mean for 3 replicates. (C) Mitotic cells were 
treated with either DMSO or triptolide. error bars, standard error of the mean for 3 






figure S8. Identification of transcripts by time of first increase over mitosis (0’).	  	  
 
(A) Filtering for transcripts that first increase at each time point. (B) Quantification of 






figure S9. The 80 min burst is similar to the spike seen at 90 min in murine 
erythroblasts.	  	  
 
(A) Amplitude of log2 fold change for transcripts first increased at each time point. bar, 
mean; whiskers, quartiles; P < 0.001; n, top 400 transcripts by fold change. (B) Ranked 
fold change from previous time point for each transcript that was first activated at 80’ in 
HUH7 cells. (C) The projection onto the first principle component of homologs to murine 
erythroblast genes that first increase at 80’ or are only in the asynchronous HUH7 cells. 






figure S10. Genes involved in basic cell functions are prioritized over cell type-
specific genes, independent of transcript length.	  	  
 
(A) Proportion of the liver-specific genes that are expressed in HUH7 cells and come up 
in each category. representative genes are indicated; P = 0.002. (B) Length of 
transcripts that first increase at the indicated time points. bar, mean, whiskers, quartiles; 
P < 0.001; n, top 400 transcripts by fold change. (C) Length of longest (upper quartile) 
40-80’ genes and shortest (lower quartile) 300’-asynchronous genes. bar, mean; 
whiskers, quartiles; P < 0.001. (D) Representative GO categories for the longest (upper 
quartile) 40-80’ genes. (E) FPKMs of the shortest third of liver-specific genes at all time 
points. bar, mean; whiskers, quartiles; P < 0.01; n = 149. (F) Proportion of the shortest 
third of liver-specific genes, that are expressed in HUH7 cells and come up in each 






figure S11. Dynamics of eRNA expression during mitotic exit.	  	  
 
(A) Mitotic and asynchronous FPMs of all intergenic enhancers detected in 
asynchronous HUH7 cells. bar, mean; whiskers, quartiles; n = 75,563; P < 0.001. (B) Z-





2.9 Supplemental Tables 
	  
	  





table S2. Spike-in control #1 alignment data.	  	  
 
The number of reads aligned to control locus #1 were normalized for sequencing depth 






table S3. Spike-in control #2 alignment data.	  
 
The number of reads aligned to control locus #1 were normalized for sequencing depth 






table S4. Spike-in scalars. 
 
The average of RPM-normalized reads mapped for 5e-5 ug of control #1 and 1/10 of the 
RPM-normalized reads mapped for 5e-4 ug of control #2 was calculated for each library. 

















1 Late G1 S  0.00 1 
2 G2 S HSPA1A 0.01 1 
3 S Late G1 TOR2A,F2RL2, MTRNR2L8 0.08 1 
4 S G2  0.00 1 
5 Early G1 Late G1 PGAM4 0.02 1 
6 Late G1 Early G1 LOC643387, DLX2 0.03 1 
7 G2 Early G1 CDK2AP2 0.02 1 
8 S Early G1  0.00 1 
9 Late G1 G2  0.00 1 
10 G2 Late G1  0.00 1 
 
table S9. Mitotically-enriched genes do not represent another cell cycle stage. 
 
Genes in each cell cycle phase cluster (Singh et al., 2013) were compared to those that 




2.10 Materials and Methods 
	  
Cell Culture 
 HUH7 human hepatoma cells were cultured in DMEM High Glucose with L-
glutamine (Invitrogen, 11965), 10% FBS (HyClone), and 1% penicillin-streptomycin 
(Invitrogen) at 37˚C in 5% CO2. For mitotic arrest experiments, the cells were 
synchronized at the G1/S transition by culturing for 24 hr in complete DMEM 
supplemented with 2 mM thymidine (Sigma, T1895). The thymidine media was removed 
and cells were washed once with PBS. The cells were then cultured for 2 hr in complete 
DMEM to complete synchronization. The media was then supplemented with 
nocodazole (Sigma, M1404) for a final concentration of 0.06 ug/mL, and incubated at 
37˚C for 16 hours. Mitotic cells were manually collected by shake-off. To release the 
cells from arrest, mitotic cells were washed twice with PBS and re-plated in complete 
DMEM. 
 
H3S10p Immunofluorescence  
 HUH7 cells were fixed in 4% PFA for 30 minutes at room temperature, 
permeabilized with 0.5% Triton X-100 for 30 minutes at room temperature, blocked in 
10% FBS/0.1% Triton X-100 for 3 hours at room temperature, and incubated with 1 
ug/mL primary antibody (Abcam ab5176) in 10% FBS/0.1% Triton X-100 overnight at 






Quantification of Mitotic Arrest  
 Immediately following shake-off, a fraction of the mitotic cells was removed, 
washed once with PBS and fixed in 4% paraformaldehyde at room temperature and 
stained with DAPI. A Nikon inverted widefield microscope was used to image the fixed 
cells at 20X magnification, and the number of mitotic (highly compact chromatin) and 
non-mitotic cells were manually quantified based on chromatin morphology. A minimum 
of 250 cells per replicate were counted for EU-labeling. The average mitotic index was 
97% for the cells that had spike-ins added after EU-labeling for mitotic versus 
asynchronous comparison, and 94.5% for the cells that were subsequently labeled with 
EU during exit. Mitotic cells were similarly quantified (blinded) at each time point during 
mitotic exit to assess their ability to re-enter G1 following nocodazole arrest. 
 
Custom Spike-In Control Sequences 
 We designed and generated our own biotinylated spike-in controls to normalize 
between mitotic (0’) and asynchronous nascent RNA populations since commercial 
spike-ins are not biotinylated and thus would not be pulled down in our assay. Two 
endogenous loci were chosen (control #1 = hg19:chr7:110258409-110258798 and 
control #2 = hg19:chr13:107098286-107098585) that we found not to be transcribed in 
HUH7 cells, unique in the genome, and amplified linearly as described below. These 
sequences were PCR-amplified from HUH7 genomic DNA, Sanger-sequenced, cloned 





EU Pulse-Labeling of HUH7 Cells  
 Cells were pulse labeled with 0.5 mM EU in standard growth media for 40 
minutes at 37˚C (Caravaca et al., 2013). The media was removed and the cells were 
collected with TRIzol Reagent (Ambion). Total RNA was isolated using miRNeasy 
(Qiagen). Biotin-azide was then conjugated to EU with the Click-iT Nascent RNA 
Capture Kit (Invitrogen). Both custom biotinylated, spike-in control RNAs were then 
added to 1.7 ug of each biotinylated sample (5e-5 ug of control #1 and 5e-4 ug of control 
#2). Biotin-EU-RNAs and spike-in controls, where applicable, were pulled down from 
total RNA using streptavidin-coated magnetic beads (Invitrogen), and used for stranded, 
ribo-depleted cDNA library generation directly off the beads (Ovation Human FFPE 
RNA-Seq Multiplex System). 
 
Sequencing and Alignment 
 The EU-RNA-Seq libraries were sequenced on the Illumina NextGen500. Reads 
were trimmed to 35 nucleotides, extended to a total length of 300, and aligned to human 
genome build hg19 using Bowtie2 2.2.9 TopHat “very sensitive” option in end-to-end 
mode (Langmead and Salzberg, 2012). Bed files were then reduced to unique, non-PCR 
duplicated fragments with a custom script. Read alignment data for EU-RNA-Seq 
libraries are presented in table S1; read alignment data for spike-in control reads are 
presented in tables S2 and S3. 
 
Transcription Rate Quantification  
 Reads present in the “NoEU” negative labeling control were subtracted on a base 




the fragments per million fragments mapped per kilobase of transcript model (FPKM) 
was calculated for all transcripts for each sample. To quantify over nascent transcripts, 
introns were included in the transcript model, unlike a traditional FPKM that maps 
fragments per million per kilobase of exons. 
 
Global Normalization  
 For the mitotic and asynchronous replicates that received spike-ins, sequencing 
reads were aligned to the individual control loci. Total reads aligned to each locus were 
normalized to sequencing depth to produce each library’s spike-in scalar (table S4). All 
FPKMs in the mitotic and asynchronous libraries were then multiplied by their spike-in 
scalar prior to further analysis. 
 
Modeling Interphase Contamination  
 All RNA-Seq data sets for human liver cell lines were downloaded from the Short 
Fragments Archive (SRA) (Leinonen et al., 2010) giving 222 samples. This includes 
approximately 20 cells lines across a heterogenous range of conditions and treatments, 
and no samples were excluded. We aligned 5M fragments from each sample to the 
human genome build hg19 with STAR v2.4.2a (Dobin et al., 2012). We did the same for 
the asynchronous and mitotic arrest (0’) EU-labeled triplicates. The FPM (Fragments Per 
Megaread) of gene G is calculated as the number of fragments mapping to (any 
transcript of) gene G, divided by the number of millions of aligned fragments out of the 
5M total (Mortazavi et al., 2008). For gene G denote this value by FG. This normalized 






 Cells were treated with either DMSO or 5 uM triptolide for 1 hour at 37˚C prior to 
RNA harvest with TRIzol reagent (Ambion). Primary transcripts were detected using 
intron/exon primer pairs, with the exception of GAPDH which was detected with exonic 
primers. Sequences are available upon request. 
 
Transcription Run-On of Intact Mitotic Cells with FITC-UTP 
 As previously described (Liu et al., 2015), the chromosome spreads were first 
treated with 0.2 % Triton X-100 and then FITC-UTP (+/- α-amanitin) was added onto 
slides. The slides were then incubated at room temperature for 20 minutes to allow 
transcription to incorporate FITC-CTP into newly synthesized RNA. The cells were then 
fixed with 4% paraformaldehyde and stained with DAPI. Fluorescence was observed 
with a microscope. Fluorescence intensities of DNA and RNA on chromosome arms 
were converted into numerical values by Image J. After background subtraction, the 
mean intensities of DNA and RNA for each cell were obtained. The values of RNA 
intensity were normalized to DAPI intensity to obtain relative intensity. A two-tailed t-test 
was performed in Excel between control and α-amanitin-treated cells. 
 
RNA FISH 
 Hybridizations were carried out as previously described (Raj et al., 2008). Briefly, 
asynchronous HUH7 cells were grown on 18 mm #1 cover slips, fixed in 3.7% 
formaldehyde for 10 min at room temperature, and permeabilized in 70% ethanol 
overnight (minimum) at 4˚C. The cover slips were then incubated in wash buffer (2X 




introns and exons of KLF4, ATF3, and ELF3 were designed using LGC Biosearch 
Technologies’ Stellaris® RNA FISH Probe Designer. Probes were prepared as per 
manufacturer’s recommendation. Hybridization of 1:100 probes in hybridization buffer 
(dextran sulfate, formamide, SSC) was carried out at 37˚C overnight. Cells were then 
stained with DAPI and imaged on a widefield fluorescent microscope at 100X 
magnification. Maximum projections were compiled with ImageJ, and intron and exons 
signals were quantified as previously described (Raj et al., 2008). Images were false 
colored and merged in ImageJ for identification of intron/exon colocalization events. A 
one-sample t-test was performed in R for colocalization events in each category. 
 
Identification of Transcripts First Increased at Each Time Point During Mitotic Release  
 For all transcripts that had an FPKM of at least 19 in the asynchronous 
population, we pulled out those that had an FPKM at least 1.5 fold higher than the FPKM 
in mitosis (0’) for the first time. That is, if the FPKM is 1.5 fold higher at 80’ min than at 
0’, but less than 1.5 fold higher at 40’ than at 0’ then that transcript was called an 80’ 
transcript. 
 
Comparison to Murine Erythroblasts 
 The study by Hsiung et al. used principle component analysis to determine that 
approximately half of the genes expressed in their murine cells line spiked at 90 minutes 
of mitotic exit. Projection of all genes onto the first principle component indicates the 
similarity between a given gene and the 90 minute spike. These values were plotted for 
homologs that first increase in our HUH7 cells after 80 minutes or were only expressed 




performed in R between the PC1adj values of the mouse orthologs of our 80’ transcripts 
and the PC1adj values of the 90’ transcripts.  
 
Gene Ontology Enrichment  
 Unique genes corresponding to the transcripts found to first increase at a specific 
time point were used to perform GO analysis for cellular component, molecular function, 
and biological process categories on DAVID (Huang et al., 2009; 2008), relative to all 
transcripts with an FPKM of at least 19 in the asynchronous population and ≥1.5 fold 
higher than in mitosis (i.e. expressed in asynchronous cells). Significant categories were 
filtered for those that were at least 1.3 fold enriched over background with the FDR 
controlled at 10%. 
 
eRNA Expression with Putative Targets 
 The 292,429 enhancers from Leung et al. (Leung et al., 2015) were mapped to 
hg19 and measured for RNA FPKM during mitosis and mitotic exit. Enhancers were 
defined as -200 to +200 bp around the central nucleotide position and were associated 
to genes by the nearest TSS and classified by the time of first 1.5 fold increase of their 
putative regulatory targets. Only intergenic enhancers, those falling into the region 1kb to 
100kb upstream of their target gene, without overlapping other genes, were considered. 
Because high EU-RNA-Seq background was detected at SINE elements, all tags 
overlapping annotated SINE elements were removed. The FPKMs of both + and – 
strand non-SINE nascent EU-RNA-Seq tags were then averaged at the enhancer locus.  
 To rule out enhancers inactive in asynchronous cells, the enhancers were filtered 




which occur in regions of broad background enrichment, for each enhancer two 
additional intergenic 1 kb windows 1.2 kb away from the enhancer centers were 
measured for EU-RNA-Seq signal. Each enhancer was tested to see whether its fold 
over background at the activation time was greater than 2X (the background was the 
maximum of both strands on both regions). Enhancers failing this filter (or without a 
matching background region) were rejected. 
 For each activation group, the filtered list of intergenic enhancers is box-plotted 
over the mitotic exit time-course. The p-value of the time point of activation vs t=0 (blue) 
or vs the previous time point (red) was computed by a Wilcoxon rank sum test. 
 
eRNA Expression in Mitosis and Asynchronous HUH7 Cells 
 Enhancers were filtered as described above. FPM scores reflect the average of 
both strands at a 400 bp window surrounding the enhancer center. eRNA scores were 
adjusted using the spike-in scalar normalization, and SINE overlapping RNA-seq tags 
were excluded. The p-value between spike-in normalized mitotic and asynchronous 
eRNAs was computed by a Wilcoxon rank sum test. 
 
Identification of eRNAs First Increased at Each Time Point  
 For all eRNAs that had an FPKM of at least 0.1 in the asynchronous population, 
we pulled out those that had an FPKM at least 1.5 fold higher than the FPKM in mitosis 
(0’) for the first time. That is, if the FPKM is 1.5 fold higher at 80’ min than at 0’, but less 






 The Wilcoxon rank sum test was used for figures 1D, 2M, 4B-C, S3C, S9C, 
S10B-C, S10E, and S11A. The Pearson correlation coefficient was computed between 
all replicates for experiment 2 in figure S3D. The Spearman rank correlation coefficient 
was computed between all spike-in normalized replicates for experiment 1 in figure S5D. 
A two-tailed t-test was used to compute all p-values in figures S6A-B and S6U. A one-
sided t-test was used to compute all p-values in figure S7D. A Kruskall Wallis test was 
used to compute the p-value in figures S9A. A hypergeometric test for enrichment was 
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3.2 Respective Contributions 
 The majority of the experiments and analyses presented in this chapter were 
designed and performed by myself, under the guidance of Dr. Kenneth S. Zaret.  The 
HeLa FITC-UTP labeling, image collection, and analysis were performed by Dr. Hong 
Liu in the lab of Dr. Hongtao Yu at University of Texas Southwestern Medical Center. 
The cluster and gene ontology enrichment analyses were performed by Dr. Dario Nicetto 
of Dr. Zaret’s lab, with guidance from Dr. Simoni Sidoli of Dr. Ben Garcia’s lab. The 





 Mitosis is thought to be a period of transcriptional silence due to the compact 
nature of mitotic chromosomes and the apparent exclusion of RNA Pol II and many 
transcription factors from mitotic chromatin. Yet accurate reactivation of a cell’s specific 
gene expression program is needed to re-establish functional cell identity after mitosis. 
The majority of studies on protein regulation and localization during mitosis have relied 
extensively on antibodies and crosslinking-based approaches, which are known to 
artifactually exclude proteins from mitotic chromatin. Here we show that RNA Pol II 
localization in mitosis is antibody- and fixation-dependent, and that direct assessment of 
transcription by pulse-labeling nascent RNA reveals global, low-level mitotic 
transcription. We also find a hierarchy of gene reactivation as the cells transition from 
mitosis to their interphase amplitude of gene expression. Re-setting of gene transcription 
during mitotic exit is coincident with enhancer transcription. Our work thus shifts focus 
from assessing mitotic exit as a binary transcription switch to a more nuanced concert of 
transcription amplitude and enhancer usage. We suggest that understanding how gene 
expression patterns are conserved during mitosis rests upon deciphering how 





	   During development, lineage specification and differentiation are carried out by 
the successive expression of key transcription factors. Once a cell’s functional identity 
has been established, it is imperative that its identity is maintained by the inheritance of 
the cell type-specific gene expression profile through cell division. Mitosis is the period of 
the cell cycle during which the recently duplicated sister chromatids are divided into two 
separate nuclei. At the onset of mitosis, chromosomes condense to help ensure 
separation of the sister chromatids. It has been thought that this condensation excludes 
transcriptional machinery (Martínez-Balbás et al., 1995; Prasanth et al., 2003) resulting 
in the termination of transcription (Parsons and Spencer, 1997; Prescott and Bender, 
1962), and others showed a global repression of RNA synthesis by nucleotide 
incorporation (Johnson and Holland, 1965; Konrad, 1963; Parsons and Spencer, 1997; 
Prescott and Bender, 1962). However, there are caveats to each of these studies 
surrounding the approaches used and conclusions drawn that may have misinterpreted 
the transcriptional state of mitotic cells. 
 The CTD of Rpb1, the largest and enzymatic subunit of RNAP2, is composed of 
multiple, conserved heptapeptide repeats of Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7. 
Many studies have described the role of CTD post-translational modifications (PTMs) in 
the transcription regulatory cycle of recruitment, pausing, initiation, elongation and 
termination (Heidemann et al., 2013). In general, phospho-Serine 5 RNAP2 (Ser5-P) is 
found at the transcription start site, and diminishes toward the 3' end of the transcribed 
region of a gene, while phospho-Serine 2 RNAP2 (Ser2-P) is low near the transcription 
start site and increases toward the 3' end (Heidemann et al., 2013; Komarnitsky et al., 




factor P-TEFb (Shim, 2002), Ser5-P is considered the transcription initiating form of 
RNAP2 while Ser2-P is considered the elongating form of RNAP2. Notwithstanding the 
implications of these PTMs in transcription, both Ser2-P and Ser5-P were detected in 
mitotic cell extracts by Western Blot (WB) (Bregman et al., 1995), though it was unclear 
whether RNAP2 was transcriptionally engaged.  
 Notably, Ser2 can be phosphorylated independent of P-TEFb by the atypical 
kinase, Brd4 (Devaiah et al., 2012), which is associated with mitotic chromatin (Dey et 
al., 2009). Thus it is unclear as to whether Ser2-P is indicative of active transcription. 
Moreover, these studies have relied on specific CTD antibodies: the H5 monoclonal 
antibody for Ser2-P and the H14 monoclonal antibody for Ser5-P. It is important to note, 
however, that H5 does not recognize a CTD that is only phosphorylated at serine 2. 
Rather, the epitope appears to be Ser2-P followed by Ser5-P on the same heptapeptide 
unit (Chapman et al., 2007). In contrast, H14 recognizes Ser5-P on one heptapeptide 
unit followed by Ser2-P on the next (Chapman et al., 2007). Thus, given the 
combinatorial potential for CTD PTMs, the transcriptional status of RNAP2 may not be 
reduced to a two epitope-based model.  
 More importantly, RNAP2 and associated proteins have been detected by mass 
spectrometry of mitotic chromatin (Figure 1) (Ohta et al., 2010). Also, flavopiridol-based 
transcription inhibition studies have shown that RNAP2 is associated with mitotic 
chromosomes (Liang et al., 2015). Though RNAP2 was not detectable in mitotic HeLa 
cells by chromatin immunoprecipitation followed by high throughput sequencing (ChIP-
seq), the addition of transcription elongation inhibitor resulted in paused RNAP2 peaks 
at several promoters in mitotic cells (Liang et al., 2015). These results suggest that low 
levels of transcribing RNAP2 are present, and that only when elongation is blocked and 




studies have shown that formaldehyde crosslinking artifactually removes proteins from 
mitotic chromatin (Lerner et al., 2016; Teves et al., 2016). Even though transcription 
factors were visibly excluded from mitotic chromatin by immunofluorescence (IF), 
fluorescently-labeled versions of the same proteins colocalized with mitotic chromatin in 
live cells.   
 In this chapter we investigate the role that  fixation- and antibody-based methods 
have played in establishing the traditional paradigm of transcriptional machinery 
exclusion from mitotic chromatin and the role of pulse-labeling transcripts in uncovering 
mitotic transcription. We find that there does exist a global, low-level of mitotic 
transcription which may be enhancer-independent. We also show that the genes that 
encode more basic cell functions are the first to increase during mitotic exit, and that 
enhancer activity apparently coincides with gene reactivation. 
 
3.5 RNA Pol II During Mitosis 
 In a previous study, we used the HUH7 human hepatoma cell line to show that 
the pioneer factor, FoxA1, remains bound to a subset of its interphase binding sites 
during mitosis (Caravaca et al., 2013). Here, we employ this cell line as it is amenable to 
efficient cell cycle synchronization and enrichment of mitotically-arrested cells. 
Furthermore, upon release from a mitotic block, the cells efficiently re-enter the cell 
cycle. Rather than rely on the H5 and H14 antibodies that have traditionally been used in 
the literature, we performed IF for endogenous RNAP2 with an antibody raised against a 
synthetic RNAP2 Ser2-P peptide. We found RNAP2 Ser2-P colocalized with chromatin 




 Since this observation contradicts previously reported IF studies that show that 
RNAP2 is evicted from chromatin during mitosis, we sought to confirm the antibody’s 
epitope specificity by pre-incubating the antibody with excess peptide prior to IF. Indeed, 
we found that the RNAP2 Ser2-P signal was lost in both IF (Figure 2, M to P) and WB 
(Figure 2, Q to R) analyses when the antibody was pre-incubated with the Ser2-P 
peptide, and that the level of Ser2-P was similar between mitotic and asynchronous cells 
when the antibody was not blocked. Given that the antibody we used was raised against 
a synthetic phospho peptide, and not endogenous RNAP2, we needed further evidence 
that the epitope that we were detecting on the mitotic chromatin was in fact RNAP2 and 
not one of the many other phosphorylated proteins present in mitosis. To this end, we 
performed reciprocal immunoprecipitation (IP) followed by immunoblot (IB) analyses with 
the Ser2-P antibody and an antibody against the amino-terminal domain (NTD) of Rbp1, 
which recognizes RNAP2 independent of the CTD phospho status. In both pull downs, 
the antibodies pulled down RNAP2 (Figure 2, S to V). Thus, the epitope detected on 
mitotic chromatin by IF is indeed a form of RNAP2. 
 We repeated the mitotic IF with a second Ser2-P antibody raised against the 
same synthetic Ser2-P peptide. This time, in agreement with previous reports, we found 
that RNAP2 Ser2-P was largely excluded from the mitotic chromatin (Figure 2, W to X). 
These results indicate that there is strong antibody dependence on RNAP2 localization 
in fixed cells, which reinforces the notion that formaldehyde fixation can artifactually 
exclude epitopes. 
 To circumvent the issue of fixation, we obtained a functional RNAP2-EGFP 
fusion construct which was previously shown to rescue temperature-sensitive RNAP2 
mutants (Sugaya et al., 2000). Though the construct was lethal to the cells,  live cell 




(Figure 2, Y to Z). We thus conclude that detection of RNAP2 in mitotic chromatin is both 
antibody dependent and that cases of exclusion are likely due to fixation artifacts, as 
previously reported for transcription factors (Lerner et al., 2016; Teves et al., 2016). 
Importantly, the presence of an active form of RNAP2 in mitosis has been reported at 
the centromere (Liu et al., 2015), but our observation agrees with various hints 
throughout the literature that it is also present at low levels throughout mitotic chromatin 
(Gariglio et al., 1974; Liang et al., 2015; Matsui et al., 1979). 
 
3.6 Mitotic Transcription 
 Based on our above observation that RNAP2 can be detected on mitotic 
chromatin, we next sought to directly quantify RNA synthesis during mitosis. Unlike 
crosslinking-based approaches for detection of RNAP2, which indirectly assess the 
transcriptional state of mitotic chromatin in fixed cells, metabolic labeling of nascent 
transcripts with labeled nucleotide is a direct assessment of RNA synthesis in live, 
mitotic cells. Previously, HeLa cell metaphase spreads were incubated with FITC-UTP to 
allow incorporation of the FITC-UTP into any RNA currently synthesized (Liu et al., 
2015). The spreads were then fixed and imaged. To aid in the analysis, images were 
masked such that only the FITC signal that colocalized with centromeres was visible (Liu 
et al., 2015). Importantly, faint FITC signal was present outside of centromeres, along 
metaphase chromosome arms, once the mask was removed (Figure 3, A to D). 
Furthermore, the detected RNA synthesis was significantly reduced when the cells were 
treated with the transcriptional inhibitor α-amanitin (Figure 3, E to I). From these results 
we conclude that global, low levels of transcription occurs throughout mitotic 




 The previous study (Liu et al., 2015) also found that centromeric transcription is 
dependent on Bub1. The Bub1 kinase phosphorylates H2A T120 at the centromere for 
the recruitment of Sgo and RNAP2 to H2A T120-P nucleosomes (Liu et al., 2015). When 
Bub1 activity is diminished by knock-down or enzymatic inhibition, RNAP2 is no longer 
recruited to the centromere, preventing the transcription of centromeric repeats (Liu et 
al., 2015). Since the transcription of these repeats is necessary for Sgo recruitment, Sgo 
is no longer recruited to protect the centromere, causing the cells to fail to segregate 
properly (Liu et al., 2015). Furthermore, ectopic expression of H2A T120-P was not 
sufficient to recruit RNAP2 to metaphase chromosome arms (Liu et al., 2015). We find 
that RNAP2 transcription along metaphase chromosome arms is Bub1-independent 
(Figure 3 I). Thus, mitotic transcription is occurring distinct from that at the centromere. 
 To assess the profile of global mitotic transcription, we developed EU-RNA-seq 
as a way to capture and sequence nascent RNAs in vivo (Palozola et al., 2017; 
Yokoyama et al., 2016). Mitotic and asynchronous cells were pulse-labeled with the cell 
permeable uridine analogue, 5’-ethynyleuridine (EU) for 40 minutes. The total RNA from 
each sample was harvested and a click reaction was carried out to allow the conjugation 
of biotin azide to the ethynyl group of EU (Jao and Salic, 2008) on any EU-RNAs present 
in the total RNA harvested. Once the click reaction was complete, we added custom, 
biotin-RNA spike-in controls to both mitotic and asynchronous samples (Palozola et al., 
2017), and then streptavidin-coated magnetic beads were used to isolate biotinylated 
RNAs from unlabeled RNAs in each sample. We were then able to generate cDNA 
libraries directly off the magnetic beads for sequencing.  
 After global normalization between the asynchronous and mitotic samples, based 
on the relative spike-in sequence amplification in each replicate, there were 




al., 2017). Of these, 8,074 were reproducibly expressed among all three mitotic 
replicates, accounting for 28% of the genes expressed in an asynchronous population. 
However, the mitotic transcriptome was much lower than in asynchronous, with a five-
fold mean decrement in transcript levels (Palozola et al., 2017). From these studies we 
conclude that mitosis is not a period of transcriptional silence as has long been 
considered the case.  
 
3.7 Hierarchical Reactivation During Mitotic Exit 
 Previous studies from our lab (Caravaca et al., 2013) and others (Kadauke et al., 
2012) measured reactivation of individual genes during mitotic exit by RT-qPCR with 
primers targeting adjacent introns and exons, thus assessing primary transcripts. In 
doing so, it was evident that not all genes are reactivated synchronously and with the 
same amplitude. However, these studies were limited to a handful of genes. We thus 
sought to determine the hierarchy with which the transcriptome returned to interphase 
levels during mitotic exit, on a genome-wide level. We again employed EU-RNA-seq in 
mitotic cells and as cells exited mitosis (Palozola et al., 2017). Intact HUH7 cells were 
pulsed-labeled with EU for 40 minutes during nocodazole-induced mitotic arrest (0’) and 
at 40’, 80’, 105’, 165’, and 300’ after the nocodazole was washed out and the cells were 
allowed to resume cycling.  
 To assess the various dynamics of transcription reactivation we first removed all 
genes that are not expressed in asynchronous HUH7 cells. We then performed 
automated fuzzy c-means clustering (Schwämmle and Jensen, 2010) for each time 
point. Clusters were organized from those with genes most highly expressed at 40’ to 




4).  Four main patterns emerged: 1) genes that are highest at 40’ and then continue to 
decrease (Figure 4, A to D), 2) genes that are highest at 80’ and then continue to 
decrease (Figure 4 E, and G to H), 3) those that increase from 40’ until 105’ or 165’ and 
then decrease (Figure 4, I to K), and 4) those that continuously increase at each time 
point after 40’ (Figure 4, M to N). Thus, as indicated by a small number of genes in 
previous studies (Caravaca et al., 2013; Kadauke et al., 2012), the amplitude of the 
interphase transcriptome is not achieved synchronously during mitotic exit. 
 Since our previous study showed that the liver-specific pioneer factor FoxA 
remains bound to a subset of liver-specific genes during mitosis (Caravaca et al., 2013), 
we originally hypothesized that the first genes to increase expression during mitotic exit 
in our hepatoma cell line would be liver-specific. To test this, we performed Gene 
Ontology (GO) enrichment analysis on early- and late-activated clusters. We were 
surprised to find that genes highest at 40’-80’ (Figure 5, A and E) are those involved in 
basic cellular functions such as transport and signal transduction. Conversely, genes 
that are highest at later time points (Figure 5, L and N) are enriched for genes involved 
in more cell type-specific functions like metabolism. However, because EU-RNA-seq 
measures the rate of transcription by EU incorporation, and shorter transcripts may 
undergo more rounds of transcription than longer transcripts in a given time point, we 
sought to determine whether gene length biased the functional gene categories at each 
time point. To do so, we compared the enriched GO categories of transcripts that first 
increase ≥1.5 fold over mitosis at 40’ or 80’ when quantifying the FPKM over (Figure 5 
P) the entire transcript or (Figure 5 Q) the first 10 kb of transcripts that are ≥10 kb in 
length. Indeed, the enriched GO terms in both scenarios are for basic cell functions. 
Thus, exiting mitosis and rebuilding daughter cells is prioritized over liver-specific gene 




3.8 Enhancer Usage 
 Despite the physical condensation of mitotic chromosomes, global ATAC-seq 
profiles are highly similar between asynchronous and mitotic cells (Teves et al., 2016), 
indicating an overall retention in accessibility at the molecular level. At a finer level, it has 
been shown that promoter accessibility is maintained during mitosis (Hsiung et al., 2015; 
Martínez-Balbás et al., 1995), though enhancer accessibility is lost (Hsiung et al., 2015). 
Long distance interactions are also lost (Naumova et al., 2013), with enhancer-promoter 
loops reforming 60~90’ after nocodazole wash-out, concordant with a spike-in RNAP2 
binding to enhancers and promoters (Hsiung et al., 2016).  
 Given the sensitivity of EU-RNA-seq, we sought to estimate the timing of 
enhancer usage during mitotic exit by using eRNA transcription as a surrogate for 
enhancer activity. We curated all previously-reported human enhancers (Leung et al., 
2015) for those that were both intergenic and have a detectable signal in asynchronous 
HUH7 cells, and clustered them by their expression at each time point (Figure 6). We 
see waves of apparent enhancer reactivation (Figure 6 A), with the largest increase 
occurring at 80’ (Figure 6 B), akin to the large burst in transcription rate increase at 80’ 
(Palozola et al., 2017), and the previously-reported spike in RNAP2 binding at 
enhancers and reformation of enhancer-promoter contacts at 90’ (Hsiung et al., 2016). 
However, the sensitivity of EU-RNA-seq uncovers the dynamics of enhancer usage. 
Interestingly, it is the eRNAs that are most lowly transcribed in asynchronous cells which 
are the first to increase during mitotic exit, with the highest asynchronous eRNAs 
increasing later (Figure 6 C). Based on these observations, we conclude that enhancers 
are not generally employed during low-level mitotic transcription, but are reactivated as 




3.9 Final Remarks 
  Our increasing ability to reprogram cell identity for eventual therapeutic and 
analytic purposes has fostered interest in the basis of identity maintenance during 
mitosis. This interest was originally rooted in early observations of reduced RNA 
production during mitosis and then, with the increasing use of antibody-based detection 
methods such as IF and ChIP, the observation that RNAP2 and several transcription 
factors are evicted from mitotic chromatin. These latter studies have dominated the 
conversation and the original studies showing reduced, but not erased, transcription, 
have been overlooked (Gariglio et al., 1974; Johnson and Holland, 1965; Konrad, 1963; 
Parsons and Spencer, 1997).  
 Here we have re-examined the mitotic transcriptional state in decades of studies. 
The localization of RNAP2 is both antibody- and fixation-dependent, and the complete 
phospho status of the CTD during mitosis remains unclear, though it does carry Ser2-P. 
Furthermore, global RNAP2-dependent transcription is not entirely erased. Indeed, there 
exists a low-level pattern of transcription throughout metaphase cells, which is distinct 
from that at the centromere. We also found that the interphase amplitude of gene 
expression is not achieved synchronously during the transition from mitosis to 
interphase, as gene reactivation occurs in waves, with the earliest waves including 
genes involved in basic cell functions. Gene reactivation appears to be congruent with 
enhancer usage, as eRNA activity also increases in waves during mitotic exit.  
 Based on these observations, and on previous reports of loss of long-range 
interactions (Naumova et al., 2013) and enhancer accessibility during mitosis (Hsiung et 
al., 2015), we propose that mitotic transcription occurs largely in an enhancer-




expression units (MEUs), much like the rudimentary transcriptional units in yeast, which 
lack enhancers. In this MEU model, the cell type-specific gene expression pattern is 
retained throughout mitosis and enhancer usage drives the re-establishment of the 
interphase amplitude of gene expression during mitotic exit (Figure 7). Mutagenesis of 
candidate enhancers will be necessary to confirm an enhancer’s putative target, and 
thus whether enhancer deletion affect interphase, but not mitotic, expression of the 
target gene. Regardless, our data, together with previous reports (Hsiung et al., 2015; 
2016; Martínez-Balbás et al., 1995) indicate that the key to understanding the re-
establishment of the interphase transcriptome during mitotic exit likely lies in how 
promoters maintain transcription of many genes during mitosis, and how enhancers are 








Figure 1. RNA Pol II is a structural constituent of mitotic chromatin.  
 
(A) Analysis of mass spectrometry results from HeLa metaphase chromatin generated in 
(Ohta et al., 2010) shows proteins enriched in chromatin compared to cytoplasmic 







Figure 2. RNA Pol II Ser2-P colocalizes with mitotic chromatin.  
 
HUH7 cells stained with DAPI or Ser2-P in (A-B) interphase, (C-D) prophase, (E-F) 
prometaphase, (G-H) metaphase, (I-J) anaphase, and (K-L) telophase. Metaphase 
HUH7 cells stained with (M) DAPI and (N) Ser2-P, or (O) DAPI and (P) Ser2-P after pre-
incubation with Ser2-P peptide. Mitotic and asynchronous HUH7 whole cell lysate 
blotted with (Q) Ser2-P or (R) Ser2-P after pre-incubation with Ser2-P peptide. 
Reciprocal IP-IB of asynchronous HUH7 cells: (S) IP with Ser2-P and blot for Ser2-P, (T) 
IP with NTD and blot for Ser2-P, (U) IP with Ser2-P and blot for NTD, (V) IP with NTD 




HUH7 cells stained with (W) DAPI and (X) Ser2-P. Overlay indicates Ser2-P is enriched 
around the periphery; Ser2-P antibody, ab5095 GR99671. (Y) HUH7 cell transiently 







Figure 3. Transcription on metaphase chromosome arms is independent of Bub1.  
 
HeLa metaphase spreads labeled with FITC-UTP without (A-B) and with (C-D) α-
amanitin treatment. solid arrows, FITC at centromere; dashed arrows, FITC on 
chromosome arms; boxes, no FITC detected above background. (E) Quantification of 
FITC-UTP signal over chromosome arms, with and without α-amanitin or Bub1 siRNA 







Figure 4. Dynamic patterns of reactivation during mitotic exit.  
 
Cluster analysis of the dynamic transition in expression amplitude during mitotic exit. 
Clusters are ordered from those with genes highly expressed at 40’, to genes highly 







Figure 5. Basic cell functions are prioritized during mitotic exit.   
 
(A-O) Heatmap of the clusters shown in figure 4, including representative enriched GO 
categories. (P) Representative enriched GO terms for genes that first increase ≥1.5 fold 
over mitosis at 40’ or 80’. (Q) Representative enriched GO terms for genes associated 






Figure 6. eRNAs are activated in waves during mitotic exit.  
 
(A) FPM z-score of intergenic enhancers. hierarchical cluster number on the left; number 
of eRNAs in each cluster on the right; n = 709. (B) log2 fold increase of each eRNA over 
mitosis (0’) for  eRNAs that first increase at each time point. n, top 250 eRNAs most 
highly expressed at that time point; Wilcoxon rank-sum test between each time point and 
80’. (C) Asynchronous FPM of each eRNA that first increases over mitosis (0’) for the 
first time at each time point. n, top 250 eRNAs with the highest fold change at that time 
point; Wilcoxon rank-sum test between each time point and asynchronous. n.s., not 







Figure 7. Enhancer usage is diminished in mitosis and is re-established during 
mitotic exit.  
 
Interphase cells use enhancers to drive the cell type-specific gene expression program, 






3.11 Materials and Methods 
Re-Analysis of Mitotic Mass Spectrometry Data 
	   The mass spectrometry of mitotic chicken cells was performed by (Ohta et al., 
2010) and colleagues, and table S1, category CII contains the proteins enriched over 
cytoplasm. The top 5% of proteins enriched over the cytoplasm were excluded from the 
data set and the remaining values were plotted for the following categories: chaperones, 
cytosolic, mitochondria, RNAP2, centromere, and telomere. 
 
Immunofluorescent Labeling of RNAP2 
 HUH7 cells were fixed in 4% PFA for 30 minutes at room temperature, 
permeabilized with 0.5% Triton X-100 for 30 minutes at room temperature, blocked in 
10% FBS/0.1% Triton X-100 for 3 hours at room temperature, and incubated with 1 
ug/mL primary antibody in 10% FBS/0.1% Triton X-100 overnight at 4˚C. A Nikon 
inverted widefield microscope was used to image the fixed cells at 30X magnification. 
For peptide blocking, antibody was first incubated with 2X peptide ab12793 in blocking 
media for at least an hour at room temperature. 
 
Western Blot Analysis of RNAP2 
 Mitotic and asynchronous HUH7 cells were harvested in cold PBS and 
resuspended in RIPA buffer (with protease inhibitors). The cells were then sonicated on 
a bioruptor for 5 minutes (30 s on, 30 s off), centrifuged at max speed at 4˚C, and the 
pellet was discarded. Following protein quantification, 1X and 3X cell equivalents of the 




onto PVDF membrane. The membrane was incubated in blocking buffer (5% BSA, 0.1% 
Tween in PBS) at room temperature for 2 hours. The primary antibodies were diluted 
1:5,000 in blocking buffer and added to the membrane for 2 hours at room temperature. 
For peptide blocking, the antibody was first incubated with 2X peptide for 1 hour at room 
temperature. 
 
Reciprocal Immunoprecipitation of RNAP2 
 HUH7 cell were arrested in mitosis with nocodazole and harvested by shake off, 
as described in Chapter 2. Mitotic whole cell lysate was then prepared as described 
above. Lysate was diluted in binding buffer (20 mM Tris-Cl ph 8, 137 mM NaCl, 10% 
glycerol, 1% NP-40, 2 mM EDTA, protease inhibitors, phosphatase inhibitors) and 
rocked at 4˚C to complete the lysis. Antibody (2 ug) was added to the lysate (100 ug) 
and rotated overnight at 4˚C. rProtein G Agarose beads (50 uL) were resuspended in 
blocking buffer (5% BSA in TBS-tween) and rotated overnight at 4˚C. Lysate/antibody 
was added to the blocked beads and rotated for 2 hours at 4˚C. Beads were washed 
with TBS-tween and the samples were denatured and run on a 3-8% Tris-Acetate gel 
before transfer onto a PVDF membrane. The membrane was incubated in blocking 
buffer (5% BSA, 0.1% Tween in PBS) at room temperature for 1 hour. The primary 
antibodies were diluted 1:1,000 for Ser2-P ab5095 GR57686 and 1:200 for sc-899 N-20 
(as per manufacturer recommendations) in blocking buffer and added to the membrane 





Live Cell Imaging of RNAP2-EGFP 
 The RNAP2-EGFP construct was given to us by Dr. Kimihiko Sugaya (Sugaya et 
al., 2000).  Cells were transfected into asynchronous HUH7 cells with lipofectamine and 
imaged with the help of Dr. Andrea Stout on the EVOS FL Auto Imaging System at the 
Cell and Developmental Biology Microscopy, Perelman School of Medicine, University of 
Pennsylvania. Images were processed in Image J. 
 
FITC-UTP Labeling of Metaphase HeLa Cells 
 As previously described (Liu et al., 2015), the chromosome spreads were firstly 
treated with 0.2 % Triton X-100 and then FITC-UTP (+/- α-amanitin) was added onto 
slides. The slides were then incubated at room temperature for 20 minutes to allow 
transcription to incorporate FITC-CTP into newly synthesized RNA. The cells were then 
fixed with 4% paraformaldehyde and stained with DAPI. Fluorescence was observed 
with a microscope. Fluorescence intensities of DNA and RNA on chromosome arms 
were converted into numerical values by Image J. After background subtraction, the 
mean intensities of DNA and RNA for each cell were obtained. The values of RNA 
intensity were normalized to DAPI intensity to obtain relative intensity.  
 
Clustering of FPKMs During Mitotic Exit 
 From the original FPKMs table, non-expressed genes or genes expressed in 1 
single time point and having a FPKM value lower than 19 have been removed. Unique 
values have been considered by removing duplicates. This led to a reduction in the 
number of the transcript ID from 48,205 to 32,098. Automated fuzzy c-means clustering 




(Schwämmle and Jensen, 2010). Clusters were organized from clusters showing genes 
expressed mainly at t=40 to clusters showing genes highly expressed in the 
asynchronous population of cells. The heatmap was generated by averaging the z-
scores of the individual time points within each cluster. Gene Ontology analysis was 
performed with Gorilla (Eden et al., 2009) using the “two unranked lists of genes” option. 
Genes belonging to representative clusters (target set) were compared to all the genes 
considered in the clustering analysis (background set).  
 
10 kb Transcript Fragment FPKMs 
 For all transcripts that were at least 10 kb in length, we reassigned the 
transcriptional stop site to be 10 kb downstream of the transcriptional start site. We then 
calculated the FPKM over these 10 kb transcript fragments at all time points. For all 10 
kb transcript segments that had an FPKM of at least 19 in the asynchronous population, 
we pulled out those that had an FPKM at least 1.5 fold higher than the FPKM in mitosis 
(0’) for the first time. That is, if the FPKM is 1.5 fold higher at 80’ min than at 0’, but less 
than 1.5 fold higher at 40’ than at 0’ then that transcript was called an 80’ transcript.  
 
Gene Ontology Enrichment Analysis 
 Unique genes corresponding to the 10 kb transcript fragments found to first 
increase at a specific time point were used to perform GO analysis for cellular 
component, molecular function, and biological process categories on DAVID (Huang et 
al., 2009; 2008), relative to all total length transcripts with an FPKM of at least 19 in the 
asynchronous population and ≥1.5 fold higher than in mitosis (i.e. expressed in 




the GO analysis of the full length transcripts (Chapter 2) and of the 10 kb transcript 
fragments.  
 
eRNA Curation and Clustering 
 As in Chapter 2, the 292,429 enhancers from Leung et al. were mapped to hg19 
and measured for RNA FPM during mitosis and mitotic exit. Enhancers were defined as 
-200 to +200 bp around the central nucleotide position and were associated to genes by 
the nearest TSS and classified by the time of first 1.5 fold increase of their putative 
regulatory targets. Only intergenic enhancers, those falling into the region 1kb to 100kb 
upstream of their target gene, without overlapping other genes, were considered. 
Because high EU-RNA-seq background was detected at SINE elements, all tags 
overlapping annotated SINE elements were removed. The FPMs of both + and – strand 
non-SINE nascent EU-RNA-seq tags were then averaged at the enhancer locus.  
 To rule out enhancers inactive in asynchronous cells, the enhancers were filtered 
to remove those with an FPM ≤ 0.1 in the asynchronous state. To eliminate enhancers 
which occur in regions of broad background enrichment, for each enhancer two 
additional intergenic 1 kb windows 1.2 kb away from the enhancer centers were 
measured for EU-RNA-seq signal. Each enhancer was tested to see whether its fold 
over background at the activation time was greater than 2X (the background was the 
maximum of both strands on both regions). Enhancers failing this filter (or without a 
matching background region) were rejected. All enhancers, independent of time of first 
increase of their target gene, were clustered by the z-score of their transcription level at 





eRNA Curation and Identification of eRNAs First Increased at Each Time Point  
 Enhancers identified by (Leung et al., 2015) were filtered to exclude those 
outside 1-100 kb upstream of the TSS for all RefSeq genes and those in gene bodies. 
FPM scores reflect the average of both strands at a 400 bp window surrounding the 
enhancer site. SINE overlapping EU-RNA-seq tags were excluded. For all eRNAs that 
had an FPM of at least 0.1 in the asynchronous population, we pulled out those that had 
an FPM at least 1.5 fold higher than the FPM in mitosis (0’) for the first time. That is, if 
the FPM is 1.5 fold higher at 80’ min than at 0’, but less than 1.5 fold higher at 40’ than 
at 0’ then that eRNA was called an 80’ eRNA.  
 
Statistics 
 A two-tailed t-test was performed in Excel between control and α-amanitin-
treated cells in figure 3E. For Gene Ontology enrichment, significant categories were 
filtered for those that were at least 1.3 fold enriched over background with the FDR 
controlled at 10% in figure 5P-Q. A Wilcoxon rank sum test was performed between 
each group and 80’ in figure 6B. A Wilcoxon rank sum test was performed between each 




CHAPTER 4: PERSPECTIVES AND FUTURE DIRECTIONS 
	  
4.1 Summary of Major Conclusions 
 Mitosis has long been assumed to pose a challenge to cell identity maintenance, 
based on a few key observations. The first observation is that chromatin is drastically 
rearranged in mitosis: visually, it appears much more compact than in interphase, 
interactions with the nuclear envelope are dismantled, and higher-order chromatin 
structures are lost in mitosis (Naumova et al., 2013). Much along the lines of 
heterochromatin, it was assumed that mitotic chromatin is too condensed to be 
accessible to transcriptional machinery. However, several recent studies have begun to 
demonstrate that not only is mitotic chromatin not nearly as compact as it appears 
(Vagnarelli, 2013), but it is certainly accessible to transcriptional machinery (Chen et al., 
2005; Teves et al., 2016).  
 In addition, decades of studies have used antibody-based detection of proteins in 
fixed cells to demonstrate the absence of the majority of transcriptional machinery from 
mitotic chromatin. In recent years, these results have been challenged by the discovery 
that formaldehyde fixation causes the mitotic-specific exclusion of many proteins from 
mitotic chromatin (Lerner et al., 2016; Teves et al., 2016). When tagged with a 
fluorescent protein and then imaged in live cells, several transcription factors that are 
shown to be excluded from mitotic chromatin in formaldehyde-fixed cells are clearly 
colocalized with mitotic chromatin in the absence of fixation (Teves et al., 2016). Yet, 




whether the gene expression program ever truly shut down, and if so, whether 
reactivation of the interphase transcriptome is a synchronous or hierarchical process. 
 Along those lines, the most frequently cited evidence for mitosis as a challenge 
to cell identity comes from the assumed absence of RNA synthesis during mitosis. As far 
back as the 1960’s, crude quantification of radio-labeled nascent transcripts showed that 
mitotic cells produce significantly less RNA than do interphase cells (Parsons and 
Spencer, 1997; Prescott and Bender, 1962; Taylor, 1960). A closer look at the data 
presented often shows that, depending on the gene, mitotic transcription occurs 
anywhere from 5% to 40% of interphase levels (Gariglio et al., 1974; Johnson and 
Holland, 1965; Konrad, 1963). If not for the assumption that mitotic chromatin is simply 
too compact to allow for transcription, the residual RNA synthesis in these studies would 
have warranted investigation into the extent and character of mitotic transcription. 
However, there was no way to directly capture and sequence nascent transcripts in 
mitotic cells. 
 The conventional method for sequencing nascent transcripts (GRO-seq), and 
more recent variations of the protocol, are not suitable for mitotic studies. Because 
bromouridine, the RNA label used in these protocols, is not cell permeable, the cells are 
first lysed and the nuclei are harvested prior to labeling in vitro. At the onset of mitosis, 
the nuclear envelope is disassembled and so lysis of the cells at this phase would not 
allow for isolation of the mitotic chromatin. To circumvent this issue, we developed a new 
method for nascent RNA sequencing, EU-RNA-seq. Since EU is cell-permeable, we are 
able to add EU directly to the growth media, thus allowing for labeling of nascent 
transcripts in intact cells in vivo. We have confirmed that isolation of the labeled RNAs is 




 The sensitivity of our approach revealed extensive, low-level transcription 
throughout the genome in mitosis. Approximately 28% of interphase-expressed genes 
are also expressed to some degree in mitosis. Importantly, we were able to control for 
the difference in basal levels of transcription between mitotic and asynchronous cells 
with the use of custom biotin-RNA spike-in controls. We further tested for interphase 
contamination using computational models of the asynchronous transcriptome, and 
found that the mitotic transcriptome was unique from that which we would expect from a 
contaminating interphase transcriptome.  
 To further validate our sequencing, we employed FITC-UTP labeling and imaging 
in mitotic and interphase cells, with and without transcription inhibition. These imaging 
analyses confirmed the existence of global, low-level, RNAP2-dependent transcription 
along metaphase chromosome arms in both transformed and non-transformed cell lines. 
In contrast, knockdown of Bub1, which is required for transcription at the centromere (Liu 
et al., 2015), did not affect transcription along the metaphase chromosome arms, 
indicating that global mitotic transcription is occurring independent of that at the 
centromere. We used single molecule RNA FISH to show that mitotic transcription is not 
due to the prolonged mitosis resulting from nocodazole blocking. Based on these 
studies, we conclude that mitosis is not a period of transcriptional silence, as has long 
been assumed. 
 This work was also the first to directly capture and sequence nascent RNAs as 
cells transition from mitosis to G1. Due to the sensitivity of EU-RNA-seq, we found that 
transcription is not reactivated in one large burst, as has been suggested by indirect, 
antibody-based assessments of RNAP2 localization (Caravaca et al., 2013; Hsiung et 
al., 2016). Rather, the interphase transcriptome arises through dynamic alterations in 




that the first transcripts to pick up during mitotic exit are those involved in basic cell 
functions. Though the more cell type-specific genes are expressed early in mitotic exit, 
their transcription rate remains relatively low until the end of mitotic exit and the 
beginning of G1. This is in contrast to our original hypothesis that the cell type-specific 
genes would be prioritized in early mitotic exit. The original hypothesis was based on a 
narrow view of the few genes which distinguish a liver cell from vastly different cell types, 
and did not take into consideration that fact that the majority of the transcriptome 
contributes to a cell identity. 
 In an attempt to understand how the robust interphase transcriptome arises from 
the basic cohort of genes lowly expressed in mitosis, we looked to enhancers. Previous 
studies had shown that promoters retain accessibility in mitosis, though enhancers do 
not (Hsiung et al., 2015; Michelotti et al., 1997), and another recent study indicated that 
enhancer-promoter loops are broken down in mitosis and re-established during mitotic 
exit (Hsiung et al., 2016). In keeping with these studies, we also found a reduction in 
enhancer usage during mitosis, as quantified by eRNA transcription. However, rather 
than a simple, genome-wide activation of enhancer usage, we found that, like their 




 Since mitosis is not a period of transcriptional silence, cell identity, at least at the 
level of the transcriptome, may not be as challenged during division. Indeed, mitotic 
transcription itself may be an epigenetic mechanism, carrying forward the minimal 




genes may have evolved to continue transcribing off the promoter as the chromatin 
rearranges. Though the transcript output decreases to the low levels that we see in our 
study, the reduction in expression is likely due to the fact that enhancer-promoter loops 
are broken and the nuclear envelope is disassembled, which would decrease the 
efficiency of RNAP2 recruitment and local concentration, respectively. 
 Despite the breakdown and detachment of the nuclear envelope, recent studies 
have shown that much of a mitotic chromosome is not made up of chromatin. In fact, as 
much as 30~50% of the total mass is non-histone protein, a significant portion of which 
resides in the layer that coats each mitotic chromosome (Booth et al., 2016; Ohta et al., 
2010). These proteins, notably Ki-67, are located in the nucleolous in interphase and are 
relocated to the surface in late prophase (Cuylen et al., 2016; Gautier et al., 1992). The 
role of Ki-67 is believed to be of a “biological surfactant” as knock-down of Ki-67 causes 
the individual mitotic chromosomes to clump together (Booth et al., 2016; 2014; Cuylen 
et al., 2016). Further, Ki-67 is actually required for the assembly of mitotic chromosomes 
(Booth et al., 2014).  
 Given these important functions of at least one of the surface proteins, it is 
intriguing to think of the role that global mitotic transcription may play in their recruitment 
or assembly. Conversely, the mitotic chromatin surface may serve to protect mitotic 
transcription. As Ki-67 is an amphilic protein – the CTD is attracted to chromatin 
whereas the NTD is largely unstructured and attracted to the cytoplasm – it may provide 
a phase transition between the cytoplasm and chromatin to protect the chromatin in the 
absence of the nuclear envelope. In such a scenario, it may be possible that enough 
transcriptional machinery remains trapped inside, allowing for the low-level transcription 
that we have seen. This model may also explain the observed role for importins in 




 On a more local level, we cannot over-look the 484 genes in HUH7 cells that, by 
EU-RNA-seq, appear to be more highly transcribed in mitosis than in asynchronous 
cells. These loci themselves may play an important structural role. Much like 
transcription at the centromere, where RNAP2-dependent transcription is required for 
the recruitment of Sgo to protect cohesin from displacement during sister chromatin 
resolution (Liu et al., 2015), mitotic transcription outside of the centromere may also play 
a structural role. One way to test this may be to perform immuno-FISH for the mitotically-
enriched genes to visualize their genomic location in the mitotic chromatin relative to the 
periphery, mitotic spindle, or other structures.  
 Alternatively, mitotically-enriched transcripts may be required for cell cycle 
regulation as several were assigned gene ontology terms for cell cycle and transcription. 
Yet, it is difficult to speculate about the function of these transcripts as their stability has 
not been assessed. It is always possible that the mere act of their transcription, and not 
the role of the resulting transcripts, provides the epigenetic memory. If so, it is possible 
that the residual RNAP2 left behind in mitosis continues transcribing. In turn, the 
chromatin would remain open, thus preserving the accessibility of important genes for 
when mitosis is complete. 
 
4.3 Re-establishing genome architecture during mitotic exit  
 It is of great interest to understand the role of mitotic transcription in the structural 
rearrangements of the chromatin during the transition in and out of the mitotic state. To 
this end, we attempted to map higher-order chromatin structures by Hi-C during mitotic 
exit. The goal was to overlay loci of transcription rate increase at each time point with 




insight into whether transcription drives structure or vice versa. Unfortunately, the HUH7 
cells that we used in our study have several inversions, deletions, and rearrangements 
relative to the consensus human genome. Due to the nature of Hi-C analysis, our 
collaborator informed us that it would be difficult to map contacts with a high degree of 
certainty using data generated from non-consensus genome. For example, what appear 
to be strong TAD boundaries may be genomic inversions mapped to the consensus 
human genome. We were thus unable to gather structural information from our system. 
 
4.4 Future Directions 
 The immediate next step is to test the MEU model. The enhancer-promoter units 
(EPUs) that were used for the analysis in Chapter 2, Figure 4C were not experimentally 
verified. That is, we assigned enhancers to the nearest promoter and whether or not the 
enhancer was intergenic. This method of assigning the nearest promoter to an enhancer 
is far from ideal since enhancers can act on genes thousands of kb away with genes in 
between them. However, it is still a reasonable first approach. 
 In testing the MEU model the first step will be to validate candidate EPUs. To do 
so, we will use CRISPR/Cas9 genome editing to delete the 200 bp around the center 
point of a candidate enhancer. Once the deletion is confirmed by PCR, we will quantify 
the putative target gene’s expression with and without the deletion in asynchronous 
cells. If the enhancer does indeed act on that gene, then we will see a significant 
reduction in expression of the gene when the enhancer is deleted compared to wild type. 
Alternatively, capture-C may be used to discover enhancer-promoter loops, using the 
promoter of a gene expressed in mitosis as bait to identify enhancers. For confirmed 




enhancer, in mitotic and asynchronous cells. If enhancers are not required for mitotic 
transcription, but are required for expression in interphase, then we will see a significant 
reduction in expression of the target gene in asynchronous cells when the enhancer is 
deleted versus when it is not, but will not see this change in mitotic cells. 
 It will also be of great interest to assess the role of global transcription in mitosis, 
however it may take clever engineering to circumvent the requirement for transcription at 
the centromere. One possibility may be to forcibly tether Sgo to the kinetochore so that 
RNAP2 is not necessary to recruit it. In this case, it will be important to consider the 
method of forcible tethering and whether it would impact endogenous Sgo function. In 
addition, the forcible tethering would need to be reversible since Sgo needs to be 
removed once the metaphase plate is established, so that cohesin can be removed. 
Thankfully, the Blobel group and others have already shown that fusion of the 
degradation domain of cyclin B1 to any protein causes that protein to be targeted to and 
degraded by the anaphase-promoting complex (Kadauke et al., 2012; Liu et al., 2017b).  
 Given the known relationship between transcription and structure, it will be of 
interest to repeat the mitotic exit EU-RNA-seq in a cell line more favorable to Hi-C 
analysis. Studies from the Gilbert lab have already performed 4-C during mitotic exit and 
showed that TADs reform at the same time as replication domain boundaries (Dileep et 
al., 2015). This finding reinforces the notion that TADs, while not cell type-dependent, 
serve as boundaries for replication domains (Pope et al., 2014) which are cell type-
dependent (Hansen et al., 2010; Hiratani et al., 2010; 2008; Pope et al., 2012; Rivera-
Mulia et al., 2015; Ryba et al., 2010). Given our work, I would like to see if the timing of 
TAD/replication domain boundary establishment is concordant with transcription during 





 The focus of this dissertation has been on transcription, though it is quite likely 
that protein stability also plays an important role in cell identity maintenance during 
mitosis. To start, two bookmarking studies in embryonic stem cells showed that Sox2 
(Deluz et al., 2016) and Oct4 (Liu et al., 2017b) are required in mitosis for maintenance 
of pluripotency after division. In addition, a previous study from our lab showed a 
spectrum of protein stability of liver transcription factors during mitosis in HUH7 cells 
(Caravaca et al., 2013). In fact, it was the transcription factors that played the most 
prominent role in liver cell identity that remained most stable in mitosis, whereas those 
that were involved later in liver cell development were more likely to be displaced from 
the chromatin or degraded in mitosis (Caravaca et al., 2013). It has also been shown 
that the order of action of transcription factors on a genome affects the resulting cell 
identity (Iwasaki et al., 2006), a concept well understood in the reprogramming 
community. Together, these studies suggest a model in which the transcription factors 
that are degraded in mitosis are those that, if not degraded, may be able to act on the 
genome during mitosis or early in mitotic exit. It will therefore be of great interest to 
investigate the regulation of protein stability in mitosis and how it may or may not affect 
the transcriptome as it transitions from mitosis to interphase. 
 Interactions between the chromatin and nuclear envelope are also known to 
impart cell identity. Given that the nuclear envelope is disassembled in mitosis, it is 
unclear as to how the chromatin is organized in the daughter nucleus such that the 
proper contacts are made with the newly-formed nuclear envelope. Prophase chromatin 
structures begin to form where the chromatin contacts the inner nuclear membrane 
(Booth et al., 2016), though it is not clear which components are making the contacts. It 
is possible that whatever they are, be it the lamina, nucleoporins, etc., that it stays 




reassembly of the envelope around the chromatin in the daughter nuclei. If transcription 
plays a role in envelope reassembly, then there may be a correlation between such 
regions and the early or late activated genes. 
 Lastly, the importin proteins of the nuclear envelope may also support ongoing 
transcription in mitosis. Though they are associated with the nuclear envelope and so 
are seemingly absent from mitotic chromatin, a recent study by Lerner and colleagues 
demonstrated their role in mitotic protein localization (Lerner et al., 2016). Based on the 
rapid relocalization of a temperature-sensitive HNF1β mutant to mitotic chromatin when 
shifted to the permissive temperature, the authors speculated that localization to mitotic 
chromatin may involved an active process. It was previously understood that the Ran-
importin-β system, which acts to shuttle proteins between the nucleus and the 
cytoplasm, was also required for mitotic spindle assemble (Clarke and Zhang, 2008). 
Indeed, the addition of importazole, which specifically inhibits importin-β (Soderholm et 
al., 2011), resulted in the diminished and delayed relocalization of the temperature-
sensitive HNF1β mutant to mitotic chromatin when shifted to the permissive temperature 
indicating a role for the Ran-importin-β system in localization to mitotic chromatin (Lerner 
et al., 2016). 
 We could also apply importazole during mitotic arrest or mitotic exit, to assess 
the requirement for importins in mitotic transcription and during mitotic exit, respectively. 
The concept of importin complexes to maintain local concentration of transcriptional 
machinery is appealing given the absence of the nuclear envelope in mitosis. Such a 
model may also explain the “mitotic advantage” in which somatic cell nuclear transfer 
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APPENDIX A: EU-RNA-SEQ PROTOCOL 
	  
 This appendix provides a detailed overview of the EU-RNA-seq protocol used in 
Chapters 2 and 3. It was specifically designed for HUH7 cells either arrested in mitosis 
or during mitotic exit. Variations in cell permeability require cell type-specific optimization 
of EU-labeling. The protocols outlined in this appendix are based on those published by 
Invitrogen and NuGEN, but were adapted to allow for the use of low amounts of RNA 
tethered to beads. All adjustments to the published protocols were designed by myself, 
with guidance from Dr. Zaret. 
 
I. Objective 
 EU-RNA-Seq is unique from other version of nascent RNA sequencing due to the 
ability of EU to permeate the cell membrane, thus allowing for the labeling of transcripts 
in whole cells. 
 
II. Reagents 
 Invitrogen Click-iT Nascent RNA Capture Kit Cat No. C10365 






EU-Labeling and Total RNA Harvest 
 HUH7 cells were pulse labeled with 0.5 mM EU in standard growth media for 40 
minutes at 37˚C. The media was removed and the cells were collected with TRIzol 




Prepare 2.3 ug sample in a final volume of 15.75 uL water (to accommodate a 50 uL 
click reaction, see below). 
 
Invitrogen’s Click-iT Nascent RNA Capture Kit 
 










Pipette up and down to gently mix after the addition of each component. 
*exactly 3 minutes between addition of E and addition of F 
 
Incubate at room temp (24˚C) on heat block while rotating 700 RPM for 30 minutes. 
 
order component stock conc. final conc. volume per rxn 
1 water - - - 
2 Click-iT buffer (B) 2X 1X 25 uL 
3 CuSO4 (D) 25 mM 2 mM 4 uL 
4 biotin azide (C) 10 mM 0.5 mM 2.5 uL 
5 EU-RNA - - 15.75 uL 
6* additive 1 (E) 400 mM 10 mM 1.25 uL 





1. Add 1 uL of glycogen, 50 uL of 7.5 M ammonium acetate, and 700 uL of chilled 
100% EtOH, invert the tube to mix and incubate at -70˚C overnight. 
2. Spin at 13,000 x g for 20 minutes at 4˚C. 
3. Remove the supernatant from the tube without disturbing the pellet and add 700 
uL of chilled 75% EtOH. 
4. Vortex briefly to mix and spin t 13,000 x g for 5 minutes at 4˚C. 
5. Repeat the 75% EtOH wash. 
6. Let the pellet air dry at room temperature.  
7. Thoroughly resuspend the pellet in 10 uL water. 
 
Pull-Down and Library Generation 
 
DAY ONE: ~6.5 hours 
 
Sign up for machines: start time are relative to the time you begin sample prep 
1. heat block @ 69˚C for 5 minutes at 1.5 hours 
2. heat block @ 24˚C for 30 minutes at 1.5 hours 
3. qPCR machine for 3 hours at 3.5 hours 
 
Sample Set up:  
For each sample, combine 1.7 ug input, 5e-5 ug control #1, 5e-4 ug control #2, and bring 
the total volume to 10 uL. 
  
Invitrogen’s Click-iT Nascent RNA Capture Kit 
 
Perform the biotin-EU-RNA pull-down, as per manufacturer’s protocol, but with only 5 uL 
beads. The wash and elution volumes have been adjusted accordingly. 
1. dispense 5 uL beads per sample into a 1.5 mL eppi 
2. wash 3X with 9 uL of wash buffer 2 (per 5 uL beads) 
3. resuspend beads in 5 uL of wash buffer 2 (per 5 uL beads) 
4. dilute RNaseOUT 1:10 by adding 2 uL to 18 uL water 







6.  add 15 uL to each 10 uL sample  
7.  incubate on heat block at 69°C for 5 minutes 
8.  add 5 uL pre-washed beads to each reaction 
9.  incubate on a heat block at 24°C for 30 minutes at 700 RPM 
10.  use magnetic rack to wash beads:  
a. 5X with 50 uL of wash buffer 1 
b. 5X with 50 uL of wash buffer 2 
11.  resuspend beads in 5 uL wash buffer 2 
 
Component 1X 
Click-iT buffer (G) 12.5 uL 
RNaseOUT 0.2 uL 




NuGen’s Ovation Human FFPE RNA-Seq kit: First Strand cDNA Synthesis 
Perform as per manufacturer’s protocols with the noted adjustments. 
 
Remove the following from -20°C storage: 
a. First Strand Primer Mix (blue: A1 ver 13)  
b. First Strand Buffer Mix (blue: A2 ver 8) 
c. First Strand Enzyme Mix (blue: A3 ver 4) 
d. Nuclease-Free Water (green: D1)  
2. Spin down the contents of A3 and place on ice. 
3. Thaw the other reagents at room temperature, mix by vortexing, spin and place 
on ice. Leave the Nuclease-Free Water at room temperature. 
4. Add 2 uL of A1 to a 0.2 mL PCR tube. 
5. Transfer the 5 uL sample/beads to the tube with A1. 
6. Mix by pipetting (at least half volume) 5 times and place on ice. 
7. Place tubes in a pre-warmed thermal cycler programmed to run Program 1. 
a. Program 1 = ORSP1 and is used for primer annealing 
i. 65°C – 1 minute 
8. Immediately remove the tubes from the thermal cycler and snap chill on ice.  
9. Once Primer Annealing (step 7) is complete, prepare a master mix by combining 





10. Add 3 uL of the First Strand Master Mix to each sample tube. 
11. Mix by pipetting (at least half volume), cap the tubes and place on ice. 
12.  Place the tubes in a pre-warmed thermal cycler programmed to run Program 2. 
a. Program 2 = ORSP2 and is used for first strand cDNA synthesis 
i. 25°C – 5 min 
ii. 40°C – 5 min 
iii. 70°C – 15 min 
iv. hold at 4°C 
b. Adjustment to protocol: remove samples and pipette up and down (at 
least half volume) every few minutes to keep beads from settling 
13. Remove the tubes from the thermal cycler, spin to collect condensation and 
place on ice. 
14. Continue immediately to Second Strand cDNA Synthesis protocol. 
 
NuGen’s Ovation Human FFPE RNA-Seq kit: Second Strand cDNA Synthesis 
Perform as per manufacturer’s protocols with the noted adjustments. 
 
1. Remove the following from -20°C storage: 
a. Second Strand Buffer Mix (yellow: B1 ver 6) 
b. Second Strand Enzyme Mix (yellow: B2 ver 4) 
c. Second Strand Stop Mix (yellow: B3 ver 2)  
2. Spin down the contents of B2 and place on ice. 
3. Thaw reagents B1 and B3 at room temperature, mix by vortexing, spin and place 
on ice. 
4. Prepare a master mix by combining B1 and B2 in a 1.5 mL capped tube. 
 
 BLUE: A2 ver 8 BLUE: A3 ver 4 




 YELLOW: B1 ver 6 YELLOW: B2 ver 4 
1X 63 uL 2 uL 
 
5. Add 65 uL of Second Strand Master Mix to each First Strand reaction tube. 
6. Mix by pipetting (at least half volume) and place on ice. 
7. Place the tubes in a pre-cooled thermal cycler programmed to run Program 3. 
a. Program 3 = ORSP3 and is for second strand cDNA synthesis 
i. 16°C – 60 minutes 
ii. hold at 4°C 
b. Adjustment to protocol: remove samples and pipette up and down (at 
least half volume) every few minutes to keep beads from settling 
8. Remove the tubes from the thermal cycler and spin to collect condensation. 
9. Add 45 uL of the Second Strand Stop Buffer, B3. Mix by pipetting (at least half 
volume) and spin to collect. 
10. Adjustment to protocol: Transfer to 1.5 mL tube and place on magnetic rack for at 
least 2 minutes to remove streptavidin-coated magnetic beads. Store at -20°C. 
 
DAY TWO: ~7 hours 
Must know which adapters go with each sample before beginning. 
 
Sign up for machines: start time are relative to the time you begin sample prep 
1. Covaris – begin to cool down at 0 hours 
2. qPCR for 2.5 hours at 3 hours 
 
cDNA Fragmentation: 
1. Turn on Covaris and begin cooling, takes ~1 hour. 
2. Thaw samples on ice. 
3. Transfer each sample to a Covaris microtube and top off with TE. 
a. This is a good time to put the Agencourt RNAClean XP beads and 
Nuclease-Free Water (D1) at room temperature since they need to sit for 
at least 15 minutes. 
4. Perform sonication with the following parameters (specific to HUH7 cells): 
a. W: 175 
b. Duty Factor: 10% 
c. Cycles per burst: 200 
d. Treatment time (s): 180 
e. Temperature (°C): 7 (5-9) 
5. Once sonication is complete, transfer the sample to a fresh 1.5 mL tube and 
measure and record the recovered volume. 
 
cDNA Concentration After Fragmentation: 
1. Ensure the Agencourt RNAClean XP beads and Nuclease-Free Water (D1) have 
completely reached room temperature. 
2. Resuspend the beads by inverting and tapping the tube. Ensure the beads are 
fully resuspended before adding to the samples. After resuspending, do not spin 
the beads.  





4. Prepare a 70% EtOH wash solution. It is critical that this solution be prepared 
fresh on the day of the experiment from a recently opened stock container. 
Measure both the EtOH and the H2O components carefully prior to mixing. 
Failure to do so can result in a higher than anticipated aqueous content, which 
may reduce yield.   
5. At room temperature, add fragmented cDNA to the 234 uL of the bead 
suspension. Adding the DNA to the beads results in tighter bead pellets that are 
much easier to resuspend.  
6. Mix thoroughly by pipetting up and down (at least half volume). 
7. Split each sample into two equal aliquots of 182 uL. 
8. Incubate at room temperature for 10 minutes. 
9. Transfer tubes to the magnetic rack and let stand 5 minutes to completely clear 
the solution of beads. 
10. Carefully remove 167 uL of the binding buffer and discard it. Leaving some of the 
volume behind minimizes bead loss at this step. 
a. Note: The beads should not disperse; instead, they will stay on the walls 
of the tubes. Significant loss of beads at this stage will impact the amount 
of DNA carried into end repair, so ensure beads are not removed with the 
binding buffer or the wash. 
11. With the tubes still on the magnet, add 200 uL of freshly prepared 70% EtOH and 
allow to stand for 30 seconds.  
12. Remove the 70% EtOH wash using a pipette. 
13. Repeat the 70% EtOH wash one more time, for a total of two washes. 
a. Note: With the final wash, it is critical to remove as much of the EtOH as 
possible. Use at least two pipetting steps and allow excess EtOH to 
collect at the bottom of the tubes after removing most of the EtOH in the 
first pipetting step. 
14. Air-dry the beads on the magnet for 10 minutes. Inspect each tube carefully to 
ensure that all of the EtOH has evaporated. It is critical that all residual EtOH be 
removed prior to continuing. 
15. Remove the tubes from the magnet. 
16. Add 12 uL room temperature Nuclease-Free Water (green: D1) to the first aliquot 
of dried beads. Mix thoroughly by pipetting (at least half volume) to ensure all 
beads are resuspended.  
17. Add the first aliquot of resuspended beads to the second aliquot of dried beads 
for each sample. Mix thoroughly by pipetting (at least half volume) to ensure all 
the beads are resuspended and let stand on the bench top for 3 minutes.  
18. Transfer the tubes to the magnet and let stand for 3 minutes for the beads to 
clear the solution. 
19. Carefully remove 10 uL of the eluate, ensuring as few beads as possible are 
carried over, transfer to a fresh set of PCR tubes and place on ice. 
20. Continue immediately to the End Repair protocol. 
 
NuGen’s Ovation Human FFPE RNA-Seq kit: End Repair 
Perform as per manufacturer’s protocol. 
 
1. Remove the following from -20°C storage: 
a. End Repair Buffer Mix (blue: ER1 ver 7) 




c. End Repair Enhancer (blue: ER3 ver 2) 
2. Thaw ER1 at room temperature. Mix by vortexing, spin and place on ice. 
3. Spin down contents of ER2 and ER3, and place on ice. 







5. Add 5 uL of the End Repair Master Mix to each 10 uL sample. 
6. Mix by pipetting (at least half volume), cap and spin the tubes and place on ice.  
7. Place the tubes in a pre-warmed thermal cycler programmed to run Program 4. 
a. Program 4 = ORSP4 and is for end repair 
i. 25°C – 30 minutes 
ii. 70°C – 10 minutes 
iii. hold at 4°C 
8. Remove the tubes from the thermal cycler, spin to collect condensation and 
place on ice. 
9. Continue immediately to the Ligation protocol. 
 
NuGen’s Ovation Human FFPE RNA-Seq kit: Ligation 
Perform as per manufacturer’s protocol. 
 
1. Remove the following from -20°C storage: 
a. Ligation Buffer Mix (yellow: L1 ver 4) 
b. Ligation Adapter Mixes (yellow: L2) 
c. Ligation Enzyme Mix (yellow: L3 ver 4) 
d. Nuclease-Free Water (green: D1) 
2. Thaw L1, L2 and D1 at room temperature. Mix by vortexing, spin and place on 
ice. 
3. Spin L3 and place on ice 
4. Add 3 uL of the appropriate L2 Ligation Adaptor Mix to each sample.  
 
Adapter ID Adapter Barcode 
L2V12DR-BC1 AAC CAG 
L2V12DR-BC2 TGG TGA 
L2V12DR-BC3 AGT GAG 
L2V12DR-BC4 GCA CTA 
L2V12DR-BC5 ACC TCA 
L2V12DR-BC6 GTG CTT 
L2V12DR-BC7 AAG CCT 
L2V12DR-BC8 GTC GTA 
 
5. Mix thoroughly by pipetting (at least half volume). Make sure a unique barcode is 
used for each sample. 
6. Prepare a master mix by combining Nuclease-Free Water (D1), L1 and L3 in a 
0.5 mL capped tube. Mix by pipetting slowly (at least half volume), without 
introducing bubbles, spin and place on ice. 
 BLUE: ER1 ver 7 BLUE: ER2 ver 4 BLUE: ER3 ver 2 








7. Add 12 uL of the Ligation Master Mix to each reaction tube. Mix thoroughly by 
pipetting slowly and gently (at least half volume), spin and place on ice. Proceed 
immediately with the incubation. 
8. Place the tubes in a pre-warmed thermal cycler programmed to run Program 5. 
a. Program 5 = ORSP5 and is to ligate the adapters 
i. 25°C – 30 minutes 
ii. hold at 4°C 
9. Remove the tubes from the thermal cycler, spin to collect condensation and 
place on ice. 
10. Continue immediately to the Strand Selection I protocol. 
 
 
NuGen’s Ovation Human FFPE RNA-Seq kit: Strand Selection I 
Perform as per manufacturer’s protocol. 
 
1. Remove the following from -20°C storage: 
a. Strand Selection Buffer Mix I (purple: SS1) 
b. Strand Selection Enzyme Mix I (purple: SS2) 
2. Thaw SS1 at room temperature. Mix by vortexing, spin and place on ice. 
3. Spin down SS2 and place on ice. 
a. this is a good time to move the RNAClean XP beads and Nuclease-Free 
Water (D1) to room temperature since they need to be out for at least 15 
minutes prior to using. 





5. Add 70 uL of the Strand Selection I Master Mix to each 30 uL sample. 
6. Mix by pipetting (at least half volume), cap and spin the tubes and place on ice. 
7. Place the tubes in a pre-warmed thermal cycler programmed to run Program 6. 
a. Program 6 = ORSP6 and is the first step of NuGEN’s proprietary reaction. 
i. 72°C – 10 minutes 
ii. hold at 4°C 
8. Remove the tubes from the thermal cycler, spin to collect condensation and 
place on ice. 
9. Continue immediately to the Strand Selection I Purification protocol. 
 
NuGen’s Ovation Human FFPE RNA-Seq kit: Strand Selection I Purification 
Perform as per manufacturer’s protocol. 
 
1. Ensure the Agencourt RNAClean XP beads and Nuclease-Free Water (D1) have 
completely reached room temperature. 
2. Resuspend the beads by inverting and tapping the tube. Ensure the beads are 
fully resuspended before adding to the samples.  
 GREEN: D1 YELLOW: L1 ver 4 YELLOW: L3 ver 4 
1X 4.5 uL 6 uL 1.5 uL 
 PURPLE: SS1 PURPLE: SS2 




3. Transfer 80 uL (0.8 volumes) of bead suspension to a fresh microfuge tube for 
each sample. 
4. At room temperature, add the Strand Selection I reaction product to the 80 uL of 
the bead suspension. Mix thoroughly by pipetting (at least half volume). 
5. Incubate at room temperature for 10 minutes.  
6. Transfer the tubes to the magnet and let stand 5 minutes to completely clear the 
solution of beads. 
7. Carefully remove 165 uL of the binding buffer and discard it. Leaving some of the 
volume behind minimizes bead loss at this step. 
a. Note: The beads should not disperse; instead, they will stay on the walls 
of the tubes. Significant loss of beads at this stage will impact the amount 
of DNA carried into Strand Selection II, so ensure beads are not removed 
with the binding buffer or the wash. 
8. With the tubes still on the magnet, add 200 uL of freshly prepared 70% EtOH and 
allow to stand for 30 seconds.  
9. Remove the 70% EtOH wash using a pipette. 
10. Repeat the 70% EtOH wash one more time, for a total of two washes. 
a. Note: With the final wash, it is critical to remove as much of the EtOH as 
possible. Use at least two pipetting steps and allow excess EtOH to 
collect at the bottom of the tubes after removing most of the EtOH in the 
first pipetting step. 
11. Air-dry the beads on the magnet for 10 minutes. Inspect each tube carefully to 
ensure that all of the EtOH has evaporated. It is critical that all residual EtOH be 
removed prior to continuing. 
12. Remove the tubes from the magnet. 
13.  Add 17 uL room temperature Nuclease-Free Water (D1) to the dried beads. Mix 
thoroughly by pipetting (at least half volume) to ensure all beads are 
resuspended. 
14. Transfer the tubes to the magnet and let stand for 3 minutes for the beads to 
clear the solution.  
15. Carefully remove 15 uL of the eluate, ensuring as few beads as possible are 
carried over, transfer to a fresh set of PCR tubes and place on ice. 
16. Store at -20°C. 
 
DAY THREE: ~5 hours 
 
Sign up for machines: start time are relative to the time you begin sample prep 
1. qPCR for 3 hours at 0 hours 
 
NuGen’s Ovation Human FFPE RNA-Seq kit: Strand Selection II 
Perform as per manufacturer’s protocol. 
 
1. Remove the following from -20°C storage: 
a. Strand Selection Buffer Mix II (purple: SS3 ver 2) 
b. Strand Selection Enzyme Mix II (purple: SS4) 
c. Strand Selection Reagent (purple: SS5 ver 3) 
d. Strand Selection Enzyme Mix III (purple: SS6) 





3. Spin down SS4 and SS6 and place on ice. 
4. Prepare a master mix by combining SS3, SS4, SS5, and SS6 in a 0.5 mL capped 
tube. 
 
5. Add 10 uL of the Strand Selection II Master Mix to each 15 uL sample. 
6. Mix by pipetting (at least half volume), cap and spin the tubes and place on ice. 
7. Place the tubes in a pre-warmed thermal cycler programmed to run Program 7. 
a. Program 7 = ORSP7 and is the second step of NuGEN’s proprietary 
reaction. 
i. 37°C – 10 minutes 
ii. 95°C – 2 minutes 
iii. 50°C – 30 seconds 
iv. 65°C – 5 minutes 
v. hold at 4°C 
8. Remove the tubes from the thermal cycler, spin to collect condensation and 
place on ice. 
9. Continue immediately to the Adaptor Cleavage protocol. 
 
NuGen’s Ovation Human FFPE RNA-Seq kit: Adaptor Cleavage 
Perform as per manufacturer’s protocol. 
 
1. Prepare a master mix by combining SS3 ver 2 and AC1 in a 0.5 mL capped tube. 
 
 GREEN: D1 PURPLE: SS3 ver 2 PURPLE: AC1 
1X 17.5 uL 5 uL 2.5 uL 
 
2. Add 25 uL of the Adaptor Cleavage Master Mix to each 25 uL sample. 
3. Mix by pipetting (at least half volume), cap and spin the tubes and place on ice. 
4. Place the tubes in a pre-warmed thermal cycler programmed to run Program 8. 
a. Program 8 = ORSP8 and is used to deplete rRNA sequences. 
i. 55°C – 15 minutes 
ii. 95°C – 5 minutes 
iii. hold at 4°C 
5. Remove the tubes from the thermal cycler, spin to collect condensation and 
place on ice.  
6. Continue immediately to the Library Amplification protocol. 
 
NuGen’s Ovation Human FFPE RNA-Seq kit: Library Amplification 
Perform as per manufacturer’s protocol. 
 
1. Remove the following from -20°C storage: 
a. Amplification Buffer Mix (red: P1 ver 4) 
b. Amplification Primer Mix (red: P2 ver 10) 
c. Amplification Enzyme Mix (red: P3 ver 2) 
 
2. Thaw P1 and P2 at room temperature. Mix each by vortexing, spin and place on 
ice. 
 PURPLE: SS3 ver 2 PURPLE: SS4 PURPLE: SS5 ver 3 PURPLE: SS6 




3. Spin down P3 Amplification Enzyme mix and place on ice. 
4. Prepare a master mix by sequentially combining P1 and P2 in a 1.5 mL capped 
tube. Add P3 Enzyme Mix at the last moment and mix well by pipetting (at least 
half volume) taking care to avoid bubbles. Spin the tubes and place on ice. 
 
 GREEN: D1 RED: P1 ver 4 RED: P2 ver 10 RED: P3 ver 2 
1X 31.5 uL 10 uL 8 uL 0.5 uL 
 
5. On ice, add 50 uL of the Amplification Master Mix to each 50 uL sample. 
a. this is a good time to move the RNAClean XP beads and Nuclease-Free 
Water (D1) to room temperature since they need to be out for at least 15 
minutes prior to using. 
6. Place the tubes in a pre-warmed thermal cycler programmed to run Program 9. 
a. Program 9 = ORSP9 and is used to amplify the libraries. 
i. 95°C – 2 minutes 
ii. 2 cycles of 
1. 95°C – 30 seconds 
2. 60°C – 90 seconds 
iii. 18 cycles of 
1. 95°C – 30 seconds 
2. 65°C – 90 seconds 
iv. 65°C – 5 minutes 
v. hold at 4°C 
7. Remove the tubes from the thermal cycler, spin to collect condensation and 
place on ice. 
8. Proceed to Bead Purification of the Amplified Material or store at -20°C. 
 
Bead Purification of the Amplified Material: 
1. Ensure the Agencourt RNAClean XP beads and Nuclease-Free Water (D1) have 
completely reached room temperature. 
2. Resuspend the beads by inverting and tapping the tube. Ensure the beads are 
fully resuspended before adding to the samples. After resuspending, do not spin 
the beads.  
3. Prepare a 70% EtOH wash solution. It is critical that this solution be prepared 
fresh on the day of the experiment from a recently opened stock container. 
Measure both the EtOH and the H2O components carefully prior to mixing. 
Failure to do so can result in a higher than anticipated aqueous content, which 
may reduce yield.  
4. Transfer 100 uL (1 volume) of bead suspension to a fresh microfuge tube for 
each sample. 
5. At room temperature, add the entire volume of each reaction to the 100 uL of 
bead suspension.  
6. Mix thoroughly by pipetting up and down (at least half volume). It may be helpful 
to use a multichannel pipettor to ensure the incubation times are uniform (or 
stager). 
7. Incubate at room temperature for 10 minutes 
8. Transfer the tubes to the magnet and let stand 5 minutes to completely clear the 




9. Carefully remove only 185 uL of the binding buffer and discard it. Leaving some 
of the volume behind minimizes bead loss at this step. 
a. Note: The beads should not disperse; instead, they will stay on the walls 
of the tubes. Significant loss of beads at this stage will impact the yield, 
so ensure beads are not removed with the binding buffer or the wash. 
10. Remove the tubes from the magnet, add 200 uL of freshly prepared 70% EtOH, 
mix thoroughly by pipetting up and down, transfer the tubes back to the magnet 
and let stand 3-5 minutes to completely clear the solution of beads. 
11. Remove the 70% EtOH wash using a pipette. 
12. Repeat the 70% EtOH wash one more time, for a total of two washes. 
a. Note: With the final wash, it is critical to remove as much of the EtOH as 
possible. Use at least two pipetting steps and allow excess EtOH to 
collect at the bottom of the tubes after removing most of the EtOH in the 
first pipetting step. 
13. Air-dry the beads on the magnet for at least 10 minutes. Inspect each tube 
carefully to ensure that all of the EtOH has evaporated. It is critical that all 
residual EtOH be removed prior to continuing. 
14. Remove the tubes from the magnet. 
15. Add 30 uL room temperature Nuclease-Free Water (D1) to the dried beads. Mix 
thoroughly by pipetting (at least half volume) to ensure all beads are 
resuspended. 
16. Incubate at room temperature for 5 minutes. 
17. Transfer the tubes to the magnet and let stand for 2 minutes. 
18. Carefully remove 25 uL of the eluate, ensuring as few beads as possible are 
carried over and transfer to a fresh tube. When pipetting any portion of this eluted 
library downstream, be sure to use a magnet to minimize bead carryover into any 
ensuing reactions. 





APPENDIX B: CUSTOM SPIKE-IN CONTROL DESIGN, GENERATION, 
AND VALIDATION FOR GLOBAL NORMALIZATION OF EU-RNA-SEQ 
	   	  
	   This appendix provides a detailed overview of the design and validation of the 
custom, biotin-RNA controls sequences used as spike-ins for global normalization in 
Chapter 2. All experiments and analyses were designed and performed by myself, with 
guidance from Dr. Zaret. 
 
I. Objective 
	   To control for global differences in transcription level between mitotic and 
asynchronous populations (figure 1), and the resulting over-amplification of sequences in 
low-abundance populations, I will add known quantities of control sequences to each 
EU-labeled RNA sample prior to pull down and cDNA library generation (figure 2). 
 
II. The Control Sequences 
control #1.  
hg18 chr7:110045645-110046034 





















 Primers KP13 (KZ 5078) and KP14 (KZ 5079) were used to amplify control #1 
from genomic HUH7 DNA. Primers KP17 (KZ 5080) and KP18 (KZ 5081) were used to 
amplify control #2 from genomic HUH7 DNA. Primers KP89 (KZ 5082) and KP90 (KZ 
5083) were used to qPCR quantify control #1 during validation studies. Primers KP97 
(KZ 5084) and KP98 (KZ 5089) were used to qPCR quantify control #2 during validation 
studies. 
KP13 (KZ 5078): TTA GCT GAA GAC CCC TGC TC 
KP14 (KZ 5079): TGG AAA CCA GTG ATG GGA CT 
KP17 (KZ 5080): CCT GGG ACA GCT TCA GCT AC 
KP18 (KZ 5081): GGG AGG TCA ACT GCA TGA AT 
KP89 (KZ 5082): AGA CCC CTG CTC TTT CAA CA 
KP90 (KZ 5083): TGA GCA TGG ATT TTG TGA GAG AA 
KP97 (KZ 5084): ACC CTA CGC AGC ACA GTT TT 
KP98 (KZ 5089): TGC ACA TCC TTC TGT CTC TCT 
 
IV. Plasmids 
 Both controls were cloned in to the pCR 2.1-TOPO vector. Control #1 is in 
plasmid 7-3 (KZ 1408) and glycerol stock 7-3 (KZ 2110), and control #2 is in plasmid 13-






V. iScript Spike-In Test after pull down 
Goal 
 To determine whether the control sequences are pulled down proportionally on 
streptavidin-coated magnetic beads in the presence of total asynchronous RNA 
containing an unknown amount of biotin-EU-RNA. 
 
Approach 
 Pulse-label asynchronous HUH7 cells with 0.5 uM EU for 40 minutes, harvest 
total RNA, and perform click reaction to conjugate biotin to the unknown fraction of  RNA 
that contains EU. Add control sequences 1 and 2 to 1.5 ug total RNA, pull down with 
streptavidin-coated magnetic beads, generate first and second strand cDNA, remove 
beads, and quantify controls by qPCR (figure 3 A). 
 
Results 
 Both controls are pulled down proportionately in the presence of async. biotin-
EU-RNA (figure 3 B-C). 
 
	  
VI. Pull down with different amounts of EU-RNA 
Goal 
 To determine whether the amount of cellular biotin-EU-RNA affects pull down of 
the control biotin-RNA sequences. This is important since lower basal levels of 





 Pulse-label asynchronous HUH7 cells with 0.5 uM EU for 40 minutes, harvest 
total RNA, and perform click reaction to conjugate biotin to the unknown fraction of RNA 
that contains EU. Add control sequences 1 and 2 to 0.5, 1.0, or 1.5 ug total RNA, pull 
down with streptavidin-coated magnetic beads, generate first and second strand cDNA, 
remove beads, and quantify controls by qPCR (figure 4 A). 
 
Results 
 The amount of input cellular EU-RNA does not predictably affect pull down of the 
control sequences (figure 4 B-C). 
 
	  
VII. Library Spike-In Test 
Goal 
 To determine whether the relative amounts of biotin-RNA control sequence in a 
library reflect the amount that was added to the starting sample. 
 
Approach 
 Pulse-label asynchronous HUH7 cell with 0.5 uM EU for 40 minutes, harvest total 
RNA, and perform click reaction to conjugate biotin to  the unknown fraction of that 
contains EU. Add control sequences 1 and 2 to 2 ug total RNA, pull down with 
streptavidin-coated magnetic beads, generate cDNA libraries, and quantify controls by 





 The proportionality of control #1 is retained when spiked-in at 10-6 and 10-7 ug 
(figure 5 B), and the proportionality of control #2 is retained when spiked-in at 10-4 and 




	   Here I have shown that both of the custom biotin-RNA control sequences retain 
proportionality when spiked-in to total asynchronous RNA containing an unknown 
fraction of EU-RNA. The controls are thus appropriate for use as spike-ins for global 








Figure 1. Different basal levels of transcription affect library generation. 
 
(A) An unknown fraction of the total RNA harvested is labeled with EU. (B) Biotin-azide 
is conjugated to EU via a “click” reaction. (C) All biotinylated RNAs are pulled down on 
streptavidin-coated magnetic beads. (D) cDNA libraries are generated directly off the 







Figure 2. Spike-in controls globally normalize for differences in basal 
transcriptional levels between samples. 
 
(A) An unknown fraction of the total RNA harvested is labeled with EU. (B) Biotin-azide 
is conjugated to EU via a “click” reaction. (C) Custom, biotin-RNA sequences are spiked-
in at known levels. (D) All biotinylated RNAs are pulled down on streptavidin-coated 






Figure 3.	   The custom biotin-RNA control sequences retain their proportionality 
when pulled down and converted to cDNA.  
 
(A) Experimental approach to validating controls. Ct values following RT-qPCR of (B) 
control #1 or (C) control #2, when added at the indicated levels to 1.5 ug of 
asynchronous biotin-EU-RNA and pulled down with streptavidin-coated magnetic beads. 






Figure 4. The custom biotin-RNA control sequences retain their proportionality 
independent of cellular EU-RNA levels.  
 
(A) Experimental approach to validating controls. Ct values following RT-qPCR of (B) 
control #1 or (C) control #2, when added at the indicated levels to 0.5, 1.0, or 1.5 ug of 
asynchronous biotin-EU-RNA and pulled down with streptavidin-coated magnetic beads. 






Figure 5. The custom biotin-RNA control sequences retain their proportionality 
when converted to cDNA libraries.  
 
(A) Experimental approach to validating controls. Ct values following RT-qPCR of (B) 
control #1 or (C) control #2, when added at the indicated levels to 1.5 ug of 
asynchronous biotin-EU-RNA and pulled down with streptavidin-coated magnetic beads 





APPENDIX C: MOTIFS IN ENHANCERS AND PROMOTERS DURING 
MITOSIS AND MITOTIC EXIT 
	  
	  
	   This appendix contains ten unpublished analyses which assess motif enrichment 
at enhancers or promoters during mitosis and mitotic exit. While the data were 
generated by myself, Greg Donahue performed the analyses.  
 
I. Objectives 
i. motifs in enhancers that first increase at each time point  
 The goal of this analysis is to determine which motifs are enriched in the 
enhancers that are first transcribed into eRNAs at each time point relative to intergenic 
sequences 5 kb upstream of the enhancer (Chapter 2, figure S11 B). My preliminary 
conclusion is that most motifs enriched, including those for liver-specific factors, are 
found in the 40 minute enhancers (Table 1). 
 
ii. motifs in enhancers that first increase at each time point relative to 
asynchronous cells 
 The goal of this analysis is to determine which motifs are enriched in the 
enhancers that are first transcribed into eRNAs at each time point relative to the motifs in 
the enhancers that are only transcribed into eRNAs in the asynchronous population 
(Chapter 2, figure S11 B). My preliminary conclusion is that most motifs enriched are 





iii. motifs in enhancers that target genes that first increase at each time point  
 The goal of this analysis is to determine which motifs are enriched in the 
enhancers that target genes that first increase at each time point during mitotic exit 
relative to intergenic sequences 5 kb upstream of the enhancer (Chapter 2, figure 4 C). 
My preliminary conclusion is that most motifs enriched, including those for liver-specific 
factors, are found in the 80 minute enhancers (Table 3). 
 
iv. motifs in enhancers that target genes that first increase at each time point 
relative to asynchronous cells 
 The goal of this analysis is to determine which motifs are enriched in the 
enhancers that target genes that first increase at each time point during mitotic exit 
relative to the motifs in the enhancers that target gene that are only up in the 
asynchronous cells (Chapter 2, figure 4 C). My preliminary conclusion is that most motifs 
enriched, including those for Fox, are found in the 80 minute enhancers (Table 4). 
 
v. motifs in promoters of genes that first increase at each time point  
 The goal of this analysis is to determine which motifs are enriched in the 
promoters of genes that first increase at each time point during mitotic exit relative to 
intergenic sequences 5 kb upstream of the promoter (Chapter 2, figure 3 A). My 
preliminary conclusion is that the vast majority of enriched motifs are found in the 80 
minute promoters, but the liver-specific FoxA motif isn’t enriched until later (Table 5). 
 
vi. motifs in promoters of genes that first increase at each time point relative to 
asynchronous cells 
 The goal of this analysis is to determine which motifs are enriched in the 




motifs in the promoters of genes that are only up in the asynchronous cells (Chapter 2, 
figure 3 A). My preliminary conclusion is that most enriched enhancers are found in the 
80 minute promoters, including those for liver-specific factors (Table 6). 
 
vii. motifs in promoters of mitotically-expressed genes  
 The goal of this analysis is to determine which motifs are enriched in the 
promoters of mitotically-expressed genes relative to intergenic sequences 5 kb upstream 
of the promoter (Chapter 2, figure S5 A). My preliminary conclusion is that the promoters 
of mitotically-expressed genes are heavily enriched for both liver-specific and 
pluripotency factors (Table 7). 
 
viii. motifs in promoters of mitotically-expressed genes relative to asynchronous 
cells 
 The goal of this analysis is to determine which motifs are enriched in the 
promoters of mitotically-expressed genes (Chapter 2, figure S5 A) relative to the motifs 
in the promoters of asynchronously-expressed genes (Chapter 2, figure S4 A). My 
preliminary conclusion is that the promoters of mitotically-expressed genes are enriched 
for the  motifs of ubiquitous factors relative to asynchronously-expressed genes (Table 
8). 
 
ix. motifs in promoters of mitotically-enriched genes  
 The goal of this analysis is to determine which motifs are enriched in the 
promoters of mitotically-enriched genes relative to intergenic sequences 5 kb upstream 




of mitotically-enriched genes are enriched for the motifs of both general and liver-specific 
factors ( Table 9). 
 
x. motifs in promoters of mitotically-enriched genes relative to asynchronous cells 
 The goal of this analysis is to determine which motifs are enriched in the 
promoters of mitotically-enriched genes (Chapter 2, figure 2 M) relative to the motifs in 
the promoters of genes that are only up in asynchronous cells (Chapter 2, figure 3 A). 
My preliminary conclusion is that the promoters of mitotically-enriched genes are 
enriched for the motifs of both general and liver-specific factors, relative to the promoters 
of genes that are only up in asynchronous cells ( Table 10). 
 
II. Approach 
 For each of the analyses, Greg Donahue ran HOMER to compare motifs within a 
250 bp window in the test and control groups. The cutoff for enrichment was a 
Benjamani-adjusted P-value of 0.05. Each table below presents the number of 






Table 1. Motifs in enhancers that first increase at each time point. 
 
motif 40’ 80’ 105’ 165’ 300’ 
AR-halfsite 470 0 137 0 0 
Erra 298 0 0 0 0 
Foxo1 267 105 0 72 0 
ERG 252 0 0 0 0 
Sox3 239 0 0 85 0 
ETV1 228 0 0 57 0 
MYB 219 0 0 0 0 
Rbpj1 206 0 61 0 29 
GATA3 200 0 73 71 0 
BMYB 188 0 0 0 42 
AMYB 188 0 0 0 0 
RXR 175 69 45 55 0 
Ap4 173 76 0 0 0 
ETS1 167 62 0 0 0 
FOXA1 165 68 0 46 45 
Atoh1 163 0 0 0 0 
Tcf12 152 56 0 39 0 
AP-2gamma 148 0 0 0 0 
GABPA 148 0 0 41 0 
Fox 132 61 0 0 0 
Sox2 119 0 0 0 0 
TEAD 116 51 33 43 0 
MyoD 115 0 0 0 0 
MafA 106 46 0 0 0 
Myf5 103 0 0 0 0 
Stat3+il21 102 39 0 0 19 
Atf3 101 0 0 39 24 
PRDM1/BMI1 98 0 25 0 0 
NFY 85 0 0 0 0 
RUNX-AML 84 41 0 0 0 
Unknown 82 0 0 0 0 
PU.1 78 32 0 28 0 
Elk1 73 0 0 12 0 
Atf1 71 29 0 0 0 
PRDM9 67 0 0 0 0 
TRa 63 0 0 0 0 
Stat3 62 0 0 0 12 
IRF4 61 0 0 0 0 
Arnt 60 0 0 12 0 
Phox2a 60 0 0 0 0 
Hoxc9 59 30 18 0 0 
BORIS 54 17 0 14 0 
CTCF 51 17 9 12 0 
E2F6 47 22 0 8 0 
STAT1 43 23 0 0 0 
Six1 40 0 0 17 0 




c-Jun-CRE 34 0 0 0 0 
PRDM14 33 0 0 11 0 
ERE 33 0 0 7 0 
MafK 31 8 0 0 7 
Srebp1a 23 7 0 0 0 
Reverb 21 0 0 0 0 
Tbox 21 0 0 0 0 
E2F4 21 0 0 6 0 
CEBP 20 0 31 35 20 
Tcfcp2l1 13 0 0 0 0 
GATA-DR8 12 0 0 0 0 
ETS 11 9 10 6 0 
NRF1 11 0 0 0 0 
Nrf2 11 0 0 0 0 
NF-E2 10 0 0 0 0 
LXRE 9 0 0 0 0 
Bach1 9 0 0 0 0 
GFY 6 0 0 0 0 
ZFX 0 0 53 0 0 
Gfi1b 0 0 0 32 0 
Nkx3.1 0 128 0 0 0 
HRE 0 12 7 0 0 
Foxa2 0 0 0 0 27 
NF1-halfsite 0 0 0 81 0 
Ets1-distal 0 20 0 15 0 
Eomes 0 0 0 78 0 
RBPJ 0 0 0 19 12 
Egr2 0 7 0 0 0 
Pbx3 0 0 10 0 0 
AP-1 0 41 0 44 0 
Klf4 0 0 7 0 7 
Isl1 0 115 0 93 58 
EHF 0 0 0 62 0 
mES-Nanog 0 38 0 0 0 
Jun-AP1 0 0 10 23 0 
RUNX1 0 66 0 0 0 
Hnf1 0 0 0 0 8 
Foxh1 0 0 22 0 0 
BATF 0 0 0 39 24 
Nkx2.1 0 160 0 0 0 
FOXP1 0 19 0 0 0 
Nkx2.5 0 123 0 0 0 
Ptf1a 0 151 0 0 0 
CRX 0 131 0 0 0 
Max 0 0 0 20 0 
CRE 0 0 0 6 0 
USF1 0 0 0 16 0 
SCL 0 251 0 174 0 
Lhx2 0 66 0 0 0 
Lhx3 0 113 88 94 0 
NFkB-p50,p52 0 7 0 0 0 
GATA-IR3 0 9 0 0 0 
NF1 0 24 0 0 0 




Gata2 0 0 0 33 0 
TR4 0 0 7 0 0 
Gata1 0 0 0 26 0 
Nkx6.1 0 159 0 0 82 
RUNX2 0 52 0 0 0 
HNF4a 0 0 16 20 0 
PAX5 0 0 9 0 0 
NeuroD1 0 0 0 41 0 
Tbx5 0 172 0 0 0 
EWS 0 52 0 0 0 
MyoG 0 67 0 0 0 
IRF2 0 0 0 6 0 
HIF2a 0 0 0 7 0 
Nanog 0 243 0 0 0 
Rfx5 0 0 0 14 0 
Egr1 0 27 16 0 0 
Rfx2 0 0 0 6 0 
Olig2 0 0 0 88 0 
Bach2 0 11 11 15 9 
HIF-1a 0 12 8 0 0 
Nur77 0 9 0 9 0 
STAT4 0 61 0 0 0 
X-box 0 0 0 7 0 
Srebp2 0 7 0 0 0 
Smad2 0 0 54 0 0 
Smad3 0 0 106 126 0 
E2A 0 88 0 0 0 
Pitx1 0 243 177 195 0 
EKLF 0 0 0 9 0 
Esrrb 0 36 0 0 0 
IRF1 0 0 0 10 0 
Atf4 0 0 0 10 0 
Pax8 0 0 16 8 0 
HOXA9 0 35 0 32 0 
Tcf4 0 25 0 0 0 
Tcf3 0 10 0 0 0 
Cdx2 0 41 0 36 0 
NFkB-p65 0 28 0 0 0 
ELF5 0 48 0 33 0 
TEAD4 0 67 0 53 21 
GRHL2 0 0 0 21 0 
RUNX 0 40 0 0 0 
Maz 0 0 42 0 0 
NPAS2 0 0 0 31 0 
Usf2 0 0 0 11 0 
Elk4 0 20 0 12 8 
TATA-Box 0 76 0 0 0 
bHLHE40 0 0 7 0 0 
FXR 0 0 0 0 11 
ELF1 0 20 0 13 0 
EBF1 0 61 0 41 0 
NFAT 0 53 42 0 20 
PU.1-IRF 0 0 0 65 0 




OCT4 0 7 21 0 0 
Bcl6 0 0 0 68 0 
ARE 0 0 0 9 0 
E2A-nearPU.1 0 0 0 42 0 
total 6,545 4,119 1,171 2,669 485 
 
n = 1,559 enhancers at 40 min 
n = 588 enhancers at 80 min 
n = 422 enhancers at 105 min 
n = 442 enhancers at 165 min 




Table 2. Motifs in enhancers that first increase at each time point relative to 
asynchronous cells. 
 
motif 40’ 80’ 105’ 165’ 300' 
Sox3 239 0 0 0 0 
Maz 167 0 0 0 0 
KLF5 137 0 0 47 0 
Tlx 60 29 0 0 0 
BORIS 54 0 0 0 0 
CTCF 51 0 0 0 0 
Six1 40 0 0 17 0 
Chop 38 0 0 0 0 
CRE 15 0 0 0 0 
IRF2 14 0 0 6 6 
Egr2 13 0 0 0 0 
p53 13 6 0 0 0 
TR4 12 0 0 0 0 
Nrf2 11 0 0 0 0 
NF1 9 0 0 0 0 
LXRE 9 0 0 0 0 
Pax7-long 8 0 0 0 0 
GATA-DR4 0 6 0 5 0 
RUNX2 0 52 0 0 0 
RUNX 0 0 0 40 0 
Klf4 0 20 0 14 0 
ISRE 0 0 0 7 6 
EKLF 0 12 0 9 0 
NRF1 0 6 0 0 0 
total 890 131 0 145 12 
 
n = 1,559 enhancers at 40 min 
n = 588 enhancers at 80 min 
n = 422 enhancers at 105 min 
n = 442 enhancers at 165 min 
n = 263 enhancers at 300 min 





Table 3. Motifs in enhancers that target genes that first increase at each time 
point.	  
motif 40’ 80’ 105’ 165’ 300’ 
SCL 0 90 0 0 0 
Tbx5 0 82 0 0 0 
Ptf1a 0 67 0 0 0 
Nkx3.1 0 66 25 0 0 
Nkx2.5 0 53 0 24 0 
Sox3 0 52 0 0 0 
Erra 0 51 0 0 0 
Olig2 0 51 0 0 0 
ERG 0 47 0 0 0 
PR 0 47 0 0 7 
Sox6 0 46 0 0 0 
Znf263 0 45 0 0 0 
ZNF711 0 45 0 0 0 
BMYB 0 44 0 0 0 
MYB 0 43 0 0 0 
TATA-Box 0 42 0 0 8 
ZFX 0 40 0 0 0 
AMYB 0 38 0 0 0 
FOXA1 0 38 0 0 0 
E2A-nearPU.1 0 38 0 0 0 
E2A 0 37 0 0 0 
Fli1 0 33 0 0 0 
Atoh1 0 33 0 0 0 
TEAD4 0 31 0 0 0 
Tbet 0 29 0 9 0 
ETS1 0 28 0 0 0 
RXR 0 28 16 0 0 
AP-2gamma 0 27 0 0 0 
Maz 0 26 0 8 0 
GABPA 0 26 0 0 0 
Foxa2 0 25 0 0 0 
Tcf12 0 24 0 0 0 
ELF5 0 22 0 0 0 
Egr1 0 21 0 0 0 
NFkB-p65 0 20 0 0 0 
MyoD 0 18 0 0 0 
Gfi1b 0 17 0 0 0 
Max 0 16 0 0 0 
Elk1 0 16 7 0 0 
OCT4 0 16 0 0 0 
ELF1 0 15 0 0 0 
Elk4 0 15 0 0 0 
Atf1 0 15 0 0 0 
CEBP 0 14 0 0 0 
PU.1 0 14 0 0 0 
IRF4 0 13 0 0 0 
Phox2a 0 12 0 0 0 
bZIP 0 11 0 0 0 




p63 0 10 0 0 0 
Tbx20 0 10 0 0 0 
BORIS 0 9 0 0 0 
HIF2a 0 8 0 0 0 
c-Jun-CRE 0 8 0 0 0 
OCT2 0 8 0 0 0 
Hnf1 0 8 0 0 0 
CTCF 0 8 0 0 0 
CArG 0 7 0 0 0 
Tbox 0 7 0 0 0 
ARE 0 7 0 0 0 
Cdx2 0 0 7 0 0 
RUNX-AML 0 0 0 8 0 
MafA 0 0 0 10 0 
RUNX1 0 0 0 11 0 
PRDM1/BMI1 0 0 0 11 0 
STAT4 0 0 16 0 0 
Gata2 0 0 16 0 0 
Eomes 0 0 0 22 0 
Gata4 0 0 22 0 0 
Gata1 0 0 15 0 0 
Hoxc9 0 0 7 0 0 
Stat3+il21 0 0 11 0 0 
RUNX2 0 0 0 9 0 
EWS 0 0 7 0 0 
RUNX 0 0 0 9 0 
Bcl6 0 0 0 0 7 
total 0 1,727 149 121 22 
 
n = 33 enhancers at 40 min 
n = 291 enhancers at 80 min 
n = 140 enhancers at 105 min 
n = 106 enhancers at 165 min 




Table 4. Motifs in enhancers that target genes that first increase at each time point 
relative to asynchronous cells. 
motif 40’ 80’ 105’ 165’ 300’ 
Lhx3 0 55 0 0 0 
Olig2 0 51 0 0 0 
ZFX 0 40 0 0 0 
E2A 0 37 0 0 0 
Atoh1 6 33 0 0 0 
Fox 0 29 0 0 0 
NeuroD1 0 25 0 0 0 
Tcf12 7 24 13 0 0 
Unknown 0 23 0 0 0 
MyoG 7 23 0 0 0 
NFkB-p65 0 20 0 0 0 
MyoD 0 18 8 0 0 
HOXA9 0 18 0 0 0 
Gfi1b 0 17 0 10 0 
Oct4 0 16 0 0 0 
IRF4 0 13 0 0 0 
Tbx20 0 10 0 0 0 
HIF2a 0 8 0 0 0 
Tbox 0 7 0 0 0 
RBPJ 0 7 0 0 0 
Smad3 0 0 0 35 0 
PRDM1/BMI1 0 0 0 11 0 
Rfx5 0 0 0 5 0 
Myf5 5 0 0 0 0 
Ap4 8 0 0 0 0 
total 33 474 21 61 0 
 
n = 33 enhancers at 40 min 
n = 291 enhancers at 80 min 
n = 140 enhancers at 105 min 
n = 106 enhancers at 165 min 
n = 45 enhancers at 300 min 




Table 5. Motifs in promoters of genes that first increase at each time point.	  
motif 40’ 80’ 105’ 165’ 300’ 
Pitx1 280 1,478 544 0 256 
AR-halfsite 245 1,189 427 0 0 
Maz 159 875 0 154 109 
Znf263 158 794 0 180 0 
CRX 151 783 0 0 127 
AP-2gamma 122 553 0 115 0 
ETV1 0 502 0 0 81 
Sox3 86 490 0 163 0 
Fli1 88 479 165 0 68 
EHF 0 459 170 0 0 
Sox6 82 457 0 155 0 
E2F6 64 404 0 62 59 
Ap4 96 356 0 0 0 
NPAS2 0 349 0 0 48 
MyoG 74 337 0 0 0 
HOXD13 85 323 0 127 0 
GABPA 67 320 109 72 42 
SPDEF 0 315 0 0 62 
Atoh1 0 309 0 0 0 
Sp1 41 288 45 0 14 
ELF5 72 274 89 0 0 
RUNX1 73 272 0 0 0 
n-Myc 0 269 0 51 38 
TEAD4 0 266 0 0 36 
Arnt 0 256 87 51 0 
c-Myc 0 245 63 39 25 
Sox2 47 238 108 0 0 
NFY 48 236 0 59 0 
Max 0 224 0 0 36 
E2F1 0 216 42 24 21 
CLOCK 0 209 0 32 26 
RUNX 47 204 0 0 38 
RUNX-AML 41 201 67 0 32 
RUNX2 0 200 0 0 44 
c-Myc 0 190 0 0 28 
Gfi1b 0 179 78 54 0 
Foxh1 0 172 77 70 0 
USF1 0 166 0 30 22 
PU.1 35 160 0 0 0 
IRF4 28 158 42 0 26 
TEAD 0 157 0 0 33 
HIF2a 0 150 47 0 28 
Hoxc9 0 146 0 0 0 
bHLHE40 14 146 24 0 17 
HNF6 0 137 0 60 0 
E2F7 0 107 0 16 10 
CArG 0 97 29 27 0 
PAX5 20 95 0 0 0 
Tlx 0 92 37 28 24 
Egr2 17 91 29 0 10 




HIF-1a 0 87 24 0 21 
Rfx5 0 74 0 0 0 
Pbx3 16 64 28 19 11 
c-Jun-CRE 0 60 0 21 0 
VDR 16 58 0 0 0 
Srebp1a 16 55 18 18 0 
Tbx20 24 49 0 0 14 
IRF1 0 48 23 17 0 
Nur77 13 47 21 15 0 
Tbox 0 47 23 12 0 
HRE 21 44 28 0 15 
CEBP 0 41 80 16 0 
NFAT 13 41 0 18 13 
E-box 0 36 0 0 0 
Tcfcp2l1 0 36 0 0 0 
ZBTB33 0 34 0 0 0 
Hoxb4 13 31 0 13 0 
Reverb 12 31 0 0 11 
Rfx2 0 31 0 0 0 
YY1 0 31 0 0 0 
Srebp2 14 30 13 0 0 
IRF2 0 29 0 16 0 
ETS 26 29 13 0 16 
RFX 0 28 0 0 0 
GATA-DR8 0 25 0 0 0 
ISRE 0 25 0 0 0 
JunD 0 21 0 0 0 
p53 0 17 13 0 0 
PBX1 0 16 12 0 0 
NF1 37 16 43 27 0 
ZFX 170 0 185 135 87 
NF1-halfsite 155 0 189 153 97 
Unknown 55 0 0 0 45 
Tbet 60 0 0 0 0 
Nkx3.1 0 0 253 232 108 
Foxa2 0 0 0 0 48 
Ets1-distal 0 0 28 0 12 
Usf2 0 0 20 0 0 
bZIP 29 0 0 0 0 
RBPJ 0 0 0 21 0 
KLF5 137 0 0 0 86 
AP-2alpha 96 0 149 89 0 
PRDM1/BMI1 40 0 0 62 0 
ETS1 73 0 0 0 48 
Atf4 21 0 34 22 0 
MYB 141 0 216 0 0 
Atf1 43 0 0 67 32 
Myf5 50 0 0 0 0 
Isl1 137 0 0 0 115 
Klf4 0 0 0 0 13 
GATA3 101 0 0 171 0 
MafF 0 0 0 33 0 
mES-Nanog 66 0 0 0 0 




BMYB 102 0 181 0 0 
FOXA1 56 0 0 109 64 
Hnf1 0 0 0 17 0 
CTCF 0 0 14 0 0 
Nkx2.1 181 0 298 250 0 
Nkx2.5 0 0 217 213 0 
CRE 14 0 13 18 0 
AMYB 107 0 169 0 0 
Lhx2 76 0 0 0 59 
Lhx3 108 0 0 0 0 
NFkB-p50,p52 18 0 31 0 0 
CHR 0 0 0 83 0 
Six1 16 0 25 0 0 
GATA-IR3 0 0 14 12 0 
Tcf12 75 0 0 0 0 
Gata4 69 0 0 113 56 
Gata2 0 0 0 54 0 
Gata1 0 0 0 49 0 
GRE 12 0 23 0 0 
Stat3 0 0 70 55 40 
Nkx6.1 174 0 0 0 138 
HNF4a 0 0 0 41 30 
NeuroD1 0 0 0 0 36 
OCT4-SOX2-TCF-NANOG 14 0 0 26 0 
EWS 49 0 96 0 28 
BORIS 24 0 0 0 12 
PRDM14 29 0 33 31 23 
Nanog 262 0 0 0 0 
STAT1 0 0 38 0 19 
TRa 0 0 45 37 0 
Egr1 76 0 0 78 0 
Stat3+il21 55 0 88 72 40 
PAX3 15 0 0 18 11 
AP-1 0 0 0 44 0 
FOXP1 0 0 0 51 0 
Rbpj1 0 0 0 0 95 
BMAL1 0 0 182 0 0 
STAT5 0 0 46 0 22 
STAT4 0 0 126 96 0 
Smad4 0 0 191 0 0 
Smad2 0 0 181 0 0 
E2F 0 0 15 10 0 
E2A 124 0 0 0 0 
Nr5a2 0 0 41 0 0 
Esrrb 32 0 72 0 0 
Fox 56 0 0 0 48 
Chop 0 0 0 21 0 
E2F4 41 0 78 55 45 
Pax8 0 0 0 22 0 
ERE 0 0 25 0 0 
NRF1 0 0 36 10 0 
ZNF143|STAF 0 0 33 22 0 
Atf3 0 0 0 44 0 




HOXA9 47 0 0 0 45 
NRF1 0 0 36 0 11 
STAT6 0 0 70 0 0 
Tcf3 0 0 0 26 0 
Cdx2 52 0 0 83 0 
NFkB-p65 44 0 0 0 32 
Mef2c 26 0 55 0 37 
ELF1 52 0 77 0 31 
Mef2a 0 0 47 0 26 
ERG 123 0 0 0 78 
Phox2a 25 0 0 0 26 
GRHL2 0 0 37 0 14 
Eomes 136 0 0 0 0 
Foxo1 132 0 0 0 0 
Elk1 52 0 77 48 35 
Elk4 57 0 79 58 32 
TATA-Box 0 0 169 0 82 
SCL 0 0 0 0 220 
GFY-Staf 0 0 12 0 0 
FXR 28 0 46 0 0 
EBF1 0 0 153 0 0 
PU.1-IRF 99 0 0 0 0 
EBF 0 0 0 19 0 
OCT4 26 0 0 28 0 
OCT2 14 0 0 0 0 
ZNF711 0 0 0 183 119 
Bcl6 0 0 194 134 99 
ARE 18 0 0 0 0 
DMC1 0 0 12 0 0 
total 6,786 17,883 7,173 4,998 3,805 
 
n = 819 unique promoters at 40 min 
n = 4,170 unique promoters at 80 min 
n = 1,417 unique promoters at 105 min 
n = 1,221 unique promoters at 165 min 




Table 6. Motifs in promoters of genes that first increase at each time point relative 
to asynchronous cells. 
motif 40’ 80’ 105’ 165’ 300’ 
Maz 0 880 0 0 0 
KLF5 0 764 0 0 0 
BMAL1 0 521 0 0 0 
PU.1-IRF 0 515 0 0 0 
Sp1 0 289 0 0 0 
ELF5 72 274 0 0 0 
n-Myc 0 270 0 0 0 
c-Myc 0 247 0 0 0 
NFY 0 236 0 0 0 
Max 0 224 0 0 0 
CEBP 0 191 0 0 0 
c-Myc 0 190 0 0 0 
Klf4 0 187 0 0 0 
IRF4 0 158 0 0 0 
bHLHE40 0 146 0 0 0 
TRa 0 144 0 0 0 
PRDM9 0 129 0 0 0 
HNF4a 0 125 0 0 0 
RBPJ 0 101 50 0 0 
PRDM14 29 101 0 0 0 
Usf2 0 81 0 0 0 
EKLF 0 60 0 0 0 
E-box 0 36 0 0 0 
ZBTB33 0 34 0 0 0 
ETS 0 32 0 0 0 
Pax7 0 28 0 0 0 
GATA-DR8 0 25 0 0 0 
ISRE 0 25 0 0 0 
p53 0 17 13 0 0 
NF-E2 0 10 0 0 0 
ZFX 170 0 0 0 0 
Unknown 55 0 0 0 0 
MYB 141 0 0 0 0 
HNF6 0 0 82 0 0 
Tbx20 24 0 0 0 0 
MafK 19 0 0 0 0 
Srebp2 14 0 0 0 0 
OCT4 0 0 0 28 0 
ZNF711 220 0 0 0 0 
Jun-AP1 18 0 0 0 0 
total 762 6,040 145 28 0 
 
n = 819 unique promoters at 40 min 
n = 4,170 unique promoters at 80 min 
n = 1,417 unique promoters at 105 min 
n = 1,221 unique promoters at 165 min 
n = 674 unique promoters at 300 min 





Table 7. Motifs in promoters of mitotically-expressed genes. 
















































































































































Table 8. Motifs in promoters of mitotically-expressed genes relative to 
asynchronous cells. 











n = 4,873 unique mitotically-expressed promoters 





Table 9. Motifs in promoters of mitotically-enriched genes. 
























































































n = 689 unique mitotically-enriched promoters 




Table 10. Motifs in promoters of mitotically-enriched genes relative to 
asynchronous cells. 






























APPENDIX D: BET Inhibitors Suppress ALDH Activity by Targeting 
ALDH1A1 Super-Enhancer in Ovarian Cancer 
  
 This appendix contains a manuscript which was published in Cancer Research 
(Volume 76(21), pages 6,320-6,330) in November 2016, of which I am an author. The 
majority of the work was performed by Yuhki Yokoyama and Hengrui Zhu in the lab of 
Dr. Rugang Zhang at the Wistar Institute. My contribution was the development of EU-
RNA-Seq during my thesis work in Dr. Kenneth S. Zaret’s lab. The manuscript was 
written by Yuhki Yokoyama, Hengrui Zhu, Andrew V. Kossenkov, Sherry Y. Wu, Louise 
C. Showe, Qin Liu, David Speicher, Jose R. Conejo-Garcia, Anil K. Sood, Tamas Ordog, 




Molecular and Cellular Pathobiology
BET Inhibitors Suppress ALDH Activity by
Targeting ALDH1A1 Super-Enhancer in Ovarian
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Yuhki Yokoyama1, Hengrui Zhu1, Jeong Heon Lee2, AndrewV. Kossenkov3, Sherry Y.Wu4,5,
Jayamanna M.Wickramasinghe3, Xiangfan Yin6, Katherine C. Palozola7,
Alessandro Gardini1, Louise C. Showe3,6, Kenneth S. Zaret7, Qin Liu6, David Speicher6,
Jose R. Conejo-Garcia8, James E. Bradner9, Zhiguo Zhang2,10, Anil K. Sood4,5,11,
Tamas Ordog10, Benjamin G. Bitler1, and Rugang Zhang1
Abstract
The emergence of tumor cells with certain stem-like char-
acteristics, such as high aldehyde dehydrogenase (ALDH)
activity due to ALDH1A1 expression, contributes to chemo-
therapy resistance and tumor relapse. However, clinically
applicable inhibitors of ALDH activity have not been reported.
There is evidence to suggest that epigenetic regulation of stem-
related genes contributes to chemotherapy efficacy. Here, we
show that bromodomain and extraterminal (BET) inhibitors
suppress ALDH activity by abrogating BRD4-mediated
ALDH1A1 expression through a super-enhancer element and
its associated enhancer RNA. The clinically applicable small-
molecule BET inhibitor JQ1 suppressed the outgrowth of
cisplatin-treated ovarian cancer cells both in vitro and in vivo.
Combination of JQ1 and cisplatin improved the survival of
ovarian cancer–bearing mice in an orthotopic model. These
phenotypes correlate with inhibition of ALDH1A1 expression
through a super-enhancer element and other stem-related
genes in promoter regions bound by BRD4. Thus, targeting
the BET protein BRD4 using clinically applicable small-mol-
ecule inhibitors, such as JQ1, is a promising strategy for
targeting ALDH activity in epithelial ovarian cancer. Cancer
Res; 76(21); 6320–30. !2016 AACR.
Introduction
Chemotherapeutic drugs, such as cisplatin, have had a major
impact on the therapeutic management of many tumors, and in
particular in epithelial ovarian cancer (EOC; ref. 1). However,
chemotherapy resistance is amajor cause of cancer morbidity and
mortality. For example, although EOC, in particular high-grade
serous carcinoma (HGSC), initially respond well to platinum-
based chemotherapy, relapse often occurs with decreased chemo-
therapy sensitivity (2). The hypothesis that this occurs due to
cancer stem-like cells (CSC) remains controversial. However,
there is substantial evidence in the literature that cells with CSC
characteristics contribute to chemotherapy resistance and tumor
relapse (3). Putative EOC CSCs are typically characterized by
increased aldehydedehydrogenase (ALDH) activitywith concom-
itant upregulation of ALDH1A1 (4–6). ALDH activity is function-
ally important in EOC, as suppressing ALDH activity by knocking
down ALDH1A1 has been shown to sensitize EOC cells to
chemotherapy (4). In addition, a population of normal ovarian
stem cells also has increased ALDHactivity (7), further supporting
its functioning in putative ovarian CSCs. Despite the mounting
evidence on the critical role of ALDH1A1 in regulating CSCs (8),
the molecular mechanisms underlying its regulation remain
poorly understood. Notably, clinically applicable inhibitors of
ALDH activity or ALDH1A1-targeting approaches have not been
reported.
Recent genome-wide next-generation sequencing studies in
human cancers have revealed frequent alterations in genes and
proteins that are critical in regulating the epigenetic landscape of
chromatin (9, 10). This suggests that proteins encoded by these
genes may be cancer therapeutic targets. Accordingly, small-mol-
ecule inhibitors targeting chromatin-regulating epigenetic
enzymes have been developed (11). The bromodomain and
extraterminal (BET) family of proteins recognize acetylated lysine
on histones through their bromodomains (12). BET proteins
control the transcription of their target genes either directly by
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recruiting transcriptional machinery or indirectly through involv-
ing enhancer elements in a lineage and context-specific manner
(12). Highly specific BET inhibitors are in clinical trials (13).
Pharmacologic inhibitors of BET proteins have shown efficacy in
the clinic in a number of pathologies, most notably in cancer.
There is evidence to suggest that epigenetic regulation of stem-
related genes contributes to chemotherapy efficacy (14, 15).Using
unbiased approaches, here, we have identified BET inhibitors as
suppressors of ALDH activity that potentiate the antitumor effects
of cisplatin in EOC.
Materials and Methods
Cell lines and epigenetic small-molecule screen
HumanEOC cell lineswere obtained fromATCCwithin 3 years
and were reauthenticated by The Wistar Institute's Genomics
Facility at the end of the experiments within last 3 months using
short tandem repeat profiling using AmpFLSTR Identifiler PCR
Amplification Kit (Life Technologies) and cultured as described
previously (16). The Structural Genome Consortium generously
provided the epigenetic compound library. OVCAR3 cells
were plated in 384-well plates and treated with serial dilutions
(0–20 mmol/L) of 24 epigenetic compounds with or without IC20
cisplatin. Data were analyzed with GraphPad (Prism).
In situ 3C assay
In situ chromosome conformation capture (3C) samples were
prepared as described previously withmodifications (17). Briefly,
cells (5 ! 106) were cross-linked with 1% formaldehyde and
quenched by 2.5 mol/L glycine. Cells were collected and resus-
pended in Hi-C lysis buffer (10 mmol/L Tris-HCl pH 8.0, 10
mmol/L NaCl, 0.2% NP-40) with proteinase inhibitor (Sigma).
The cell suspension was incubated on ice, washed with Hi-C
buffer, resuspended in 0.5% SDS, and incubated at 65"C for 5
minutes. After quenching the SDS, chromatin was digested over-
night by MboI and then ligated. Ligated DNA was purified using
Wizard SV Gel and PCR Clean-Up System (Promega). Quantita-
tive PCR was performed by using Quantitect Probe PCR Master
Mix (Qiagen) with custom probe and primers as described
previously (18). Probe and primer sequences are indicated in
Supplementary Table S1.
Nascent RNA sequencing and chromatin immunoprecipitation
sequencing
For nascent RNA sequencing (RNA-seq), cells were incubated
with 0.5 mmol/L ethidium uridine (EU) and treated with
125 nmol/L JQ1 or vehicle control for 40 minutes. Total RNA
was extracted with TRIzol reagent and RNeasy Mini Kit. The EU-
labeled RNAs were biotinylated and precipitated by using the
Click-it Nascent RNA Capture Kit (Life Technologies) following
the manufacturer's instructions. Briefly, 5 mg EU-labeled RNA was
biotinylated with 0.25 mmol/L biotin azide in Click-it Reaction
Buffer. Biotinylated RNAs were ethanol precipitated and resus-
pended in ultrapurewater. BiotinylatedRNAswere incubatedwith
Dynabeads MyOne Streptavidin T1 magnetic beads in Click-it
RNA and subjected to library preparation. Libraries for RNA-seq
were prepared with Ovation Human FFPE RNA-Seq Multiplex
System1–8 (NuGEN)andsequencedonan IlluminaNextSeq500.
For chromatin immunoprecipitation sequencing (ChIP-seq),
cells were cross-linked with 1% formaldehyde for 10 minutes,
followed by quenching with 125 mmol/L glycine for 5 minutes.
Fixed cells were resuspended in cell lysis buffer (10 mmol/L
Tris-HCl, pH 7.5, 10 mmol/L NaCl, 0.5% NP-40) and incubated
on ice for 10 minutes. The lysates were washed with MNase
digestion buffer (20 mmol/L Tris-HCl, pH 7.5, 15 mmol/L
NaCl, 60 mmol/L KCl, 1 mmol/L CaCl2) once and incubated
for 20 minutes at 37"C in the presence of 1,000 gel units of
MNase (NEB, M0247S) in 250 mL reaction volume. After adding
the same volume of sonication buffer (100 mmol/L Tris-HCl,
pH 8.1, 20 mmol/L EDTA, 200 mmol/L NaCl, 2% Triton X-100,
0.2% sodium deoxycholate), the lysates were sonicated for 5
minutes (30 seconds on/off) in a Diagenode Bioruptor and
centrifuged at 15,000 rpm for 10 minutes. The cleared super-
natant equivalent to 2–4 ! 106 cells was incubated with 2 mg of
anti-BRD4 antibody (Bethyl, A301-985A) on a rocker overnight.
Bound chromatin was eluted and reverse cross-linked at 65"C
overnight. For next-generation sequencing, ChIP-seq libraries
were prepared from 10 ng of ChIP and input DNAs with the
Ovation Ultralow DR Multiplex system (NuGEN). The ChIP-seq
libraries were sequenced in a 51 base pairs paired end run using
the Illumina HiSeq 2000.
In vivo orthotopic xenograft mouse model
The Institutional Animal Care and Use Committee (IACUC) at
The Wistar Institute (Philadelphia, PA) approved all animal
protocols described in this study. NOD/scid gamma (NSG) mice
were injected intraperitoneally with OVCAR3 luciferase cells (5!
106). Tumors were allowed to establish for 3 weeks and random-
ized into four groups: control (n ¼ 12), JQ1 (n ¼ 11), cisplatin
(n¼ 12), and cisplatin/JQ1 (n¼ 13). Tumor growthwas followed
by noninvasive imaging as described previously (19). Briefly,
tumors were visualized by injecting luciferin (4 mg/mice i.p.)
resuspended in PBS, and imaged with an IVIS Spectrum. JQ1 was
resuspended in 10% 2-hydroxypropyl-b-cyclodextrin solvent
(Sigma-Aldrich) as described previously (20). Cisplatin was pur-
chased fromSelleckChemand dissolved in PBS.Micewere treated
daily with intraperitoneal injections of vehicle controls and/or
JQ1 (20 mg/kg) and/or biweekly with cisplatin (750 mg/kg).
Tumor cells collected from peritoneal washes were incubated
with ammonium chloride to lyse erythrocytes and then used for
the ALDEFLUOR assay and stained with PE-anti-mouse CD45
(BD Biosciences) antibody to excludemouse-derived hematopoi-
etic cells. Survival of tumor-bearing mice was evaluated on the
basis of IACUC criteria.
Analysis using primary human ovarian tumors
For analyzing ALDH activity, the protocol for using the
primary human ovarian tumor specimen was approved by the
Wistar Institute Institutional Review Board (IRB). For expres-
sion of enhancer RNA (eRNA), BRD4 and ALDH1A1, the
protocol using human ovarian tumor specimens was approved
by the IRB at The M.D. Anderson Cancer Center (Houston,
Texas). RNA was extracted from 26 high-grade serous ovarian
tumors using the mirVana RNA Isolation Kit (Thermo Fisher
Scientific) according to the manufacturer's protocol. Analysis
of RNA levels was performed on a 7500 Fast Real-Time PCR
System (Applied Biosystems) with SYBR Green–based real-
time PCR using the primers as detailed in Supplementary
Methods. Expression of b-actin was used as a housekeeping
gene control. Analysis was performed using the 7500 Real-
Time PCR software.
Targeting ALDH Activity with BET Inhibitors
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BET inhibition decreases ALDH enzymatic activity and suppresses ALDH1A1 expression. A, plot of ratio of the quantified ALDH-positive cells OVCAR3 cells
treated with the IC20 dose of the indicated epigenetic inhibitors or vehicle controls. For epigenetic inhibitors whose IC20 dose was not achieved, the highest dose
tested (20 mmol/L) was used in the assay. Error bars, SEM of three independent experiments. B, representative changes in ALDH activity in OVCAR3 cells
treated with the indicated positive "hits" identified in the evaluation. DEAB-treated cells were used as a negative control for ALDH activity. C, OVCAR3 cells were
treatedwith the indicated doses of the BET inhibitor JQ1, andALDH activity wasmeasured by FACS. The percentages of positive cells are indicated.D, same asC, but
for primary ovarian cancer cells isolated from a serous histosubtype ovarian tumor. E, same as C, but for the BET inhibitor I-BET-762. F, JQ1 inhibits ALDH activity
in vivo in an intraperitoneal xenograft model using OVCAR3 cells. Percentages of ALDH activity–positive cells collected from peritoneal washes of the
indicated treatment groups are indicated. Please see Materials and Methods for experimental details. G, quantification of F. Error bars, SEM. H, same as C, but
examined for ALDH1A1 mRNA expression by qRT-PCR. Mean of three independent experiments with SEM. ! , P < 0.03. I, same as C, but examined for
ALDH1A1 protein expression by immunoblotting.
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JQ1 synergizes with cisplatin, which correlates with inhibition of ALDH activity. A, synergy analysis for JQ1 and cisplatin in the indicated ovarian cancer cell lines.
Cells were treated with the indicated concentration of JQ1 and cisplatin for 72 hours. The combination index (CI) value was calculated. Combination index values: <1,
synergism; 1, additive effect; >1, antagonism. Error bars, SEM and n¼ 3. B, logarithmic combination index plot of JQ1 (200 nmol/L) is generated in combination with
cisplatin in cisplatin-resistant CP70 ovarian cancer cells. C, OVCAR3 cells treated with 125 nmol/L JQ1, 250 nmol/L cisplatin, or in combination for 12 days were
assayed for colony formation. D, quantification of C. Mean of three independent experiments with SEM E, same as C, but cells were only treated for 72 hours
and examined for the percentage of ALDH activity–positive cells by FACS. F, same as E, but examined for ALDH1A1 expression by immunoblotting.G, same as E, but
examined for the indicated markers of apoptosis. H, ALDH1A1 protein expression in FACS-sorted ALDH activity–positive and negative cells determined by
immunoblotting. I, sphere formation by the indicated ALDH activity–negative cells or ALDH activity–positive cells treated with or without JQ1. Scale bar, 40 mm.
J, quantification of I. Mean of three independent experiments with SEM.
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Bioinformatics and statistical analysis
For ChIP-seq, alignment was done versus hg19 version of
human genome using bowtie algorithm. BRD4 ChIP-seq for
vehicle control–treated cells was compared versus input and
versus JQ1 using HOMER algorithm with "-histone" option. FDR
<1% was set as a significance threshold. RNA-seq data were
aligned using bowtie2 algorithm, and RSEM was used for esti-
mating number of reads for each gene. EdgeR was used to test for
differential expression and FDR <10% was used as a significance
threshold unless stated otherwise. Ingenuity Pathway Analysis
software was used to test gene sets for enrichment of cellular
functions and canonical pathways, and IngenuityKnowledgeBase
was used to create regulation and protein–protein interaction
network for stem-related genes.Differences in percentage between
different classes were tested using Fisher exact test, with P < 0.05
used as a significance threshold. H3K4Me1 and H3K27Ac broad
peaks were downloaded from ENCODE for GM12878, H1-hESC,
HSMM, HUVEC, K562, NHEK, and NHLF cell lines for overlap
with BRD4 peaks. To determine the effect of combination treat-
ment, CI (combination index) values were calculated by using
Compusyn software (21). CIs <1, 1, and >1 represent synergism,
additive effect, and antagonism, respectively.
Results
BET inhibitors suppress ALDH activity and inhibit ALDH1A1
expression
As ALDH activity regulates the putative ovarian CSCs and
stem-related genes are subjected to epigenetic regulation (4–6,
14, 15), we evaluated a panel of 24 small-molecule inhibitors
known to target epigenetic regulators obtained from The Struc-
ture Genomics Consortium on their ability to suppress ALDH
activity (Fig. 1A; Supplementary Table S2). We examined the
expression of ALDH1A1, the major determinant of ALDH
activity (4, 8), in a panel of high-grade serous EOC cell lines
(Supplementary Fig. S1A and S1B; ref. 22). We performed the
evaluation of ALDH activity in OVCAR3 cells because these
cells have high ALDH1A1 expression (Supplementary Fig. S1B).
To limit the potential bias introduced by different growth
inhibition potential among the small-molecule inhibitors, we
established a growth inhibition curve for each small-molecule
inhibitor and based the dose of each small-molecule inhibitor
on the established IC20 value (Supplementary Table S2). The
highest tested dose (20 mmol/L) was used for those inhibitors
whose IC20 was not achieved. Validating our experimental
design, a previously reported positive regulator of ALDH activ-
ity, an HDAC inhibitor, was identified (23). We identified four
small-molecule inhibitors that significantly suppressed ALDH
activity (Fig. 1A and B). Notably, all three BET inhibitors in the
panel scored as "hits" that significantly suppressed ALDH
activity. As JQ1 is clinically applicable (known as TEN-010 in
clinical trials), we performed further validation on this inhib-
itor. We validated that JQ1 decreased ALDH activity in a dose-
dependent manner (Fig. 1C and Supplementary Fig. S1C) and
in primary EOCs (Fig. 1D). Similar results were also obtained
by using I-BET 762, another BET inhibitor that is now in clinical
development (Fig. 1E). We further validated that JQ1 decreases
ALDH activity of EOC cells in vivo in an orthotopic xenograft
mouse model (Fig. 1F and G). As a positive control, cisplatin
increased ALDH activity in vivo as reported previously (4).
Notably, both ALDH1A1 mRNA and ALDH1A1 protein levels
were decreased by JQ1 treatment in a dose-dependent manner
in multiple cell lines (Fig. 1H and I and Supplementary Fig.
S1D and S1E). This suggests that JQ1 decreases ALDH activity
by suppressing ALDH1A1 expression at the transcriptional
level.
BRD4 inhibition suppresses ALDH activity and inhibits
ALDH1A1 expression
As high ALDH activity is implicated in chemotherapy response
(8), we determined whether BET inhibitors synergize with cis-
platin by inhibiting ALDH activity. Indeed, JQ1 displayed a
synergistic effect with cisplatin in multiple EOC cell lines
(Fig. 2A). In addition, JQ1 displayed a synergistic effect with
Figure 3.
BRD4 regulates ALDH1A1 expression
and ALDH activity. A–C, OVCAR3
cells were infected with lentivirus
encoding the indicated short hairpin
RNA to the human BRD4 gene
(shBRD4) or control. The drug-
selected cells were examined for the
expression of BRD4 (A) and ALDH1A1
(B) mRNA by qRT-PCR or for the
expression of BRD4 and ALDH1A
protein expression by immunoblotting
(C). Mean of three independent
experiments with SEM. !, P < 0.002.
D, same as A, but examined for ALDH
activity by FACS. The percentage of
ALDH activity–positive cells is
indicated.
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cisplatin in the in vitro–derived cisplatin-resistant EOC cell line
A2780 CP70 (Fig. 2B). Furthermore, in colony formation assays,
JQ1 significantly suppressed the outgrowth of EOC cells after
cisplatin treatment in multiple EOC cell lines (Fig. 2C and D and
Supplementary Fig. S2A and S2B). This correlated with inhibition
of ALDH activity (Fig. 2E) and suppression of the upregulated
Figure 4.
JQ1 suppresses stem-related genes. A, diagram of the strategies used for identifying direct BRD4 target genes as an overlap between BRD4 differentially occupied
genes and genes differentially expressed in response to JQ1. A total of 8,049 BRD4-binding sites showed significant reduction after JQ1 treatment (FDR < 1%).
A total of 129 genes were significantly altered by JQ1 (FDR < 10%). Twenty-one of 44 direct BRD4 target genes whose expression was affected by JQ1 are stem
related, which are all downregulated by JQ1. B, regulation and protein–protein interaction network for stem-related genes identified in A. C, enrichment
analysis of direct BRD4 target genes shows a significant enrichment of stem-related genes among direct BRD4 target genes affected by JQ1 (21/51 affected stem-
related geneswereBRD4direct targets comparedwith 282/1,196 of all genes changed, identified on the basis of the significance threshold ofP<0.05).D,BRD4ChIP-
seq and nascent RNA-seq tracks from control and JQ1-treated cellswere aligned using bowtie and bowtie 2 algorithm. LIF, HES1, andWNT5A genomic locus ChIP-seq
and nascent RNA-seq are displayed. E, validation of LIF, HES1, and WNT5A mRNA downregulation by JQ1. Relative mRNA expression level of the indicated
stem-related geneswasmeasured by qRT-PCRwith or without 125 nmol/L JQ1 treatment for 24 hours. n¼ 3; " , P < 0.001. F, JQ1 reduces the association of BRD4 and
Pol II with the promoters of the indicated stem-related genes. ChIP analysis of OVCAR3 cells treatedwith control vehicle or JQ1 (125 nmol/L) using antibodies against
BRD4 or RNA Pol II for the human LIF, HES1, and WNT5A gene promoter. An isotype-matched IgG was used as a control (n ¼ 3; " , P < 0.05). Error bars, SEM.
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BRD4 regulates ALDH1A1 expression through a super-enhancer and its associated enhancer RNA. A, flow diagram of the strategies used for identifying the putative
super-enhancer forALDH1A1 gene. B, BRD4 ChIP-seq and nascent RNA-seq tracks from control and JQ1-treated cells were aligned. The putative super-enhancer loci
are displayed together with enhancer histone marks H3K4Me1 and H3K27Ac tracks from ENCODE database from the indicated cell lines. C, validation of
downregulation of the eRNA and ALDH1A1 mRNA by JQ1. OVCAR3 cells were treated with or without 125 nmol/L JQ1 for 24 hours, and the expression of
ALDH1A1 mRNA and the eRNA expression was determined by qRT-PCR. (Continued on the following page.)
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ALDH1A1 induced by cisplatin (Fig. 2F and Supplementary Fig.
S2C). We observed an increase in apoptotic markers, such as
cleaved caspase-3, cleaved lamin A and cleaved PARP p85 and
Annexin V in the cells treated with JQ1 and cisplatin in combi-
nation compared with either treatment alone (Fig. 2G and Sup-
plementary Fig. S2D and S2E). Notably, JQ1 significantly
decreased anchorage-independent sphere formation in ALDH-
positive cells, a characteristic of putative ovarian CSCs (24), to a
degree that is comparable with those observed in ALDH-negative
cells (Fig. 2H–J).
The BET family is composed of BRD2, BRD3, BRD4, and the
testis-specific BRDT proteins (12). BRD4 is often amplified in
EOC (25). BRD4 amplification predicts a worse overall/disease-
free survival in EOC patients (26). Consistent with a previous
report (27), we showed that BRD4 is expressed in both EOC cell
lines and primary high-grade serous EOC specimens, and BRD4
knockdown suppressed the growth of EOC cells (Supplementary
Fig. S3A–S3D). Notably, cisplatin did not affect BRD4 expression
(Supplementary Fig. S3E). BRD4 knockdownbymultiple shRNAs
and in multiple EOC cell lines suppressed ALDH1A1 expression
and consequently decreased ALDH activity (Fig. 3A–D and Sup-
plementary Fig. S3F–S3I). The oncogene c-MYC is a well-estab-
lished target gene of BRD4 (27). JQ1-induced suppression of
ALDH activity and ALDH1A1 downregulation is not a conse-
quence of c-MYC downregulation, as c-MYC knockdown did not
affect either ALDH1A1 expression or ALDH activity (Supplemen-
tary Fig. S3J and S3K). In contrast to BRD4 knockdown, knock-
down of BRD2 or BRD3 did not suppress ALDH activity (Sup-
plementary Fig. S3L and S3M), suggesting that BRD4 plays a
major role in the observed suppression of ALDH activity by BET
inhibitors, such as JQ1.
BRD4 targets the promoters of stem-related genes
BRD4 transcriptionally regulates its target gene expression (12).
BRD4 is also known to regulate lineage-specific gene expression
through enhancer elements (28–30), which contributes to the
observed specificity and selectivity of BET inhibitors. We deter-
mined whether the observed phenotypes induced by JQ1 are due
to changes in BRD4 target gene expression. Nascent transcript
RNA-seq in OVCAR3 cells treated with or without JQ1 for 40
minutes was performed to identify early changes in the gene
expression that are likely directly dependent on BRD4 inhibition
(Fig. 4A). In addition, BRD4 ChIP followed by next-generation
sequencing (ChIP-seq) analysis was performed in OVCAR3 cells
treated with or without JQ1 to identify genome-wide changes in
BRD4 association induced by JQ1 (Fig. 4A and Supplementary
Fig. S4A and S4B). The nascent RNA-seq and ChIP-seq data are
available in the Gene Expression Omnibus database (accession
number GSE77568). ChIP-seq analysis indicated that BRD4
predominantly occupied promoter regions within 1 kb from
transcription starting sites (Supplementary Fig. S4A and S4B).
Cross-referencing of the RNA-seq and BRD4 ChIP-seq revealed
that BRD4 direct target genes regulated by JQ1 treatment are
significantly enriched for putative stem-related genes (Fig. 4B–
C; Supplementary Fig. S4C and S4D). We validated three genes
known to be implicated inCSCs, namely LIF (31),HES1 (32), and
WNT5A (33), as direct BRD4 targets that are downregulated by
JQ1 (Fig. 4D–E and Supplementary Fig. S4E). This observation
correlated with a decrease in the association of BRD4 and RNA
polymerase II with the promoter regions of these genes after JQ1
treatment (Fig. 4F). These results support the notion that JQ1may
affect putative ovarian CSCs by regulating BRD4 binding to the
promoters of the identified stem-related genes.
BRD4 regulates ALDH1A1 expression through a super-
enhancer element and its associated eRNA
JQ1 decreased ALDH1A1 mRNA expression (Fig. 1). How-
ever, JQ1 did not affect BRD4 binding to the ALDH1A1
promoter region (Supplementary Fig. S5A). This suggests that
JQ1 regulates ALDH1A transcription through a distal regula-
tory element. As BRD4 is known to regulate super-enhancer
elements (28–30), we examined the role of JQ1 in regulating
super-enhancers through BRD4 (Fig. 5A). To do so, we focused
on BRD4-binding regions that were enriched at least 4-fold
compared with input DNA and were significantly reduced by
JQ1 treatment (>2-fold, P < 0.05). In addition, we prioritized
the list by focusing on BRD4-binding regions that spanned >10
kb and with no known genes located within at least 100 kb. We
then overlapped these regions with ENCODE ChIP-seq data
and considered only BRD4-binding regions that overlapped
with the enhancer H3K4Me1/H3K27Ac histone marks. Our
prioritization resulted in a list of 11 candidate BRD4-binding
sites similar to those previously described for super-enhancers
(Supplementary Table S3; ref. 28). Interestingly, one of the
potential super-enhancers is 491 kb upstream of the ALDH1A1
gene (Supplementary Table S3). On the basis of RNA-seq
analysis, this region is bidirectionally transcribed into RNA
albeit with low reads (Fig. 5B), which is also a known feature of
super-enhancers (34, 35). We validated that JQ1 treatment
decreased the expression of the RNA transcribed from the
super-enhancer element (eRNA; Fig. 5C). This decrease in
eRNA expression significantly correlated with the decrease in
ALDH1A1 mRNA expression (Fig. 5C). We validated that the
super-enhancer region is enriched in BRD4 and Pol II binding,
(Continued.) D, same as C, but validated for a decrease in the association of BRD4 and Pol II with the enhancer locus by ChIP analysis. An isotype-matched IgG
was used as a control. n ¼ 3; " , P < 0.0001. E, validation of H3K27Ac and H3K4Me1 enhancer histone marks' association with the enhancer loci by ChIP analysis.
n ¼ 3; " , P < 0.002. F, BRD4 knockdown reduces the levels of eRNA expression and suppresses ALDH1A1 expression. OVCAR3 cells were infected with
lentivirus encoding the indicated shBRD4 or control. Drug-selected cells were examined for the expression of BRD4mRNA, eRNA, andALDH1A1mRNA by qRT-PCR.
n¼ 3; " , P < 0.0001. G, knockdown of the eRNA suppresses ALDH1A1 expression. OVCAR3 cells were transfected with two independent siRNAs to the eRNA for 72
hours, and expression of the eRNA and ALDH1A1 mRNA was determined by qRT-PCR. n ¼ 3; " , P < 0.002. H, same as G, but examined for ALDH activity. The
percentage of ALDH-positive cells is indicated. I–K, positive correlation between BRD4 and eRNA (I), between eRNA and ALDH1A1 (J), or between BRD4 and
ALDH1A1 (K) in a panel of 26 cases of HGSOC. Expression of BRD4, eRNA, and ALDH1A1was determined by qRT-PCR, and correlation was determined by Spearman
statistical analysis. L, diagrams of ALDH1A1 genomic regions with its enhancer (black box). Arrowheads, position of primers used for detection of chromatin
looping; stick bars, Mbo1 enzyme digestion sites (a–h). Constant primer at the anchor point is also indicated. TSS, ALDH1A1 gene transcription-starting site.
M, 3C-quantitative PCR analysis of the looping events between the enhancer and theALDH1A1 promoter regionwere detected at f and g sites, whichwere reduced by
JQ1 (125 nmol/L) treatment for 24 hours. The relative cross-linking frequency was normalized to the closest Mbo1 digestion site E1. x-axis, distance from
ALDH1A1 transcription start site (TSS).
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another feature of super-enhancers (Fig. 5D; ref. 35). Further-
more, we validated the enrichment of H3K27Ac and H3K4Me1
epigenetic histone modifications in the putative super-enhanc-
er regions (Fig. 5E). Finally, knockdown of BRD4 expression
was sufficient to decrease the eRNA expression, which corre-
lated with the decrease in ALDH1A1 mRNA (Fig. 5F). To
directly determine whether the eRNA regulates ALDH1A1
mRNA expression, we knocked down the eRNA expression
using siRNAs (36, 37). Knockdown of the eRNA downregu-
lated ALDH1A1 mRNA expression (Fig. 5G), which correlated
with a decrease in ALDH activity (Fig. 5H). Notably, there was
a significant positive correlation between BRD4, eRNA, and
ALDH1A1 expression in a panel of 26 cases of HGSC speci-
mens (Fig. 5I–K). This further highlights the established reg-
ulation of eRNA by BRD4 and subsequent ALDH1A1 expres-
sion by eRNA.
An important component of enhancer function is the for-
mation of chromatin looping, allowing enhancer and promot-
er interaction (36, 38, 39). We directly examined chromatin
looping between the super-enhancer and ALDH1A1 gene pro-
moter using 3C in cells with or without JQ1 treatment. We
observed a robust association between the super-enhancer and
the promoter region of the ALDH1A1 gene (Fig. 5L and M).
Remarkably, JQ1 treatment abrogated the chromatin looping
between the super-enhancer and the promoter of ALDH1A1
gene (Fig. 5M). These results support the notion that JQ1
regulates transcription of ALDH1A1 through the newly iden-
tified super-enhancer.
JQ1 inhibits expression of ALDH1A1 and its associated eRNA
induced by cisplatin in vivo and combination of JQ1 and
cisplatin improves survival
BET inhibitors have been proven safe in patients (40).
ALDH-positive cells contribute to tumor progression and
relapse after initial response to chemotherapy (3, 8). To
determine the effects of BET inhibitor on tumor relapse after
cisplatin treatment, we orthotopically transplanted luciferase-
expressing OVCAR3 cells into the peritoneal cavity of immu-
nocompromised NSG female mice. The injected cells were
allowed to grow for 3 weeks to establish tumors. We randomly
assigned mice into four groups and treated mice with vehicle
control (n ¼ 12), cisplatin (750 mg/kg every 2 weeks, n ¼ 12),
JQ1 (20 mg/kg daily, n ¼ 11), and a combination of cisplatin
and JQ1 (n ¼ 13) by intraperitoneal injection for an additional
4 weeks. Doses of JQ1 and cisplatin used were determined on
the basis of suppression of ALDH1A1 expression by JQ1 and
regression of ovarian tumor in a pilot experiment (Supple-
mentary Fig. S6A–S6E). Notably, the survival of the combi-
nation-treated mice was significantly extended compared with
mice treated with cisplatin alone (Fig. 6A). We followed the
Figure 6.
The combination of JQ1 and cisplatin improves survival of tumor-bearing mice. A, combination of JQ1 and cisplatin improves survival of tumor-bearing mice.
Kaplan–Meier survival curves of mice in the indicated groups posttreatment were plotted using Prism software. n ¼ 7 for the indicated groups except in the
combination group, n ¼ 8. B, quantification of tumor growth in the indicated groups after stopping drug treatment. C, same as A. Tumors from the indicated
treatment groups were examined for eRNA expression by qRT-PCR at the end of the treatment. D, same as C. Tumors were sectioned and subjected to
immunohistochemical staining using antibodies against ALDH1A1. Scale bar, 100 mm. E, a model for the mechanism underlying the observed synergy
between BET inhibitor and cisplatin.
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tumor outgrowth/relapse in mice treated with cisplatin with or
without JQ1 combination after stopping drug treatment.
Indeed, the outgrowth of the tumors in the combination
treatment group was significantly slower compared with the
cisplatin only treatment group (Fig. 6B). RNA from tumors
harvested from the control and the three different treatment
groups was utilized for qRT-PCR analysis. We observed that
eRNA expression was induced by cisplatin alone (Fig. 6C),
whereas JQ1 treatment suppressed the cisplatin-induced eRNA
expression (Fig. 6C). This correlated with changes in ALDH1A1
expression in these treatment groups (Fig. 6D and Supplemen-
tary Fig. S6F). ALDH1A1 mRNA expression was also signifi-
cantly downregulated in JQ1-treated tumors (Supplementary
Fig. S6G). In addition, stem-related genes, such as LIF and
WNT5A, were downregulated in JQ1/cisplatin-treated tumors
(Supplementary Fig. S6H). However, BRD4 expression was not
significantly changed in treatment groups (Supplementary Fig.
S6I). Together, we conclude that a combination of JQ1 and
cisplatin improves the survival of EOC-bearing mice, which
correlates with the suppression of expression of ALDH1A1 and
its eRNA.
Discussion
Here, we found that BET inhibitors suppress ALDH activity.
This correlates with the suppression of ALDH1A1 expression by a
BRD4-regulated super-enhancer and downregulation of its
encoded eRNA (Fig. 6E). BET inhibitors are now in clinical
development and are safe. This suggests that BET inhibitors can
be repurposed to target ALDH activity for improving platinum-
based chemotherapy by inhibiting tumor relapse, a major
challenge in the clinical management of EOC. Notably, BRD4
amplification/overexpression is often mutually exclusive with
"BRCAness" in EOC (25). Thus, there is an even greater need for
novel therapeutic strategies for this patient population given the
limited therapeutic options available (2).Our experiments clearly
show that BET inhibitors, an existing class of epigenetic targeting
drugs, target ALDH activity, potentiate the tumor suppression
induced by cisplatin, and improve survival of EOC-bearing mice
in vivo. These findings will facilitate the rapid evaluation of this
new strategy in the clinic for EOC.
BRD4 is a general transcriptional regulator that controls
global gene expression patterns (12). Investigation of genes
hypersensitive to BET inhibition revealed that such genes
typically exhibit BRD4 occupancy at super-enhancer elements
(28–30). This raises the possibility that BET inhibition is
selective in gene regulation and thus confers relative specificity
in a cell context–dependent manner. Our findings revealed that
in response to JQ1 treatment, BRD4 assumes a key role in
transcriptional control of the ALDH1A1 gene through regulat-
ing its super-enhancer and the associated eRNA. Although
BRD4 plays a key role in regulating ALDH1A1 transcription,
there are potentially other mechanisms than BRD4 expression
levels that regulate ALDH1A1 expression (12). BRD4 plays a
key role in CSCs by selectively regulating the ALDH1A1 super-
enhancer. In this context, BET inhibitors may selectively target
CSCs by their effect on the ALDH1A1 super-enhancer. In
addition to suppressing ALDH1A1 expression and ALDH activ-
ity, JQ1 also directly suppresses the expression of stem-related
genes through reducing BRD40s association with their promo-
ters (Fig. 4). Thus, the mode of action of BET inhibitors is
multifaceted and likely involves a broad range of changes in
transcription and the associated signaling pathways (Fig. 6E).
Given the established role of ALDH1A1 in ovarian CSCs (4),
our data support the idea that the BRD4-regulated ALDH1A1
super-enhancer plays a key role in the observed phenotypes
induced by BET inhibitors.
Our studies demonstrate that targeting BRD4 activity through
the use of clinically applicably BET inhibitors represents a novel
strategy for targeting ALDH activity. This correlates with suppres-
sion of ALDH1A1 expression via a BRD4-regulated super-enhanc-
er and its associated eRNA. Given that there is currently no
clinically applicable ALDH activity inhibitor, we expect our find-
ing to have far-reaching implications for developing future ther-
apeutic strategies using epigenetic targeting BET inhibitors in
cancers such as EOC.
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Supplemental Materials and Methods 
 
Antibodies and Immunoblotting  
Cells were lysed in Laemmli sample buffer (Biorad). Primary antibodies used in this study were 
obtained from the indicated suppliers: rabbit polyclonal anti-BRD4 (Bethyl Laboratories Inc), 
mouse monoclonal anti-ALDH1A1 (BD Transduction Laboratories), rabbit polyclonal anti-PARP 
p85 Fragment (Promega), rabbit polyclonal anti-cleaved Lamin A (Cell Signaling Technology), 
rabbit polyclonal anti-cleaved caspase 3 (Cell Signaling Technology), mouse monoclonal anti-b-
actin (Sigma-Aldrich), mouse monoclonal anti-tubulin (Sigma-Aldrich), mouse monoclonal anti-
GAPDH (Millipore). Secondary antibodies horseradish peroxidase (HRP)-conjugated anti-
mouse IgG and HRP-conjugated anti-rabbit IgG were used for detection of target proteins by 
chemiluminescent substrate (Pierce). 
 
Quantitative Reverse Transcriptase PCR 
RNA was extracted in TRIzol regent (Life technologies) and purified using RNeasy (Qiagen) 
with on-column DNase treatment.  RNA samples were subjected to quantitative RT-PCR using 
iTaq SYBR green (Bio-Rad).  Primer sequences are: ALDH1A1: forward 5’- 
CACGCCAGACTTACCTGTCC-3’ and reverse 5’- TCCTCCTCAGTTGCAGGATT-3’, ALDH1A1 
enhancer RNA (eRNA): forward 5’-GCTGGTTTAAAATCGGTGCT-3’ and reverse 5’-
GCCACACTCAAGAGAAAAACAA-3’, LIF: forward 5’- ACCAGATCAGGAGCCAACTG-3’ and 
reverse  5’- GCCACATAGCTTGTCCAGGT-3’, HES1:  forward 5’- 
TCAACACGACACCGGATAAA-3’ and reverse 5’- TCAGCTGGCTCAGACTTTCA-3’, WNT5A: 
forward 5’- TGGCTTTGGCCATATTTTTC-3’ and reverse 5’- GCAGAGAGGCTGTGCTCCTA-3’, 
BRD2: forward 5’- ACTTGGCCTGCATGACTACC-3’ and reverse 5’- 
TAAGCCGTACATCAGCAGCA-3’, BRD3: forward 5’- CTGCACGACTACCACGACAT-3’ and 
reverse 5’- GAGAACATCAGCCGGACATC-3’, BRD4: forward 5’- ACCAGTTTGCATGGCCTTT-
3’ and reverse 5’- TTGTTTTCCAAGCGCTTCTT-3’; B2M: forward 5’- 
GTGCTCGCGCTACTCTCTCT-3’ and reverse 5’- TCTCTGCTGGATGACGTGAG-3’, 
ALDH1A2: forward 5’-TTGGTTCAGTGTGGAGAAGG-3’ and reverse 5’-
AAAGCTTGCAGGAATGGTTTG-3’, ALDH1A3: forward 5’-CTTCTGCCTTAGAGTCTGGAAC-3’ 
and reverse 5’-CGTATTCACCTAGTTCTCTGCC-3’. 
 
Chromatin Immunoprecipitation 
ChIP was performed as previously described (1). The following antibodies were used to perform 
ChIP: anti-BRD4 (Bethyl Laboratories), anti-RNA polymerase II (Santa Cruz), anti-H3K27Ac 
(Millipore), and anti-H3K4Me1 (Abcam).  An isotype-matched immunoglobulin G was used as a 
negative control. ChIP DNA was analyzed by quantitative PCR using KiCqStart SYBR Green 
ReadyMix (Sigma).  
Primer sequences for the indicated gene locus are: LIF forward, 5’-
ACCTTCATTATGGGCTGCAC-3’, and reverse, 5’-CAAATTCCCCATTTGAGCAT-3’; HES1 
forward, 5’-ACCCTGGCTCCAAAAGAAAT-3’, and reverse, 5’-TACTCTCCCTCTGGGCTTTG-
3’; WNT5A forward, 5’-CAGTGGCGGCTAATAATGCT-3’, and reverse, 5’-
GAGGCCAGATTGTAGGCTTG-3’; ALDH1A1 super-enhancer forward, 5’-
GCTGGTTTAAAATCGGTGCT-3’, and reverse, 5’-GCCACACTCAAGAGAAAAACAA-3’. 
 
shRNA and Lentivirus Infection 
Lentivirus was packaged using the Virapower Kit from Invitrogen according to the 
manufacturer’s instructions as described previously (2,3).  The following shRNAs obtained from 






were used:  pLKO.1- shBRD4 (#1-TRCN0000021424, #2-TRCN0000021426, #3-
TRCN0000021427), pLKO.1-shBRD2 (TRCN0000006310), pLKO.1-shBRD3 
(TRCN0000021376) pLKO.1-shMYC (TRCN0000039642, TRCN0000039640).  
 
siRNA Transfection 
Cells were transfected with 30 pmol siRNAs with RNAiMAX reagent (Life Technologies). For 
quantitative PCR and ALDH activity assay, cells were collected 72 hours after transfection. ON-
TARGETplus Non-Targeting siRNA#1 was purchased from Thermo Scientific as a negative 
control (Thermo Scientific). siRNA sequences targeting the ALDH1A1 eRNA are as following: 
#1: 5’-GCUGUAAUUCCAACAUCUU-3’, #2: 5’-CUUAGAAAUCUGAGUACUU-3’ 
 
Aldefluor Assay and Flow Cytometry  
Aldefluor assay kit (Stem Cell) was used to measure the aldehyde dehydrogenase enzymatic 
activity (ALDH) following the manufacturer’s instructions. Briefly, 200,000 cells were re-
suspended in aldefluor assay buffer and ALDH substrate and incubated at 37 °C for 30 min. 
Cells were washed in PBS, and the fluorescence intensity was analyzed using a BD 
FACSCalibur flow cytometer. DEAB treated cells were used as a negative control.   
 
Annexin V Assay 
Annexin V assay kit (Life Technologies) was used to measure the annexin V positive cells after 
the indicated treatments.  Briefly, 100,000 cells were incubated with an Annexin V FITC labeled 
antibody.  Cells were washed with PBS, and the fluorescence intensity was analyzed using a 
LSR18 flow cytometer.  Vehicle control was used as a negative control. 
 
Sphere Formation Assay 
Sphere formation assay was performed as previously described (4).  Cells were stained with 
Aldefluor assay kit, and ALDH positive and negative cells were sorted using FACS.  Sorted cells 
were plated in ultra-low attachment plates (Corning) in a serum-free mammary epithelial growth 
medium (MEGM) supplemented with B27 (Life Technologies), 20 ng/mL EGF and 20 ng/mL 
bFGF (BD Biosciences), and 4 mg/mL heparin (Sigma). Cells were cultured in the medium with 
or without 100 nM JQ1. 7 days later, spheres larger than 50 microns were quantified. 
 
Immunohistochemistry 
Immunohistochemical staining was performed as previously described (5) on consecutive 
sections from tumors dissected from control, JQ1, cisplatin or combination-treated mice. 
Primary antibodies used were mouse monoclonal anti-ALDH1A1 (BD Transduction 







Supplemental Figure Legends 
 
Figure S1. BET inhibition reduces ALDH activity and decreases ALDH1A1 expression in 
ovarian cancer cells.   
(A) Expression of ALDH1A1 in the indicated ovarian cancer cell lines.  Expression of Tubulin or 
b-actin was used as a loading control. 
 (B) ALDH activity measured by FACS of indicated cell lines. The percentage of positive cells is 
indicated. 
(C) OVCAR10 cells were treated with the indicated doses of BET inhibitor JQ1 for 72 hours, and 
ALDH activity was measured by FACS. The percentage of positive cells is indicated.  
(D) Same as (C) but examined for ALDH1A1 mRNA expression by qRT-PCR. Mean of three 
independent experiments with S.E.M. * p<0.02. 
(E) Same as (C) but examined for ALDH1A1 protein expression by immunoblotting. Expression 
of Tubulin was used as a loading control.  
(F) PEO1 cells were treated with the BET inhibitor JQ1 (200nM) for 72 hours, and ALDH activity 
was measured by FACS. The percentage of positive cells is indicated.  
(G) CaOV3 cells were treated with the BET inhibitor JQ1 (200nM) for 72 hours, and ALDH 
activity was measured by FACS. The percentage of positive cells is indicated. 
(H) Same as (G), but for ALDH+ OVCAR3 cells were FACS sorted and treated for 24 hours with 
JQ1. The percentage of positive cell is indicated. 
(I) PEO1 mRNA expression of ALDH1A1, ALDH1A2, and ALDH1A3 was evaluated by qRT-
PCR. Expression values are shown as percentage compared to the loading control (B2M). 
(J) ALDH1A1, ALDH1A2, and ALDH1A3 mRNA expression in PEO1 cells were examined by 
qRT-PCR after JQ1 treatment (400nM). Mean of three independent experiments with S.E.M. 
*p<0.05. 
 
Figure S2. JQ1 synergizes with cisplatin and downregulates ALDH1A1.  
(A) Equal number of OVCAR3 cells were treated with 125 nM JQ1 or 250 nM cisplatin or in 
combination for 72 hours and the number of cells from the indicated groups was counted at the 
end of treatment. Error bars = S.E.M. of three independent experiments.   
(B) OVCAR10 cells treated with 125nM JQ1 or 125nM cisplatin alone or in combination were 
assayed for colony formation.  
(C) OVCAR10 cells were treated with 125nM JQ1 or 125nM cisplatin alone or in combination for 
72 hours and examined for expression of ALDH1A1 in the indicated cells.  
(D) OVCAR10 cells were treated with 125 nM JQ1, 1mM cisplatin or in combination for 72 hours 
and examined for expression of apoptosis marker cleaved PARP p85 in the indicated cells. 
(E) OVCAR3 cells were treated with 125 nM JQ1 or 250nM cisplatin alone or in combination for 
72 hours and examined via flow cytometry for apoptosis by Annexin V expression.  Error bars = 
S.E.M. of three independent experiments.   
 
Figure S3. ALDH activity and ALDH1A1 expression are regulated by BRD4 in a c-MYC-
independent manner.  
(A) Expression of BRD2, BRD3, and BRD4 in the indicated ovarian cancer cell lines and ALDH-
/ALDH+ sorted OVCAR3 cells. GAPDH expression was used a loading control. 
(B) Expression of BRD4 in normal ovarian surface epithelial cells and 6 different primary ovarian 
tumors of serous histosubtype.  
(C) OVCAR3 cells were infected with the indicated shBRD4 or control.  Drug-selected cells were 
examined for expression of BRD4.  






(E) OVCAR3 cells treated with cisplatin were used for immunoblot against BRD4.  Expression of 
Tubulin was used as a loading control. 
(F-I) OVCAR10 cells were infected with the indicated shBRD4 or control and examined for 
expression of BRD4 mRNA (F), ALDH1A1 mRNA (G) by qRT-PCR; BRD4 and ALDH1A1 
protein expression by immunoblotting (H); or measured for percentage of ALDH positive cells by 
FACS (I).  
(J-K) OVCAR3 cells were infected with two independent shc-MYC. Drug selected cells were 
examined for the expression of c-MYC and ALDH1A1 expression by immunoblotting (J), or 
assayed for ALDH activity by FACS (K). 
(L) OVCAR3 cells were infected with shBRD2, shBRD3 or shBRD4. Knockdown of the indicated 
targets was validated by qRT-PCR.  
(M) Same as (L) but examined for the percentage of ALDH positive cells by FACS.  
 
Figure S4. BRD4 directly targets stem-related genes in ovarian cancer cells, and their 
expression is suppressed by the BET inhibitor JQ1.  
(A-B) BRD4 ChIP-seq analysis was performed in OVCAR3 cells treated with or without 125 nM 
JQ1.  23375 significant BRD4 peaks (FDR<1%) were identified in controls.  The BRD4 signal 
was greatly reduced by JQ1 treatment (A) with maximum BRD4 binding signal dropping on 
average 3.8-fold (B).  
(C-D) Nascent RNA-seq was performed in OVCAR3 cells treated with or without 125 nM JQ1. 
The expression of 129 genes was significantly changed based on criteria of FDR<10%. Those 
genes were significantly enriched (1.7-fold, p=0.0001 by Fisher exact test) for genes bound by 
BRD4 within 10 kb from the transcription start site (C).  The majority of those genes (36 genes, 
83% of all with BRD4 binding reduced by JQ1) were downregulated by JQ1 (D), indicating direct 
regulation by BRD4.  
(E) JQ1 reduces the expression of ALDH1A1 mRNA, enhancer RNA (eRNA) and the indicated 
stem-related genes in OVCAR10 cells. OVCAR10 cells were treated with 125 nM JQ1 for 24 
hours. Gene expression was determined by qRT-PCR. n=3 and * p<0.002. 
 
Figure S5. ALDH1A1 is not a direct target of BRD4. 
(A) BRD4 ChIP-seq tracks from control and JQ1 treated OVCAR3 cells were aligned using the 
bowtie algorithm. ALDH1A1 genomic loci ChIP-seq tracks are displayed.  
(B) BRD4 knockdown reduces the levels of eRNA expression and suppresses ALDH1A1 
expression in OVCAR10 cells.  OVCAR10 cells were infected with lentivirus encoding the 
indicated shBRD4 or control.  Drug-selected cells were examined for the expression of BRD4 
mRNA, eRNA and ALDH1A1 mRNA by qRT-PCR. n=3 and * p<0.0002. 
 
Figure S6.  Combination of JQ1 and cisplatin treatment in vivo. 
(A) JQ1 dose determination. OVCAR3 cells were injected intraperitoneally (i.p.) into NSG mice, 
and tumors were allowed to establish.  Mice were randomized into three groups: Control (n=2), 
5 mg/kg JQ1 (n=3), and 20 mg/kg JQ1 (n=3). Mice were treated for 30 days with i.p. injections 
of vehicle control or JQ1.  Tumors from the indicated treatment groups were examined for 
ALDH1A1 mRNA expression by qRT-PCR. Note that 20 mg/kg JQ1, but not 5 mg/kg JQ1, 
significantly reduced ALDH1A1 expression.  
(B) Cisplatin dose determination.  OVCAR3-Luciferase cells were injected intraperitoneally (i.p.) 
into NSG mice, and tumors were allowed to establish for three weeks.  Mice were randomized 
into three groups: control (n=3), 750 mg/kg cisplatin (n=3), and 3 mg/kg cisplatin (n=3). Mice 
were treated biweekly with i.p. injection of vehicle control or cisplatin. The average radiance of 
luciferase bioluminescence, an indicator of the rate of tumor growth, was measured using an 






(C) OVCAR3-Luciferase cells were injected intraperitoneally (i.p.) into NSG mice, and tumors 
were allowed to establish for three weeks.  Mice were randomized into four groups: Control 
(n=12), JQ1 (n=11), cisplatin (n=12), and cisplatin/JQ1 (n=13). Mice were treated for 30 days 
with i.p. injections of vehicle control, JQ1, cisplatin or the combination of JQ1 and cisplatin. The 
radiance of luciferase bioluminescence, an indicator of the rate of tumor growth, was measured 
using an IVIS imaging system. Shown are images taken at week 7 (week 4 post treatment). 
(D) Quantitation of tumor growth as total flux (photon/sec) for the indicated groups during the 
treatment period. Values are Log10 transformed and error bars are S.E.M.  Mann-Whitney Test 
used to calculate p-values. * p = 0.0297. 
(E) Quantification of luciferase bioluminescence signal at the end of treatment for each of the 
individual mice from the indicated treatment group.  Error bars = S.E.M. 
(F) Quantification of ALDH1A1 IHC staining in the xenograft tumors obtained from the indicated 
groups as detailed in Figure 6D.  ALDH1A1 expression was scored based on histological score 
(H-score) that considers both intensity and percentage of positive staining.  
(G) ALDH1A1 mRNA expression from control and JQ1 treated tumors.  Error bars = S.E.M. 
(H) mRNA expression of stem-related genes (LIF and WNT5A) in the xenograft tumors obtained 
from the cisplatin/JQ1 treated mice. Error bars = S.E.M. 
(I) BRD4 expression in the indicated groups was scored based on histological score (H-score) 
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